10th International Meeting of Pediatric Endocrinology

September 14 - 17, 2017
Washington, DC
Marriott Wardman Park

Program Book

internationalmeeting2017.org
# Table of Contents

Welcome from the President .................................................. 1  
Program at a Glance ........................................................... 2  
Committee & Leadership ...................................................... 6  
Societies ........................................................................... 7  
Sponsors and Acknowledgements ........................................... 10  
Meeting Information ........................................................... 11  
Program Book Key ............................................................... 12  
Miscellaneous ..................................................................... 16  
Commercial Exhibition ......................................................... 19  

**Daily Program**

- Thursday, September 14 .................................................. 30  
- Friday, September 15 ....................................................... 39  
- Saturday, September 16 ................................................... 56  
- Sunday, September 17 ...................................................... 70  

Poster Sessions ................................................................... 78  
Metro Map / Floor Plans ....................................................... 90  

For the most up-to-date information, be sure to download the meeting app by searching “IMPE 2017” in your App Store.
Dear global endocrinology colleagues and friends:

Welcome to Washington DC! On behalf of the Program Organizing Committee, it gives me great pleasure to welcome you to the 10th International Meeting of Pediatric Endocrinology. This auspicious occasion continues a tradition of Joint Meetings initiated in 1981, appropriately updated for 2017 to “International Meeting” with a theme: Celebrating the Truly Worldwide Community of Pediatric Endocrinology.

This scientific gathering unites the world’s Pediatric Endocrinology Societies, including host Pediatric Endocrine Society (PES), European Society for Paediatric Endocrinology (ESPE), Australasian Paediatric Endocrine Group (APEG), Asia Pacific Pediatric Endocrine Society (APPES), African Society for Pediatric and Adolescent Endocrinology (ASPAE), Chinese Society of Pediatric Endocrinology and Metabolism (CSPEM), Japanese Society for Pediatric Endocrinology (JSPE), the Sociedad Latinoamericana de Endocrinologia Pediátrica (SLEP), Arab Society of Pediatric Endocrinology and Diabetes (ASPED) and Indian Society Pediatric and Adolescent Endocrinology (ISPAE).

The diligent commitment of your Program Organizing Committee members and others have created an exciting meeting featuring internationally renowned experts sharing the very latest advances, challenges, and controversies in the field of pediatric endocrinology. Virtually every aspect of our specialty is addressed in Plenary, Topic Symposia, Yearbook, Controversy, and New Perspective sessions and a panoply of Abstract Free Communication and Poster sessions. In addition, I encourage attendees to take full advantage of opportunities for interaction and discussion in pre-meeting Special Interest Group meetings and ever-popular Meet-the-Expert sessions. And while you are in the beautiful city of Washington DC – home to countless fascinating museums, monuments, and historical treasures – I also encourage you to enjoy all that Washington DC has to offer.

In this important time to affirm and support the global sharing of knowledge, your participation in this Meeting is especially significant and appreciated. On behalf of the host Pediatric Endocrine Society and the Program Organizing Committee, I thank you for joining in this celebration of the worldwide community of pediatric endocrinology!

David B. Allen, MD
President, 2017 International Meeting of Pediatric Endocrinology
Chair, International Meeting Program Organizing Committee
Professor of Pediatrics
University of Wisconsin School of Medicine and Public Health
# Program at a Glance

## Thursday 9/14/17

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Registration Opens</td>
</tr>
<tr>
<td>8:30 am</td>
<td>SIG1 Diabetes Technology SIG</td>
</tr>
<tr>
<td>8:45 am</td>
<td>SIG2 Pediatric Adolescent Gynecology SIG</td>
</tr>
<tr>
<td>9:00 am</td>
<td>SIG3 Obesity SIG</td>
</tr>
<tr>
<td>9:45 am</td>
<td>SIG4 Bone and Growth SIG</td>
</tr>
<tr>
<td>10:00 am</td>
<td>SIG5 Turner Syndrome SIG</td>
</tr>
<tr>
<td>10:45 am</td>
<td>SIG6 Gender Dysphoria SIG</td>
</tr>
<tr>
<td>11:00 am</td>
<td>SIG7 Global Pediatric Endocrinology and Diabetes SIG</td>
</tr>
<tr>
<td>11:15 am</td>
<td>SIG8 Allied Health SIG</td>
</tr>
<tr>
<td>11:45 am</td>
<td>SIG9 Disorders of Sex Development SIG</td>
</tr>
<tr>
<td>8:45 am</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>PL1 ASPAE - Establishing endocrine care from scratch in developing countries by Mohamed Abdullah</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>PL2 APEG – Inflammatory environment and type 1 diabetes by Jennifer Couper</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>SAT Personalized approach in diagnosis and management of short stature</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>SAT Improving care for patients with turner syndrome</td>
</tr>
<tr>
<td>3:45 pm</td>
<td>SAT Understanding short stature beyond the GH-IGF axis</td>
</tr>
<tr>
<td>4:15 pm</td>
<td>SAT Pediatric growth hormone deficiency: management of the transition from pediatric to adult care</td>
</tr>
<tr>
<td>5:00 pm</td>
<td>CPE Metformin treatment for obesity</td>
</tr>
<tr>
<td>5:15 pm</td>
<td>CPE Renal and endocrine electrolyte disorders</td>
</tr>
<tr>
<td>5:30 pm</td>
<td>CPE Diabetes and the brain *co-sponsored by ISPAD</td>
</tr>
<tr>
<td>6:00 pm</td>
<td>CPE Endocrine complications of childhood cancer and its treatment</td>
</tr>
<tr>
<td>6:45 pm</td>
<td>P1 and Exhibits</td>
</tr>
<tr>
<td>7:00 pm</td>
<td>Welcome Reception in Exhibition Hall</td>
</tr>
<tr>
<td>8:15 pm</td>
<td>PES Memorial for Colleagues - open to all</td>
</tr>
</tbody>
</table>

## Session Codes & Color Legend for Session Types:

- **FC** = Free Communication Session
- **SAT** = IMPE Satellite Symposium
- **CPE** = Controversies in Pediatric Endocrinology
- **MTE** = Meet the Expert
- **YB** = Yearbook of Paediatric Endocrinology
- **PL** = Plenary Lecture
- **S** = Topic Symposium
- **P1, P2, P3** = Poster Session (1, 2, or 3)
- **NP** = New Perspectives
- **SIG** = Special Interest/Working Groups
### Program at a Glance

**Friday 9/15/17**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Registration Opens</td>
<td></td>
</tr>
<tr>
<td>6:30 am</td>
<td>Coffee in Exhibit Hall (7:00-7:30am)</td>
<td></td>
</tr>
</tbody>
</table>
| 7:30 am| **MTE1:1** Diagnosis and management of pseudo-hypoparathyroidism and related conditions<br>Thurgood Marshall NE  
**MTE2:1** Distinguishing monogenic forms from type 1 and type 2 diabetes: Does your patient have the right diagnosis?<br>Washington 4-6  
**MTE3:1** PWS from birth to adulthood<br>Thurgood Marshall SW  
**MTE4:1** Pediatric cortical adrenal tumors<br>Virginia  
**FC1–FC5** Growth and GH/IGF Axis #1<br>Maryland  
**FC11–FC15** Bone and mineral metabolism #1<br>Delaware |
| 7:45 am| **NP1** New manipulations of mutant CaSR pathways; and Cartilage natriuretic peptide<br>Washington 4-6  
**MTE5:1** Delayed puberty: Causes, evaluation, and management<br>Thurgood Marshall NE  
**MTE6:1** Pediatric pheochromocytoma/paraganglioma<br>Thurgood Marshall SW  
**MTE7:1** Pediatric osteoporosis<br>Maryland  
**FC16–FC20** Sex differentiation and disorders of sex development<br>Virginia  
**FC21–FC25** Type 2 diabetes and other carbohydrate metabolism #1<br>Delaware |
| 8:00 am| **PL3** APPES – Prenatal environment and medical consequences by Paul Hofman<br>Marriott Ballroom |
| 8:00 am| **PL4** PES Lawson Wilkins Lecture – Metabolic pathway disruption leading to Type 2 DM by Mitchell Lazar<br>Marriott Ballroom |
| 8:00 am| **P2 and Box Lunches**                                                | Exhibition Hall        |
| 8:15 am| **Refreshment Break, Poster Viewing and Exhibits**                   |                        |
| 10:00 am| **PES Mentor/ Mentee Workshop**                                       | 11:30-12:45 Madison    |
| 10:15 am| **S** New concepts in diagnosis and treatment of CAH<br>Marriott Ballroom |
| 10:15 am| **S** Diabetes management of children in resource-limited settings<br>Washington 4-6  
**CPE1** Aromatase inhibition<br>Thurgood Marshall NE  
**S** Growth hormone safety<br>Thurgood Marshall SW  
**S** Metabolic syndrome in early childhood<br>Virginia  
**S** Puberty and ovarian disorders<br>Maryland |
| 10:45 am| **FC31–FC35** Bone and mineral metabolism #2<br>Washington 4-6  
**FC36–FC40** Type 1 Diabetes #1<br>Marriott Ballroom  
**FC41–FC45** Gender dysphoria<br>Thurgood Marshall NE  
**FC46–FC50** Obesity, lipids, and co-morbidities #1<br>Thurgood Marshall SW  
**YB1** Gender dysphoria<br>Maryland |
| 11:00 am| **Business Mtg** PES                                                  | Marriott Ballroom      |
| 11:00 am| **Business Mtg** SLEP                                                 | Virginia               |
| 11:00 am| **Business Mtg** ESPE                                                 | Thurgood Marshall NE   |
| 11:00 am| **SAT** Perspectives on growth and growth disorders<br>Maryland         |
| 11:00 am| **SAT** New therapeutic options for treating genetic obesity<br>Thurgood Marshall SW |
| 11:00 am| **SAT** The evolving portrait of X-linked hypophosphatemia
Washington 1-3 |
| 12:00 pm| **Refreshment Break and Exhibits**                                    |                        |
| 12:00 pm| **MOC Session**                                                       | Thurgood Marshall NE   |
### Saturday 9/16/17

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 am</td>
<td>Registration Opens</td>
</tr>
<tr>
<td>6:15 am</td>
<td>Breakfast SAT</td>
</tr>
<tr>
<td>6:45 am</td>
<td>Coffee in Exhibit Hall (7:00-7:30am)</td>
</tr>
<tr>
<td>7:00 am</td>
<td>MTE1:2 Diagnosis and management of pseudohypoparathyroidism and related conditions Marion Hall NE Marriott Ballroom Washington 4-6 Virginia</td>
</tr>
<tr>
<td>7:30 am</td>
<td>MTE8:1 Management of hyperthyroidism in children</td>
</tr>
<tr>
<td>7:45 am</td>
<td>MTE9:1 Diabetes in the infant</td>
</tr>
<tr>
<td>8:00 am</td>
<td>FC51–FC55 Quality improvement</td>
</tr>
<tr>
<td>8:15 am</td>
<td>FC56–FC60 Growth and GH/IGF Axis #2</td>
</tr>
<tr>
<td>8:30 am</td>
<td>FC61–FC65 Obesity, lipids, and comorbidities #2</td>
</tr>
<tr>
<td>8:45 am</td>
<td>FC66–FC70 Type 2 diabetes and other carbohydrate metabolism #2</td>
</tr>
<tr>
<td>9:00 am</td>
<td>FC71–FC75 Thyroid</td>
</tr>
<tr>
<td>9:15 am</td>
<td>FC76–FC80 NeuroEndo including hypothalamic pituitary</td>
</tr>
<tr>
<td>9:30 am</td>
<td>PLS: JSPE – Skeletal muscle glucocorticoid receptor and systemic energy metabolism by Hirotoshi Tanaka Marriott Ballroom</td>
</tr>
<tr>
<td>9:45 am</td>
<td>PL6: SLEP – César Bergadá Lecture—Disorders in sex development: a persistent challenge by Alicia Belgorosky Marriott Ballroom</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Refreshment Break, Poster Viewing and Exhibits</td>
</tr>
<tr>
<td>10:15 am</td>
<td>P3 and Boxed Lunches</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>10:45 am</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>11:15 am</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>11:30 am</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>11:45 am</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>12:00 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>12:15 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>12:45 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>1:15 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>1:45 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>2:15 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>2:45 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>3:15 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>3:45 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>4:15 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>4:45 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>5:00 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>5:15 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>5:30 pm</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td>5:45 pm</td>
<td>Marriott Ballroom</td>
</tr>
</tbody>
</table>

### General Information

- **Program at a Glance**
- **4**
- **Delaware**

### Breakfast SAT

- A rare cause of short stature you don’t want to miss

### Refreshment Break, Poster Viewing and Exhibits

- **Exhibition Hall**

### P3 and Boxed Lunches

- **Exhibition Hall**

### Refreshment Break and Exhibits

- **Exhibition Hall**

### General Information

- **SAT**: Central precocious puberty: case presentations and discussion of nuances in diagnosis, treatment, and follow-up
- **SAT**: Evolving trends in puberty
- **SAT**: Updated guidelines for the use of growth hormone therapy in children and adolescents: exploring the impact on clinical practice

### Maps

- **SAT**: Marriott Ballroom
- **SAT**: Washington 1-3
- **SAT**: Marriott Ballroom NE

### Exhibits

- **SAT**: Maryland
- **SAT**: Virginia
- **SAT**: Delaware

### Lecture Details

- **SAT**: Evolution of the concept of thyroid hormone resistance
- **SAT**: Thyroid hormone production in the placenta and its impact on fetal development
**Program at a Glance**

**Sunday 9/17/17**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Registration Opens</td>
</tr>
<tr>
<td>7:30 am</td>
<td><strong>MTE9:2</strong> Diabetes in the infant</td>
</tr>
<tr>
<td>7:45 am</td>
<td><strong>FC96–FC100</strong> Adrenal #2 Multisystem endocrine disorders</td>
</tr>
<tr>
<td>8:00 am</td>
<td><strong>Young Investigator Pres.</strong> APPES, PES, ESPE, APEG awards presented</td>
</tr>
<tr>
<td>8:15 am</td>
<td><strong>MTE12:2</strong> The etiology and management of hypophosphatemic rickets</td>
</tr>
<tr>
<td>8:30 am</td>
<td><strong>MTE5:2</strong> Delayed puberty: causes, evaluation, and management</td>
</tr>
<tr>
<td>8:45 am</td>
<td><strong>MTE8:2</strong> Management of hyperthyroidism in children</td>
</tr>
<tr>
<td>9:00 am</td>
<td><strong>PL8</strong> ESPE – Disorders of the pituitary-thyroid axis: insights from human genetics by Krishna Chatterjee Marriott Ballroom</td>
</tr>
<tr>
<td>9:15 am</td>
<td><strong>YB3</strong> Pharmacotherapy for hypothalamic obesity</td>
</tr>
<tr>
<td>9:30 am</td>
<td><strong>FC106–FC110</strong> Puberty</td>
</tr>
<tr>
<td>9:45 am</td>
<td><strong>FC111–FC115</strong> Late Breaking Abstracts</td>
</tr>
<tr>
<td>10:00 am</td>
<td><strong>MTE11:2</strong> Exercising safely with T1DM</td>
</tr>
<tr>
<td>10:15 am</td>
<td><strong>PL9</strong> President’s Poster Awards</td>
</tr>
<tr>
<td>10:30 am</td>
<td><strong>CPE3</strong> Is there a role for early surgery in the management of DSD?</td>
</tr>
<tr>
<td>10:45 am</td>
<td><strong>S</strong> Pharmacotherapy for hypothalamic obesity</td>
</tr>
<tr>
<td>11:00 am</td>
<td><strong>S</strong> New insights into growth disorders</td>
</tr>
<tr>
<td>11:15 am</td>
<td><strong>S</strong> Thyroid conundrums</td>
</tr>
<tr>
<td>11:30 am</td>
<td><strong>S</strong> Technology and diabetes</td>
</tr>
<tr>
<td>11:45 am</td>
<td><strong>S</strong> Is there a role for early surgery in the management of DSD?</td>
</tr>
</tbody>
</table>

**Session Codes & Color Legend for Session Types:**

- **FC** = Free Communication Session
- **PL** = Plenary Lecture
- **SAT** = IMPE Satellite Symposium
- **CPE** = Controversies in Pediatric Endocrinology
- **MTE** = Meet the Expert
- **YB** = Yearbook of Paediatric Endocrinology
- **S** = Topic Symposium
- **P1, P2, P3** = Poster Session (1, 2, or 3)
- **NP** = New Perspectives
- **SIG** = Special Interest/Working Groups
2017 International Program Organizing Committee (IPOC)

PEDIATRIC ENDOCRINE SOCIETY (PES)
Dave Allen - Madison, WI, United States (President)
Mitch Geffner - Los Angeles, CA, United States
Mark Palmert - Toronto, Canada
Jeff Baron - Bethesda, MD, United States
Sally Radovick - New Brunswick, NJ, United States

AFRICAN SOCIETY FOR PAEDIATRIC AND ADOLESCENT ENDOCRINOLOGY (ASPAE)
Renson Mukhwana - Kenya, East Africa
Dipesalema Joel - Botswana, South Africa

ASIA PACIFIC PAEDIATRIC ENDOCRINE SOCIETY (APPES)
Pik To Cheung - Hong Kong
Reiko Horikawa - Tokyo, Japan

AUSTRALASIAN PAEDIATRIC ENDOCRINE GROUP (APEG)
Michelle Jack - St. Leonards, Australia
Esko Wiltshire - Wellington South, New Zealand

CHINESE SOCIETY OF PEDIATRIC ENDOCRINOLOGY AND METABOLISM (CSPEM)
Xiaoping Luo - Wuhan, China

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY (ESPE)
Mehul Dattani - London, United Kingdom
Franco Chiarelli - Chieti, Italy
Lars Sävendahl - Stockholm, Sweden
Anita Hokken-Koelega - Rotterdam, Netherlands
Peter Clayton - Manchester, United Kingdom

JAPANESE SOCIETY FOR PaEDIATRIC ENDOCRINOLOGY (JSPE)
Keiichi Ozono - Suita, Japan
Tom Ogata - Hamamatsu, Japan

SOCIETY LATINOAMERICANA DE ENDOCRINOLÓGIA PEDIÁTRICA (SLEP)
Hugo Fideleff - Buenos Aires, Argentina
Rodolfo Rey - Buenos Aires, Argentina

PES BOARD OF DIRECTORS

PRESIDENT
Mary Min-Chin Lee - Worcester, MA

PRESIDENT-ELECT
Philip Zeitler - Aurora, CO

SECRETARY
John Fuqua - Indianapolis, IN

TREASURER
Peter Lee - Hershey, PA

PAST PRESIDENT
Stephen Rosenthal - San Francisco, CA

AT LARGE DIRECTORS
Dorothy Shulman - Tampa, FL
Madhusmita Misra - Boston, MA
Michael Levine - Philadelphia, PA

PES MANAGEMENT TEAM
Executive Director - Maureen Thompson
Senior Association Manager - Janice Wilkins
Association Manager - Brandi Walsh
**Pediatric Endocrine Society (PES)**

The mission of PES is to advance and promote the endocrine health and well-being of children and adolescents.

PES has over 1,400 members representing the multiple disciplines of Pediatric Endocrinology. The members are dedicated to research and treatment of children with endocrine disorders; reproductive, bone, thyroid, diabetes, obesity, growth, pituitary and adrenal. The Society works to promote the continuing education of its membership.

[www.pedsndo.org](http://www.pedsndo.org)

---

**Australasian Paediatric Endocrine Group (APEG)**

APEG is the premier professional body representing paediatric endocrinology in Australia and New Zealand and is committed to high standards of clinical care, advocacy, education, stakeholder relationships and research in paediatric endocrinology. With a broad membership of paediatric endocrinologists and allied health professionals, APEG is underpinned by a number of active subcommittees. We are a collegial society and welcome new members to both APEG membership and also to contribute to the subcommittees and working parties.

[www.apeg.org.au](http://www.apeg.org.au)

---

**Asia Pacific Paediatric Endocrine Society (APPES)**

The Asia Pacific Paediatric Endocrine Society (APPES) was formed in 1999 to provide a professional forum for those with an interest in Paediatric Endocrinology in the Asia Pacific region.

Today APPES has members in 19 countries throughout the Asia Pacific Region. The major activities are:

- Promotion of best standards care for children with endocrine diseases and diabetes by collaborating with patients’ support groups and international activities.
- Education and sharing information through fellow schools and CME symposia.
- Scientific meetings of high quality and diverse topics, working groups of specific fields to provide interactive learning opportunity in clinical and basic science.

[www.appes.org](http://www.appes.org)
African Society for Paediatric and Adolescent Endocrinology (ASPAE)
The African Society for Paediatric and Adolescent Endocrinology (ASPAE) is an international organisation with several members from African countries whose aim is to promote the highest levels of knowledge, research, education and clinical practice of paediatric endocrinology and metabolism throughout Africa.

ASPAE was formed in July 2009 and it is dedicated to serve its members and the international scientific community. It is also aims at being involved in promoting the interests of the general public and in advising on African health policy in the area of paediatric endocrinology. ASPAE is committed to welcoming and establishing close relationships with other Scientific Societies in the world.

We would like to take this opportunity to invite you to our upcoming 9th Annual Meeting of ASPAE which will be held in Nairobi, Kenya from 14-15th March 2018. To get more information about us, please visit our website at www.aspaed.org

Chinese Society of Pediatric Endocrinology and Metabolism (CSPEM)
The Chinese Society of Pediatric Endocrinology and Metabolism (CSPEM) is a national organization under the Chinese Pediatric Society, founded in 1985. Our mission is to promote the highest levels of clinical care for infants, children and adolescents with endocrine disorders and metabolic diseases throughout the nation.

It does so by:
- Advancing excellence in paediatric endocrinology, genetics and metabolism by promoting research, education and medical practice.
- Developing and assessing evidence-based clinical practice guidelines and standards of care.
- Promoting and supporting education and research by organizing annual scientific meetings and multicenter clinical researches.
- Contributing to the public health through our publicity activities to facilitate early diagnosis and treatment.
- Enhancing the communication and academic exchanges with international scientific community, other societies and institutions.
Societies

**European Society for Paediatric Endocrinology (ESPE)**
ESPE is a truly international membership organization, with over 1250 members from 90 countries. Our aim is to improve the clinical care of children and adolescents with endocrine conditions, including diabetes, through research and education. Our annual ESPE Meeting is recognised worldwide as a meeting of high scientific and educational quality. ESPE 2018, the 57th ESPE Meeting will take place from the 27-29 September 2018, in Athens, Greece.

**Japanese Society for Pediatric Endocrinology (JSPE)**
Founded in 1967, the Japanese Society for Pediatric Endocrinology (JSPE) has been leading the field of pediatric endocrinology and pediatric diabetes in Japan. JSPE has over 1,300 clinicians and researchers, who have specialized in pediatric endocrinology and diabetes. JSPE will keep on promoting the scientific research regarding children’s growth, development and maturation, in order to broaden our knowledge for pediatrics. At the same time, JSPE hopes to contribute to the public health through our research activities.

http://jspe.umin.jp/

**Sociedad Latinoamericana de Endocrinología Pediátrica (SLEP)**
SLEP, the Latin American Society for Pediatric Endocrinology was founded in 1986. The society’s main goal is to integrate scientists of Latin America involved in basic and clinical research related to the field of pediatric endocrinology.

SLEP invites you to the **César Bergadá Lecture – Disorders in Sex Development: a Persistent Challenge** by Dr. Alicia Belgorosky (Argentina), Plenary 6, Saturday 16 September 10.45 AM. This plenary lecture will discuss the complex issue of DSD. The understanding of the genetic basis of disease has a tremendous importance to recommend newborn sex assignment, better targeted therapies and genetic counseling.


The International Program Organizing Committee would like to thank the 2018 PES Program Committee for assistance with abstract reviews.
Sponsors and Acknowledgments

The 10th International Meeting of Pediatric Endocrinology would like to express its gratitude to the following companies, who through their generosity, have helped to make this meeting possible:

**Platinum Sponsors**

Merck KGaA, Darmstadt, Germany

[Merck KGaA logo]

www.merckgroup.com

Pfizer

[ Pfizer logo]

www.pfizer.com

Sandoz A Novartis Division

For US doctors/delegates: www.us.sandoz.com
For Non-US doctors/delegates: www.sandoz.com

**Gold Sponsor**

Novo Nordisk

[Novo Nordisk logo]

www.novonordisk.com

**Silver Sponsors**

Ferring Pharmaceuticals

[ Ferring Pharmaceuticals logo]

www.ferringusa.com

Sanofi Genzyme

[ Sanofi Genzyme logo]

www.sanofigenzyme.com

Ultragenyx Pharmaceutical

[ Ultragenyx Pharmaceutical logo]

www.ultragenyx.com

**Sponsored Items**

Arbor Pharmaceuticals, LLC

Friday and Saturday morning coffee breaks

Ipsen Biopharmaceuticals, Inc.

Cyber Center and Charging Stations

Merck KGaA

Hotel Key Cards

Novo Nordisk

Abstracts on USB Drives
Meeting Information

Meeting Director and Exhibition Organizer
Amy Schull
6728 Old McLean Village Drive
McLean, VA 22101
Fax: 703-556-8729
Email: amy@pedsendo.org

PES Executive Director
Maureen Thompson
6728 Old McLean Village Drive
McLean, VA 22101
Fax: 703-556-8729
Email: maureen@pedsendo.org

Contacts
Registration: registration@pedsendo.org
General Questions & Information: info@pedsendo.org
Registration Desk: 202-624-1755

Internet Access
Network: International Mtg Ped Endo
Password: IMPE2017

Meeting Website
www.internationalmeeting2017.org

Meeting Opening Hours

Registration Desk - Lobby Level
- Thursday, September 14: 6:30am-7:30pm
- Friday, September 15: 6:30am-7:30pm
- Saturday, September 16: 6:00am-6:00pm
- Sunday, September 17: 6:30am-1:30pm

Speaker Ready Room - Lobby Level, Room 8222
- Wednesday, September 13: 3:00pm-6:00pm
- Thursday, September 14: 7:30am-5:00pm
- Friday, September 15: 7:00am-6:00pm
- Saturday, September 16: 7:00am-5:00pm
- Sunday, September 17: 7:00am-12:00pm

Exhibits and Posters - Exhibition Level, Exhibit Hall C*
- Thursday, September 14: 5:45pm-8:30pm
- Friday, September 15: 7:00am-6:00pm
- Saturday, September 16: 7:00am-6:00pm
- Sunday, September 17: 7:00am-12:00pm

*for author attended poster hours, see page 78
Program Book Key

How to Read the Scientific Program

<table>
<thead>
<tr>
<th>start / end of session</th>
<th>session type and code</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 am - 11:30 am</td>
<td>Free Communication Session (FC1-FC6)</td>
</tr>
</tbody>
</table>

Session Title: Type 1 Diabetes
Room: XYZ

FC6 New perspectives
Carol Smith, United Kingdom

Session Codes & Color Legend for Session Types:

- **FC** = Free Communication Session
- **SAT** = IMPE Satellite Symposium
- **CPE** = Controversies in Pediatric Endocrinology
- **MTE** = Meet the Expert
- **YB** = Yearbook of Paediatric Endocrinology
- **PL** = Plenary Lecture
- **S** = Topic Symposium
- **P1, P2, P3** = Poster Session (1, 2, or 3)
- **NP** = New Perspectives
- **SIG** = Special Interest/Working Groups
Plenary Lecture (PL)
A Plenary Lecture is a stand-alone session on a topic that all members should know more about. The lecturers are all outstanding researchers selected to provide a state of the art review of a wider field of Pediatric Endocrinology. The aim of the Plenary Lecture is to inspire the meeting participants by addressing some particular areas of Pediatric Endocrinology, raise interest in the field, and challenge conventional ways of thinking. A Plenary Lecture is 30 minutes in length and there is one from each partnering society.

Topic Symposium (S)
A Symposium is 90 minutes in length and consists of three presentations of 25 minutes each. Each presentation is followed by 5 minutes for discussion.

New Perspectives (NP)
The New Perspectives sessions include two lectures of approximately 25 minutes followed by 5 minutes for discussion. The aim of these sessions is to provide a thorough update on new methodologies and techniques which have had a major impact in the field of Pediatric Endocrinology.

Controversies in Pediatric Endocrinology (CPE)
The Controversies sessions consist of two experts discussing a controversial topic in the field of Pediatric Endocrinology. The sessions will have a debate format; each speaker will take questions and answers and challenge each other’s knowledge.

Meet the Expert (MTE)
The Meet the Expert sessions are small interactive sessions, devoted to a clinical problem and how to manage it in the clinical setting. All Meet the Expert speakers are requested to prepare handouts and discuss 1–2 cases during the session. The handout is distributed to all participants in the meeting bag and available on the Meeting website after the Meeting.

Special Interest/Working Groups (SIG)
The Special Interest/Working Groups aim to study and debate in detail a disease or a group of diseases, a treatment, a biologic process, a diagnostic method, or a new technology. This could foster exchange of ideas and share experiences, and potentially plan multicentre trials. This year the IMPE Special Interest/Working Groups are open to all delegates coming from all over the world, in order to share further knowledge, generate lively debate and expand the possibility of studies and trials.

Yearbook of Paediatric Endocrinology (YB)
The Yearbook of Paediatric Endocrinology sessions consist of presentations of the most relevant papers published over the last 12 months. During each of the three YB sessions, experts in specific fields of Pediatric Endocrinology will summarize the year’s breakthrough developments, achieved through basic and clinical research.

IMPE Satellite Symposium (SAT)
Satellite Symposia will take place after the main program each day. These symposia have been prepared by companies who have selected the scientific content, which is then approved by the International Program Organizing Committee. This year several Satellite Symposia have been proposed on various fields of Pediatric Endocrinology.
Abstract-based Sessions
The abstract submission process is an excellent opportunity for all delegates to share their research, findings, knowledge and experience with medical professionals in the Pediatric Endocrinology community.

The abstracts are presented in the following formats:

Free Communications (FC)
The Free Communication sessions contain oral presentations where the authors are allowed 8 minutes for presentation and 2 minutes for discussion.

Posters (P1, P2, P3)
The posters are on display on the first three days of the meeting with a dedicated poster presentation during each of these three days. The presenting author is requested to stand by their poster throughout the given presentation time. The first number indicates the day the poster will be presented (ex: P1 will be Thursday, September 14, P2 Friday, September 15, P3 Saturday, September 16). The presenting author will be present at their poster during the Poster Session times indicated on the Schedule at a Glance.

Abstract Book and USB-stick
Accepted abstracts are published online, as a supplement to Hormone Research in Pediatrics (Vol. 88, Supplement 1, 2017). The Abstracts are available on the Meeting website in PDF, as well as the mobile app. In addition, a USB-stick version is given to registrants on a first-come-first-serve basis. Please collect the USB-stick at the Novo Nordisk exhibition booth by using the voucher received in the Meeting bag.

Meet the Expert Handouts
A booklet including handouts for the Meet the Expert sessions are given to all registered attendees in their meeting bag. A printer friendly PDF version is available on the International Meeting website at www.internationalmeeting2017.org.

CME Accreditation
Satisfactory completion
Participants must complete an evaluation to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. NOTE: If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians
Accreditation Statement - This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and the Pediatric Endocrine Society. Amedco is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement - Amedco designates this live activity for a maximum of 19.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
**Poster Exhibition**
Posters will be displayed according to the times indicated.

**Meet the Author Poster Sessions**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1:</td>
<td>Thursday 5:45pm - 6:45pm</td>
</tr>
<tr>
<td>P2:</td>
<td>Friday 11:30am-12:30pm</td>
</tr>
<tr>
<td>P3:</td>
<td>Saturday 12:00pm-1:00pm</td>
</tr>
</tbody>
</table>

**Poster Mount/Removal Schedule**

<table>
<thead>
<tr>
<th>Day</th>
<th>Set Up</th>
<th>Removal</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1:</td>
<td>Thursday 4:00pm</td>
<td>8:00pm</td>
</tr>
<tr>
<td>P2:</td>
<td>Friday 7:00am</td>
<td>12:30pm</td>
</tr>
<tr>
<td>P3:</td>
<td>Saturday 7:00am</td>
<td>1:00pm</td>
</tr>
</tbody>
</table>

*Please Note:* Any poster not taken down by the time indicated above will be removed by meeting management and may be picked up at the registration desk. Posters not picked up by Sunday, September 17, 2017 at 12:00pm, will be discarded.

**Speaker Ready Room**
The speaker ready room is located in room 8222 on the Lobby Level. Speakers are requested to use this facility before their session to ensure that their presentation projects clearly and are in the correct order. **All presenters are asked to please check in your presentation slides no later than 3 hours prior to the presentation time or day before if your presentation is at 7:30am.**

The speaker ready room will be open the following hours:
- Wednesday, September 13 3:00pm-6:00pm
- Thursday, September 14 7:30am-5:00pm
- Friday, September 15 7:00am-6:00pm
- Saturday, September 16 7:00am-5:00pm
- Sunday, September 17 7:00am-12:00pm

**Yearbook of Paediatric Endocrinology**
The Yearbook is given to all attendees. Please collect the Yearbook at the ESPE Society exhibition booth.
**ADA Compliance**
The Washington Marriott Wardman Park and all participating hotels are fully accessible to the physically challenged. Anyone needing special assistance should notify the appropriate hotel and indicate the type of assistance needed. The 10th International Meeting Planning Committee cannot ensure the availability of appropriate assistance without prior notice.

**App Information**
Download the app, free of charge, from the App Store or Google Play by searching “IMPE2017” and gain access to the 10th International Meeting of Pediatric Endocrinology at all times, even when offline.

**Cyber Center**
Check your email and charge your devices at the Cyber Center and Charging Stations, sponsored by Ipsen Biopharmaceuticals, Inc., located on the Mezzanine Level, in the Marriott lobby.

**Currency and Credit Cards**
It is advisable for visitors to carry U.S. cash or dollar denomination traveler’s checks when traveling in the United States. It is easy to exchange foreign currency in major cities. Credit and charge cards (American Express, Visa, Discover, and MasterCard) are widely accepted. Most major banks and American Express offices will exchange foreign currency.

**Dining**
Washington DC’s dining experience is colorful and eclectic! The District’s dining scene is rolling in accolades, as the city received its first Michelin Guide and was recently named restaurant city of the year by Bon Appétit and hottest food city by Zagat. That means you can expect each meal at every restaurant to be different. Your hotel concierge will be able to assist with reservations and suggestions.

**Food and Beverage**
Coffee breaks and two lunches are included in the registration fee. The coffee breaks will be served daily in the Exhibition Hall Friday – Sunday and the lunches will be served in the Exhibition Hall on Friday and Saturday.

**International Meeting & Exhibition Venue**
Washington Marriott Wardman Park
2660 Woodley Rd NW
Washington, DC 20008
Phone: 1-202-328-2000
Fax: 1-202-234-0015
www.marriott.com/hotels/travel/wasdt

**Airports**
The following are the closest airports, and approximate distance, to Washington Marriott Wardman Park:
Ronald Reagan Washington National Airport (DCA) – 8 miles or approximately 30 minutes
Washington Dulles International Airport (IAD) – 25 miles or approximately 45 minutes
Baltimore/Washington International Thurgood Marshall Airport (BWI) – 33 miles or approximately 80 minutes
**Internet Access**
Internet access will be available free of charge in the public meeting room areas at the Marriott.
Network: International Mtg Ped Endo
Password: IMPE2017

**List of Attendees**
The list of attendees will be available via the IMPE2017 mobile app.

**Lost and Found**
Contact the registration desk in case of personal belongings being lost or found. Any lost items that are not claimed by the close of registration on Sunday will be handed over to the hotel’s Loss Prevention.

**Nursing Mothers Lounge**
There is a nursing mother’s private room for breastfeeding and expressing milk in the conference hotel. If you are interested in using this room, please visit the meeting registration desk for a key.

**Photography/Digital Media**
In accordance with the policy of the International Meeting, it is strictly forbidden to take photographs, video or live stream during sessions and in the poster area.

**Public Transportation**
*Taxis*: Taxis have meters. The total cost depends on the distance traveled and time spent in the cab. Each fare starts with a **base charge** of $3.25. **Total distance traveled** is charged at $2.16 per mile ($0.27 per 1/8 mile). The **traffic wait time** rate is $25 per hour, or about $2 every 5 minutes. Riders pay $0.50 for "each piece of luggage the operator places in his or her trunk." Briefcases, purses, bags of groceries and parcels of similar size are exempted from the luggage charge. The extra-passenger surcharge is $1.00, regardless of the number. Any bridge or tunnel tolls will be added to the total charge; driver might ask that you pay the tolls as you go through them. Taxi drivers are usually given a 15% gratuity on top of the final metered fare. (Fares subject to change without notice)

*Metro*: The Metrorail is fast, easy and an inexpensive way to get around the city. It provides safe, clean, reliable transit service for more than 600,000 customers a day throughout the Washington, DC area. The system is the second busiest in the United States, serving 91 stations in Virginia, Maryland, and the District of Columbia. The Metrorail system has six color-coded rail lines: Red, Orange, Silver, Blue, Yellow, and Green. The layout of the system makes it possible to travel between any two stations with no more than a single transfer. The Metrorail system operates during the following times:
- Monday -Thursday: 5:00am-11:30pm
- Friday: 5:00am-1:00am
- Saturday: 7:00am-1:00am
- Sunday: 8:00am-11:00pm

The Metrorail map is located in the back of the program book, for your convenience. To plan your trip, calculate fares or obtain additional information, please visit www.wmata.com.
Smoking Policy
Smoking is prohibited inside the Washington Marriott Wardman Park. The hotel is 100% non-smoking. Throughout Washington DC, smoking is prohibited in most public areas, including metro stations, taxis, most restaurants and bars.

Telephones
United States’ telephone numbers are ten digits. For calls outside the local area, (in the same area code or exchange you are calling from) you must dial a “1” followed by the area code then the rest of the number you are calling. For calls outside the USA and Canada you must dial 001 followed by the country code, area code and the rest of the number you are calling.

Dial “411” for directory assistance. Please remember that most hotels charge a surcharge for outside calls.

Cell phone coverage is generally good in populated cities, but different carriers have exclusive systems and areas. Please check with your cellular provider regarding equipment/service compatibility prior to traveling.

Tipping
Tipping is more or less compulsory, below are guidelines.
Meals: Gratuities are seldom included in the bill, it is usual to tip 15-20% of the bill for meals served in hotels and restaurants.
Taxi: Taxi drivers are generally tipped 15%.
Lodging: Porters in hotels are usually tipped $1.00 USD per piece of luggage.
Airport: Porters in airports are usually tipped $1.00 USD per piece of luggage.

Yoga Sessions
The following yoga sessions will be offered for those that are interested (yoga mats will be provided):

**Modified Ashtanga Primary Series**
*Friday, September 15, 2017*
*6:00pm – 7:15pm*
*Room: Taft*
Come experience the magic of Ashtanga yoga in this all levels modified Primary Series class in which breath is linked with movement in a set sequence of poses that will leave you deeply satisfied.

**Vinyasa Flow**
*Saturday, September 16, 2017*
*4:30pm – 5:45pm*
*Room: Taft*
Be prepared to sweat and to laugh in this all levels Vinyasa Flow class that will include inversions, backbends, twists and hip openers.
Commercial Exhibition

During the meeting, exhibits near the scientific poster display areas will provide a unique opportunity for attendees to learn more about the services and products offered by the pharmaceuticals industry, medical suppliers and publishers.

The exhibits are located in Exhibit Hall C on the Exhibition Level and are open as follows:

- Thursday, September 14: 5:45pm-8:30pm
- Friday, September 15: 7:00am-6:00pm
- Saturday, September 16: 7:00am-6:00pm
- Sunday, September 17: 7:00am-12:00pm

The following companies will be exhibiting their products during the meeting and welcome you to their booth. Please see page 94 for the floor plan.

Exhibitor Index (Alphabetical Order)

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie</td>
<td>200</td>
</tr>
<tr>
<td>Aegerion Pharmaceuticals, a Novelion Therapeutics Company</td>
<td>613</td>
</tr>
<tr>
<td>Alexion</td>
<td>204</td>
</tr>
<tr>
<td>Arbor Pharmaceuticals, LLC</td>
<td>615</td>
</tr>
<tr>
<td>Ascendis Pharma A/S</td>
<td>301</td>
</tr>
<tr>
<td>BioMarin</td>
<td>401</td>
</tr>
<tr>
<td>Congenital Hyperinsulinism International</td>
<td>423</td>
</tr>
<tr>
<td>Cook Children’s Health Care System</td>
<td>498</td>
</tr>
<tr>
<td>Endo Pharmaceuticals</td>
<td>106</td>
</tr>
<tr>
<td>Endocrine Society</td>
<td>508</td>
</tr>
<tr>
<td>European Society for Paediatric Endocrinology (ESPE)</td>
<td>510</td>
</tr>
<tr>
<td>Ferring Pharmaceuticals, Inc.</td>
<td>311</td>
</tr>
<tr>
<td>Ferring Pharmaceuticals, Inc.</td>
<td>417</td>
</tr>
<tr>
<td>Fight ALD</td>
<td>421</td>
</tr>
<tr>
<td>Global Pediatric Endocrinology and Diabetes</td>
<td>419</td>
</tr>
<tr>
<td>Growth Analyser BV</td>
<td>429</td>
</tr>
<tr>
<td>Insulet Corporation</td>
<td>411</td>
</tr>
<tr>
<td>International Consortium of Pediatric Endocrinology (ICPE)</td>
<td>512</td>
</tr>
<tr>
<td>International Society for Pediatric and Adolescent Diabetes (ISPAD)</td>
<td>502</td>
</tr>
<tr>
<td>Ipsen Biopharmaceuticals, Inc.</td>
<td>425</td>
</tr>
<tr>
<td>Company</td>
<td>Booth Number</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>LabCorp-Endocrine Sciences</td>
<td>201</td>
</tr>
<tr>
<td>Lilly USA, LLC</td>
<td>413</td>
</tr>
<tr>
<td>Merck KGaA</td>
<td>317</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td>127</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td>405</td>
</tr>
<tr>
<td>OPKO Health</td>
<td>433</td>
</tr>
<tr>
<td>Pfizer</td>
<td>117</td>
</tr>
<tr>
<td>Prader-Willi Syndrome Association</td>
<td>136</td>
</tr>
<tr>
<td>Rhythm</td>
<td>126</td>
</tr>
<tr>
<td>Sandoz</td>
<td>111</td>
</tr>
<tr>
<td>Sanofi Genzyme</td>
<td>114</td>
</tr>
<tr>
<td>Sonic Bone Medical</td>
<td>500</td>
</tr>
<tr>
<td>The MAGIC Foundation</td>
<td>122</td>
</tr>
<tr>
<td>Ultragenyx Pharmaceutical</td>
<td>132</td>
</tr>
<tr>
<td>Versartis, Inc</td>
<td>303</td>
</tr>
<tr>
<td>Visiana</td>
<td>611</td>
</tr>
</tbody>
</table>
Exhibitor Listing

**AbbVie**
1 North Waukegan Rd.
North Chicago, IL 60064 USA
Phone: 847-932-7900
Website: www.abbvie.com
AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.

**Aegerion Pharmaceuticals, a Novelion Therapeutics Company**
One Main Street, Suite 800
Cambridge, MA 2142 USA
Website: www.novelion.com/about-novelion/aegerion-pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company that develops and commercializes innovative therapies for patients with debilitating rare diseases. Aegerion has a diverse portfolio and is an indirect subsidiary of Novelion Therapeutics, a company dedicated to developing new standards of care for individuals living with rare diseases. Novelion seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.

**Alexion**
ALEXION GLOBAL HEADQUARTERS
100 College St
New Haven, CT 06510 USA
Phone: 475-230-2596
Website: www.alexion.com
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders, including hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).

**Arbor Pharmaceuticals, LLC**
6 Concourse Parkway, Ste 1800
Atlanta, GA 30328 USA
Email: info@arborpharma.com
Website: www.arborpharma.com
Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular, hospital, neuroscience and pediatric markets. The company has over 700 employees including approximately 600 sales professionals promoting its products to physicians, hospitals, and pharmacists. Arbor currently markets over twenty NDA or ANDA approved products with over 35 more in development. For more information regarding Arbor Pharmaceuticals or any of its products, visit www.arborpharma.com or send email enquiries to info@arborpharma.com
Ascendis Pharma A/S
Tuborg Boulevard 5
Hellerup, Denmark
Website: www.ascendispharma.com
Ascendis Pharma is building a leading rare disease company focused on endocrinology. The company utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases by improving clinically validated parent drugs and creating therapies with potential for best-in-class efficacy, safety and/or convenience.

Ascendis Pharma has a wholly-owned pipeline with three programs, including once-weekly TransCon Growth Hormone, which is currently being evaluated in the Phase 3 heiGHt Trial for children with growth hormone deficiency, TransCon PTH, a long-acting prodrug of parathyroid hormone for hypoparathyroidism, and TransCon CNP, a long-acting prodrug of C-Type Natriuretic Peptide for achondroplasia. Additionally, Ascendis Pharma has multi-product collaborations with Sanofi in diabetes and Genentech in the field of ophthalmology.

BioMarin
105 Digital Drive
Novato, CA 94949 USA
Phone: (415)506-6700
Website: www.biomarin.com
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. Approved products include the first and only medications for PKU and LEMS, and the first and only enzyme replacement therapies for MPS I, MPS VI and Morquio A syndrome. Visit www.biomarin.com to learn more.

Congenital Hyperinsulinism International
PO Box 135
Glen Ridge, NJ 07028 USA
Phone: (973)544-8372
Website: www.congenitalhi.org
Twitter: @congenitalhi
Facebook: congenitalhi
Instagram: @chi_hypoglycemia
Congenital Hyperinsulinism International (CHI) is a leading organization dedicated to improving the lives of people born with congenital hyperinsulinism (HI). HI is a life-threatening disorder causing dangerously low blood sugar levels due to the over-production of insulin. Prolonged or severe low blood sugar can cause seizures, brain damage, and even death. CHI supports research toward better treatments and a cure, advocates for timely diagnosis improved standards of care, and supports people living with HI every step of the way.
Cook Children’s Health Care System
801 7th Ave.
Fort Worth, Tx 76104 USA
Phone: 682-885-4000
Website: www.cookchildrens.org
Cook Children’s Health Care System is a not-for-profit, nationally recognized pediatric health care organization comprised of six entities — a Medical Center, Physician Network, Home Health company, Northeast Hospital, Health Plan and Health Foundation. Based in Fort Worth, Texas, the integrated system has more than 60 primary and specialty care offices throughout north Texas. Its service region includes Denton, Hood, Johnson, Parker, Tarrant and Wise counties, with an additional referral area encompassing nearly half the state.

Cook Children’s traces its roots back to 1918, but throughout its continual change and robust growth, it still embraces an inspiring promise — to improve the health of every child in its region through the prevention and treatment of illness, disease and injury. To live up to this promise, Cook Children's combines the art of caring with the use of leading technology and extraordinary collaboration to provide exceptional care for every child, every day.

Endo Pharmaceuticals
1400 Atwater Dr
Malvern, PA 19355 USA
Phone: 484-216-0000
Website: www.endopharma.com
Endo Pharmaceuticals Inc., headquartered in Malvern, PA, develops and markets quality branded pharmaceutical products. Endo Pharmaceuticals is an operating company of Endo International plc.

Endocrine Society
2055 L Street NW, Suite 600
Washington, DC 20036 USA
Website: www.endocrine.org
The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions. The Society, which is entering its second century, has more than 18,000 members, including scientists, physicians, educators, nurses, and students in 122 countries. We are passionate about advancing hormone research, excellence in the clinical practice of endocrinology, broadening understanding of the critical role hormones play in human health, and advocating on behalf of the field of endocrinology in domestic and international policy communities.

European Society for Paediatric Endocrinology (ESPE)
ESPE Team Bioscientifica
Euro House, 22 Apex Court,
Woodlands, Bristol, BS32 4JT, UK
Phone: +44(0) 1454 642246
Fax: +44(0) 1454 642222
Email: espe@eurospe.org
Website: www.eurospe.org
ESPE is a truly international membership organisation, committed to serving its members and the scientific community with the aim to improve the clinical care of children and adolescents with endocrine conditions, including diabetes, through research and education.
Ferring Pharmaceuticals, Inc.
100 Interpace Parkway
Parsippany, NJ 07054 USA
Website: www.ferringusa.com
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of orthopaedics, women's health, reproductive health, gastroenterology, urology and pediatric endocrinology. To view all of our US offerings, please visit www.ferringusa.com.

Fight ALD
PO Box 3318
Vista, CA 92085 USA
Website: www.fightald.org
The Fight ALD is dedicated to fighting illness through education. Specifically, its members work to increase awareness of adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMM) among medical professionals and the public. Symptoms of these disorders often are misdiagnosed or go undetected, limiting treatment options and leading to life-threatening situations. Adrenoleukodystrophy is an inherited metabolic disorder that causes damage to the myelin sheath that surrounds nerve cells in the brain. AMM is the name given to the adult-onset form of ALD, and usually involves the myelin sheath of the spinal cord rather than the brain.

Global Pediatric Endocrinology and Diabetes
Room K4–212
4480 Oak Street
Vancouver, BC V6H 3V4 Canada
Email: info@globalpedendo.org
Website: http://globalpedendo.org
Global Pediatric Endocrinology and Diabetes (GPED) is a non-profit organization (2012) and a charity (2017). GPED’s mission is to improve the care of children living in low and middle income countries (LMICs) and presenting with endocrine disorders or with diabetes through:
• Public advocacy
• Training and education of local health professionals
• Clinical collaborations
• Development of translational clinical research

Growth Analyser BV
Stand nr 429
Growth Analyser BV
Westzeedijk 106
3016 AH Rotterdam, Netherlands
Phone: +31102251533
Fax: +31102250133
Email: info@growthanalyser.org
Website: https://www.growthanalyser.org/
Growth Analyser BV develops effective software programmes for paediatricians, researchers, patients and parents to document, monitor and analyse growth and development of children and adolescents (<0-21) with ease. Growth Analyser is an initiative of the Dutch Growth Research Foundation, the expert on growth and development of children.
Insulet Corporation
600 Technology Park Drive, Suite 200
Billerica, MA 01821 USA
Website: www.myomnipod.com
Insulet Corporation is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is an easy-to-use tubeless insulin pump that features two parts and a fully-automated cannula insertion. For more information, please visit: http://www.myomnipod.com.

International Consortium of Pediatric Endocrinology (ICPE)
c/o ESPE Team Bioscientifica
Euro House, 22 Apex Court, Woodlands, Bristol BS32 4JT, UK
Phone: +44(0) 1454 642246
Fax: +44(0) 1454 642222
Email: espe@eurospe.org
Website: www.eurospe.org
ICPE was formed in 2015 to establish international priorities for pediatric endocrinology, including the organisation of future international meetings as well as the co-ordination of other international activities, such as consensus meetings, guideline development and education and training opportunities.

International Society for Pediatric and Adolescent Diabetes (ISPAD)
ISPAD Executive Office
c/o K.I.T. Group GmbH
Association & Conference Management
Kurfürstendamm 71
10709 Berlin, Germany
Phone: +49 (0)30 24603-210
Fax: +49 (0)30 24603-200
Email: secretariat@ispad.org
Website: http://www.ispad.org/
ISPAD is a professional organization whose aims are to promote clinical and basic science, research, education and advocacy in childhood and adolescent diabetes. The strength of ISPAD lies in the scientific and clinical expertise in childhood and adolescent diabetes of its members. ISPAD is the only international society focusing specifically on all types of childhood diabetes.

Ipsen Biopharmaceuticals, Inc.
106 Allen Road
Basking Ridge, NJ 07920 USA
Phone: (908)275-6300
Website: www.ipsenus.com or www.ipsen.ca
Ipsen Biopharmaceuticals, Inc. is a US affiliate of Ipsen SA, an emerging global biotech company. At Ipsen Biopharmaceuticals, we are focused on developing and providing access to therapies across our core therapeutic areas: oncology, neurology and rare diseases. For information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
**LabCorp-Endocrine Sciences**

531 South Spring Street  
Burlington, NC 27215 USA  
Phone: 800-222-7566  
Websites: www.endocrinesciences.com  
www.labcorp.com

LabCorp is a leading clinical laboratory featuring the nation's premier service for the endocrinology specialist. LabCorp's services feature regional laboratory access with specialized testing from Endocrine Sciences, part of LabCorp's specialty testing group. Endocrine Sciences can be accessed directly from Esoterix (a wholly owned subsidiary of LabCorp) or through any of LabCorp's regional facilities.

**Lilly USA, LLC**

Lilly Corporate Center  
Indianapolis, IN 46285 USA  
Phone: 317-276-2000  
Website: www.lilly.com

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.

**Merck KGaA**

Frankfurter Strasse 250  
64293 Darmstadt, Germany  
Website: www.merckgroup.com

Merck KGaA, Darmstadt, Germany is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, alongside helping patients with infertility, endocrine and metabolic disorders as well as cardiovascular diseases, to cutting-edge systems for scientific research and production, and furthermore liquid crystals for smartphones and LCD televisions. Merck KGaA, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

**Novo Nordisk**

Thurgauerstrasse 36  
Zurich CH-8050 Switzerland  
Website: www.novonordisk.com

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries.
OPKO Health

4400 Biscayne Blvd
Miami, FL 33137 USA

Website: www.opko.com

OPKO Health is a diversified healthcare company engaged in the discovery and development and delivery of new therapeutic molecules, healthcare products and services to serve physicians and patients around the world. The biologics segment of OPKO Health takes a leading role in developing next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Our development portfolio includes hGH-CTP, a once weekly human growth and a long-acting Factor VIIa drug for hemophilia as well as novel molecules in a host of therapeutic areas.

Pfizer

235 East 42nd St
New York, NY 10017 USA

Website: www.pfizer.com

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Prader-Willi Syndrome Association (USA)

8588 Potter Park Dr, Suite 500
Sarasota, Fl 34238 USA

Phone: 800-926-4797

Website: www.pwsausa.org

Prader-Willi Syndrome (PWS) is a rare chromosomal disorder with unique, complex and sometimes life-threatening medical and behavioral challenges. Medical research has transformed outcomes in this population, and we encourage professionals to contact us for information and educational materials for their patients. Our organization provides families with parent support, health care information, and resources for schools and residential providers.

Rhythm

500 Boylston St, 11th Floor
Boston, MA 02116 USA

Phone: 857-264-4280

Website: www.rhythmtx.com

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Our lead peptide product candidate, setmelanotide, is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity.
**Sandoz**  
*Kreditorenbuchhaltung*  
*Otto-von-Guericke-Alle 1*  
*Barleben D-39179 Germany*  
*Website: US doctors/delegates - www.us.sandoz.com*  
*Non-US doctors/delegates - www.sandoz.com*  
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2016 sales of USD 10.1 billion. In 2016, our products reached well over 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

**Sanofi Genzyme**  
*500 Kendall Street*  
*Cambridge, MA 02142 USA*  
*Website: www.sanofigenzyme.com*  
Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

**Sonic Bone Medical**  
*Phone: +972-505241184*  
*Email: info@sonicbonemedical.com*  
*Website: www.sonicbonemedical.com*  
- SonicBone Medical has developed and is commercializing the BAUS™ system, an innovative ultrasound device for Bone Age Assessment & Final Adult Height Prediction, used for evaluating growth, puberty & endocrine disorders in children and adolescents.  
- Clinically validated, BAUS™ aims to replace the X-ray based conventional methods (G&P, TW3) which carry many deficiencies.  
- BAUS™ carries tremendous clinical advantages and is transforming children's healthcare practice. It enables for the first time routine checkups for early detection of Growth & endocrine disorders on children.  
- Being ultrasound based and safe, no limitations on how often BAUS™ can be used for monitoring: treatment progress, effectiveness of medication and for determining the timing of cessation of medication.  
- BAUS™ is placed at doctor's office, results are digital, objective, accurate & in real-time.  
- Substantial savings to healthcare providers, great benefits to pharmaceutical companies and developing countries.

**The MAGIC Foundation**  
*4200 Cantera, Suite 106*  
*Warrnville, IL 60565 USA*  
*Phone: 1-800-3MAGIC3*  
*Website: www.magicfoundation.org*  
The MAGIC Foundation is a national non-profit organization dedicated to helping children whose physical growth is affected by a medical disorder. The main objectives of MAGIC are to provide information and emotional support to the families of afflicted children and to create public education in the area of children's growth.
Ultragenyx Pharmaceutical

Booth # 132

60 Leveroni Court
Novato, CA 94949 USA
Phone: 415-483-8800
Website: www.ultragenyx.com

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases. Ultragenyx formed a collaboration with Kyowa Hakko Kirin to jointly develop KRN23 for the treatment of X-Linked Hypophosphatemia (XLH), a rare genetic metabolic bone disease, and Tumor-Induced Osteomalacia (TIO).

Versartis, Inc

Booth # 303

1020 Marsh Road
Menlo Park, CA 94025 USA
Phone: 650-963-8580
Website: www.versartis.com

Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan, a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of GHD in children and adults. Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving adherence and, therefore, treatment outcomes.

Visiana

Booth # 611

Agern Allé 24
DK-2970 Hørsholm
Denmark
Email: thodberg@visiana.com
Phone: (+45) 2144 7087
Website: www.BoneXpert.com and www.pcpal.eu

Visiana presents the BoneXpert software for automated determination of bone age, bone health index and adult height prediction. It is currently marketed in the EU, but not yet in the USA. PC PAL is co-exhibiting and offers the GrowthXP tool to monitor growth from infancy to adulthood and the Pedigree charting software and patient registries.

The sponsoring societies of the 10th International Meeting of Pediatric Endocrinology wish to thank all of the participating exhibitors!
### Thursday 9/14/17

#### Registration Opens

<table>
<thead>
<tr>
<th>Time</th>
<th>SIG1</th>
<th>SIG2</th>
<th>SIG3</th>
<th>SIG4</th>
<th>SIG5</th>
<th>SIG6</th>
<th>SIG7</th>
<th>SIG8</th>
<th>SIG9</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:45 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:15 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:45 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15 pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Opening Ceremony

- **12:45 pm**: Marriott Ballroom
- **1:00 pm**: Marriott Ballroom
- **1:15 pm**: Marriott Ballroom

#### PL1

**1:30 pm**: ASPAE - Establishing endocrine care from scratch in developing countries by Mohamed Abdullah

**1:45 pm**: Marriott Ballroom

#### PL2

**2:00 pm**: APEG – Inflammatory environment and type 1 diabetes by Jennifer Couper

**2:15 pm**: Marriott Ballroom
**2:30 pm**: Marriott Ballroom
**2:45 pm**: Marriott Ballroom

#### S

**2:45 pm**: Marriott Ballroom
**3:00 pm**: Marriott Ballroom
**3:15 pm**: Marriott Ballroom
**3:30 pm**: Marriott Ballroom
**3:45 pm**: Marriott Ballroom

#### P1 and Exhibits

- **4:00 pm**: Marriott Ballroom
- **4:15 pm**: Marriott Ballroom
- **4:30 pm**: Marriott Ballroom
- **4:45 pm**: Marriott Ballroom
- **5:00 pm**: Marriott Ballroom
- **5:15 pm**: Marriott Ballroom
- **5:30 pm**: Marriott Ballroom
- **5:45 pm**: Marriott Ballroom
- **6:00 pm**: Marriott Ballroom
- **6:15 pm**: Marriott Ballroom
- **6:30 pm**: Marriott Ballroom
- **6:45 pm**: Marriott Ballroom
- **7:00 pm**: Marriott Ballroom
- **7:15 pm**: Marriott Ballroom
- **7:30 pm**: Marriott Ballroom
- **7:45 pm**: Marriott Ballroom
- **8:00 pm**: Marriott Ballroom
- **8:15 pm**: Marriott Ballroom

#### PES Memorial for Colleagues - open to all

- **8:15 pm**: Maryland A

---

**SIG1**: Diabetes Technology SIG
- **Thurgood Marshall NE**
- **Virginia**
- **Maryland BC**

**SIG2**: Pediatric Adolescent Gynecology SIG
- **Thurgood Marshall SW**
- **Washington 1-3**

**SIG3**: Obesity SIG
- **Maryland BC**

**SIG4**: Bone and Growth SIG
- **Thurgood Marshall NE**
- **Washington 4-6**
- **Madison**
- **Delaware**
- **Maryland A**

**SIG5**: Turner Syndrome SIG
- **Washington 4-6**
- **Madison**

**SIG6**: Gender Dysphoria SIG
- **Washington 4-6**

**SIG7**: Global Pediatric Endocrinology and Diabetes SIG
- **Washington 4-6**

**SIG8**: Allied Health SIG
- **Washington 4-6**

**SIG9**: Disorders of Sex Development SIG
- **Washington 4-6**

## Scientific Program

### Thursday, September 14

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Registration Opens (Lobby Level)</td>
</tr>
<tr>
<td>8:30 am - 11:30 am</td>
<td><strong>Special Interest/Working Group (SIG1)</strong></td>
</tr>
</tbody>
</table>

**Session Title:** Diabeties Technology  
**Room:** Thurgood Marshall NE  
**Overall Chairs:** Moshe Phillip, Israel; Joe Wolfsdorf, United States; Tsauhiko Urakami, Japan

**DIGITAL CLINIC**

- **Current State of T1D Care**
  - David Maahs, United States
- **Nemours Children’s Health System, Division of Endocrinology - Our experience with Continuous Glucose Monitors (CGM)**
  - Larry Fox, United States
- **Experience with insulin pumps 670G and the development of 690G**
  - Stuart Weinzimer, United States
- **How to measure outcomes of digital clinics?**
  - Thomas Danne, Germany
- **Tailoring the technology to Diabetes Mellitus Patients at home**
  - Roman Hovorka, United Kingdom
- **Decision Support Systems: Physician advisor/patient advisor**
  - Tadej Battelino, Slovenia
- **Debate: Can digital health replace the HCP?**
  - Pro - Revital Nimri, Israel  
  - Con - Fergus Cameron, Australia
<table>
<thead>
<tr>
<th>Time</th>
<th>Special Interest/Working Group (SIG2)</th>
</tr>
</thead>
</table>
| 8:30 am - 11:30 am | **Session Title:** Pediatric adolescent gynecology  
|               | **Room:** Virginia  
|               | **Chairpersons:** Catherine Gordon, United States & Lourdes Ibáñez, Spain  
|               | **FIRST SESSION: PCOS: Update on genetics & treatment**  
|               | Genomics in the diagnosis and management of PCOS  
|               | Richard Legro, United States  
|               | Treatment of PCOS in obese adolescents  
|               | Thomas Reinehr, Germany  
|               | PCOS. To treat or not to treat  
|               | Sharon Oberfield, United States  
|               | **SECOND SESSION: Puberty in Rare Diseases**  
|               | **Chairpersons:** Anders Juul, Denmark & Anne-Sophie Parent, Belgium  
|               | Genomics  
|               | Nicolas de Roux, France  
|               | Clinical outcome  
|               | Marco Cappa, Italy |

<table>
<thead>
<tr>
<th>Time</th>
<th>Special Interest/Working Group (SIG3)</th>
</tr>
</thead>
</table>
| 8:30 am - 11:30 am | **Session Title:** Obesity  
|               | **Room:** Maryland BC  
|               | **Overall Chairs:** Jesús Argente, Spain; Ellen Connor, United States; Shigetaka Sugihara, Japan  
|               | Novel genetic mutations in pediatric obesity  
|               | Sadaf Farooqi, United Kingdom  
|               | Update on medications in the treatment of pediatric obesity  
|               | Jennifer Miller, United States  
|               | Progress in personalized medicine in the treatment of obesity  
|               | Peter Kühlken, Germany |

<table>
<thead>
<tr>
<th>Time</th>
<th>Special Interest/Working Group (SIG4)</th>
</tr>
</thead>
</table>
| 8:30 am - 11:30 am | **Session Title:** Bone and growth  
|               | **Room:** Thurgood Marshall SW  
|               | **Overall Chairs:** Ola Nilsson, Sweden; Leanne Ward, Canada; Noriyulki Namba, Japan  
<p>|               | On behalf of the organizing committee, we are delighted to invite you to attend the annual Bone and Growth Special Interest/Working Group Meeting as part of the 10th International Meeting of Pediatric Endocrinology. The working group will be comprised of two parts: presentations by an international panel of experts who will speak on a variety of topical issues, as well as novel case or original research oral presentations by meeting attendees. |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Special Interest/Working Group (SIG5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Session Title:</td>
<td>Turner Syndrome</td>
</tr>
<tr>
<td>Room:</td>
<td>Washington 1-3</td>
</tr>
<tr>
<td>Overall Chairs:</td>
<td>Janielle van Alfen-vanderVelden, Netherlands &amp; Philippe Backeljauw, United States</td>
</tr>
<tr>
<td>Sub-Chairs:</td>
<td>Aneta Gawlik, Poland &amp; Philippe Backeljauw, United States</td>
</tr>
<tr>
<td>8:30-8:35:</td>
<td>Welcome and Introduction (both chairs)</td>
</tr>
<tr>
<td>8:35-10:05:</td>
<td>Session 1.</td>
</tr>
<tr>
<td>8:35-9:05:</td>
<td>Genetics in TS/Newborn screening</td>
</tr>
<tr>
<td>9:05-9:35:</td>
<td>Cardiovascular co-morbidities/Sports/CVS recommendations</td>
</tr>
<tr>
<td>9:35-10:05:</td>
<td>Transition/Recommendations for management in adulthood</td>
</tr>
<tr>
<td>10:05-10:25:</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>Session Title:</td>
<td>Gender Dysphoria</td>
</tr>
<tr>
<td>Room:</td>
<td>Washington 4-6</td>
</tr>
<tr>
<td>Overall Chairs:</td>
<td>Sabine Hanna, Netherlands &amp; Jerry Olshan, United States</td>
</tr>
<tr>
<td>Sub-Chairs:</td>
<td>Patricia Fechner, United States &amp; J van Alfen-vanderVelden, Netherlands</td>
</tr>
<tr>
<td>8:30 am - 11:30 am</td>
<td>Special Interest/Working Group (SIG6)</td>
</tr>
<tr>
<td>The updated Endocrine Society guideline</td>
<td>Stephen Rosenthal, United States &amp; Sabine Hannema, Netherlands</td>
</tr>
<tr>
<td>Developmental aspects of gender identity</td>
<td>Peggy Cohen-Kettenis, Netherlands &amp; S.F. Leibowitz</td>
</tr>
<tr>
<td>Bone health and growth: have we found the optimal treatment regimens?</td>
<td>Daniel Tatting Klink, Belgium</td>
</tr>
<tr>
<td>A review of current practices in European gender clinics</td>
<td>N. Skordis</td>
</tr>
<tr>
<td>Business meeting - towards joint research activities and an international database</td>
<td></td>
</tr>
</tbody>
</table>
### Special Interest/Working Group (SIG7)

**Session Title:** Global pediatric endocrinology and diabetes  
**Room:** Madison  
**Chair:** Jean-Pierre Chanoine, Canada

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30-8:35</td>
<td>Introduction</td>
<td>Jean-Pierre Chanoine, Canada</td>
</tr>
<tr>
<td>8:35-9:10</td>
<td>Theme 1: Access to medicines in pediatric endocrinology and diabetes</td>
<td>Joel Dipesalema, Botswana</td>
</tr>
<tr>
<td>9:10-9:30</td>
<td>Non-communicable diseases in children and adolescents and access to medicines</td>
<td>Jonathan D. Klein, United States</td>
</tr>
<tr>
<td>9:30-9:50</td>
<td>Management of congenital adrenal hyperplasia in Sudanese children: barriers and opportunities</td>
<td>Mohamed Abdullah, Sudan</td>
</tr>
<tr>
<td>9:50-10:05</td>
<td>Understanding access to medicines for the management of CAH in resources-limited settings: preliminary data of a global survey</td>
<td>Jean-Pierre Chanoine, Canada</td>
</tr>
<tr>
<td>10:05-10:40</td>
<td>Theme 2: Newborn screening in low income settings</td>
<td>Maynika Rastogi, United States</td>
</tr>
<tr>
<td>10:40-11:15</td>
<td>Eradicating iodine deficiency, a prerequisite to newborn screening for congenital hypothyroidism</td>
<td>Elizabeth Pearce, United States</td>
</tr>
<tr>
<td>11:15-11:30</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Special Interest/Working Group (SIG8)

**Session Title:** Allied health  
**Room:** Delaware  
**Moderators:** Kate Davies, United Kingdom, Andrew Dwyer, Switzerland/United States, Nicole Kirouac, Canada

This will be an interactive, case-based program with international participants sharing resources & best practices for therapeutic education in pediatric endocrinology. Key Concepts:  
1) Therapeutic education across development  
2) Patient Activation and Promoting Adherence  
3) Cultural Competence

ESPE Nurses Business Meeting will follow the session.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Room</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 am</td>
<td><strong>Special Interest/Working Group (SIG9)</strong></td>
<td>Maryland A</td>
<td>Christa E. Flück, Switzerland; Reiko Horikawa, Japan; Anna Nordenström, Sweden; Peter Lee, United States</td>
</tr>
<tr>
<td>8:30-8:35</td>
<td>Introduction/Overview</td>
<td></td>
<td>Christopher P. Houk, United States</td>
</tr>
<tr>
<td>8:35-9:00</td>
<td>Shifts in approach to DSD beginning before the consensus conference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00-9:30</td>
<td>Results from the EU-study dsd-LIFE: Participants’ experiences with care and ethical issues</td>
<td></td>
<td>Birgit Köhler, Germany</td>
</tr>
<tr>
<td>9:30-9:45</td>
<td>The COST Action DSDnet &amp; European Reference Networks (ERNs)</td>
<td></td>
<td>Olaf Hiort, Germany</td>
</tr>
<tr>
<td>9:45-10:00</td>
<td>The I-DSD &amp; I-CAH Registries — a paradigm for research, benchmarking and improving clinical care of rare endocrine conditions</td>
<td></td>
<td>S. Faisal Ahmed, United Kingdom</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30-10:40</td>
<td>Short-term outcomes for children born with ambiguous genitalia</td>
<td></td>
<td>Amy Wisniewski, United States</td>
</tr>
<tr>
<td>10:40-10:50</td>
<td>Disorders/Differences of sex development — translational research network (DSD-TRN)</td>
<td></td>
<td>David E. Sandberg, United States</td>
</tr>
<tr>
<td>10:50-11:00</td>
<td>Exome sequencing in disorders of sex development: impact on patients and families</td>
<td></td>
<td>Yee-Ming Chan, United States</td>
</tr>
<tr>
<td>11:00-11:10</td>
<td>Factors influencing psychosocial outcomes in disorders of sex development</td>
<td></td>
<td>Leena Nahata, United States &amp; Amy Tishelman, United States</td>
</tr>
<tr>
<td>11:10-11:20</td>
<td>Development of an internet-delivered illness uncertainty interventions for caregivers of children with a disorder of sex development or congenital adrenal hyperplasia: a multi-center collaboration</td>
<td></td>
<td>Cortney Wolfe Christensen, United States</td>
</tr>
<tr>
<td>11:20-11:30</td>
<td>Conclusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Room</td>
<td>Speaker</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------------------------------------</td>
<td>---------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>12:45 pm - 1:15 pm</td>
<td>Opening Ceremony</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:15 pm - 1:45 pm</td>
<td>Plenary Session 1 (PL1)</td>
<td>Marriott Ballroom</td>
<td>David Allen, United States; President, 10th International Meeting of Pediatric Endocrinology</td>
</tr>
<tr>
<td>1:45 pm - 2:15 pm</td>
<td>Plenary Session 2 (PL2)</td>
<td>Marriott Ballroom</td>
<td>Mohamed Abdullah, Sudan</td>
</tr>
<tr>
<td>2:30 pm - 4:00 pm</td>
<td>Topic Symposium (S)</td>
<td>Washington 4-6</td>
<td>Pik To Cheung, Hong Kong &amp; Leanne Ward, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Somatic mutations that cause skeletal disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Matt Warman, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Genotype-phenotype correlation in skeletal dysplasias</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Outi Mäkitie, Finland</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Manipulation of bone anabolism and catabolism</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Aaron Schindeler, Australia</td>
</tr>
<tr>
<td>2:30 pm - 4:00 pm</td>
<td>Controversy (CPE1)</td>
<td>Marriott Ballroom</td>
<td>Sally Radovich, United States &amp; Chris Romera, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Proposition: Metformin is used as a treatment for obesity.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Is it justified?</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PRO: Shubha Srinivasan, Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CON: Billy White, United Kingdom</td>
</tr>
</tbody>
</table>
**Thursday, Sept 14**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Room</th>
<th>Moderators</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:30 pm - 4:00 pm</td>
<td><strong>Topic Symposium (S)</strong></td>
<td>Delaware</td>
<td>Tom Ogata, Japan &amp; Asma Deeb, United Arab Emirates</td>
</tr>
<tr>
<td></td>
<td><strong>Renal and endocrine electrolyte disorders</strong></td>
<td>Delaware</td>
<td>Tom Ogata, Japan &amp; Asma Deeb, United Arab Emirates</td>
</tr>
<tr>
<td></td>
<td><strong>Bartter and Gitelman syndromes</strong></td>
<td>Delaware</td>
<td>Detlef Bockenhauer, United Kingdom</td>
</tr>
<tr>
<td></td>
<td><strong>Pseudohypoaldosteronism</strong></td>
<td>Delaware</td>
<td>Eisei Sohara, Japan</td>
</tr>
<tr>
<td></td>
<td><strong>Familial hyperaldosteronism</strong></td>
<td>Delaware</td>
<td>Evangelia Charmandari, Greece</td>
</tr>
<tr>
<td>2:30 pm - 4:00 pm</td>
<td><strong>Topic Symposium (S)</strong></td>
<td>Virginia</td>
<td>Esko Wiltshire, New Zealand &amp; Joseph Wolfsdorf, United States</td>
</tr>
<tr>
<td></td>
<td>*<em>Diabetes and the brain <em>co-sponsored by ISPAD</em></em></td>
<td>Virginia</td>
<td>Esko Wiltshire, New Zealand &amp; Joseph Wolfsdorf, United States</td>
</tr>
<tr>
<td></td>
<td><strong>Aspects of diabetic dysglycemia that are the most injurious to the developing brain</strong></td>
<td>Virginia</td>
<td>Fergus Cameron, Australia</td>
</tr>
<tr>
<td></td>
<td><strong>Changes in affect, behavior and cognition related to type 1 diabetes</strong></td>
<td>Virginia</td>
<td>Tamara Hershey, United States</td>
</tr>
<tr>
<td></td>
<td><strong>Morphological, spectroscopic and functional brain changes in type 1 diabetes</strong></td>
<td>Virginia</td>
<td>Allan Reiss, United States</td>
</tr>
<tr>
<td>2:30 pm - 4:00 pm</td>
<td><strong>Topic Symposium (S)</strong></td>
<td>Maryland</td>
<td>Rodolfo Rey, Argentina &amp; Warren Lee, Singapore</td>
</tr>
<tr>
<td></td>
<td><strong>Endocrine complications of childhood cancer and its treatment</strong></td>
<td>Maryland</td>
<td>Rodolfo Rey, Argentina &amp; Warren Lee, Singapore</td>
</tr>
<tr>
<td></td>
<td><strong>Management of endocrine late effects including fertility preservation</strong></td>
<td>Maryland</td>
<td>Yoko Miyoshi, Japan</td>
</tr>
<tr>
<td></td>
<td><strong>Central precocious puberty caused by Bbain tumors and radiotherapy</strong></td>
<td>Maryland</td>
<td>Wassim Chemaitilly, United States</td>
</tr>
<tr>
<td></td>
<td><strong>Bone health in childhood cancer survivors</strong></td>
<td>Maryland</td>
<td>Sogol Mostoufi-Moab, United States</td>
</tr>
</tbody>
</table>
### 2:30 pm - 4:00 pm  
**Topic Symposium (S)**

**Session Title:** New insights in DSD  
**Room:** Thurgood Marshall  
**Moderators:** Reiko Horikawa, Japan & Nils Krone, United Kingdom  
**DSD insights from targeted gene sequencing of a large international patient cohort**  
*Andrew Sinclair, Australia*

**Evaluation of the infant or adolescent with a suspected disorder of sexual development**  
*Syed Faisal Ahmed, United Kingdom*

**Genetic testing strategy for 46,XY DSD diagnosis**  
*Chunxiu Gong, China*

### 4:15 pm - 5:45 pm  
**IMPE Satellite Symposium (SAT)**

**Session Title:** Personalized approach in diagnosis and management of short stature  
**Room:** Thurgood Marshall  
**Sponsor:** Merck KGaA, Germany  
*NOT INTENDED FOR US AUDIENCE*

**Session Title:** Improving care for patients with Turner Syndrome  
**Room:** Marriott Ballroom  
**Sponsor:** American Academy of CME, Inc. and Scherer Clinical Communications (Under an educational grant from Novo Nordisk Inc.)

**Session Title:** Understanding short stature beyond the GH-IGF axis  
**Room:** Washington 1-3  
**Sponsor:** Sandoz

**Session Title:** Pediatric growth hormone deficiency: Management of the transition from pediatric to adult care  
**Room:** Washington 4-6  
**Sponsor:** Ferring Pharmaceuticals

### 5:45 pm - 6:45 pm  
**Poster Session (P1)**

**Session Title:** Poster Session #1 and Exhibits  
**Room:** Exhibition Hall  
For further details, see page 79.

### 6:45 pm - 8:00 pm  
**Welcome Reception**  
**Room:** Exhibition Hall

### 8:00 pm - 9:00 pm  
**PES Memorial for colleagues (all are welcome)**  
**Room:** Maryland
## Daily Program

### Friday 9/15/17

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Speakers/Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Registration Opens</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 am</td>
<td><strong>MTE1:1</strong> Diagnosis and management of pseudo-hypoparathyroidism and related conditions</td>
<td>Marriott Ballroom</td>
<td>Washington 4-6, Marriott Marshall NE, Marriott Marshall SW</td>
</tr>
<tr>
<td>7:45 am</td>
<td><strong>MTE2:1</strong> Distinguishing monogenic forms from type 1 and type 2 diabetes: Does your patient have the right diagnosis?</td>
<td>Marriott Ballroom</td>
<td>Washington 4-6, Marriott Marshall NE, Marriott Marshall SW</td>
</tr>
<tr>
<td>8:00 am</td>
<td><strong>MTE3:1</strong> PWS from birth to adulthood</td>
<td>Marriott Ballroom</td>
<td>Thurgood Marshall NE</td>
</tr>
<tr>
<td>8:15 am</td>
<td><strong>MTE4:1</strong> Pediatric cortical adrenal tumors</td>
<td>Marriott Ballroom</td>
<td>Thurgood Marshall SW</td>
</tr>
<tr>
<td>8:30 am</td>
<td><strong>FC1–FC5</strong> Growth and GH/IGF Axis #1</td>
<td>Marriott Ballroom</td>
<td>Virginia, Maryland, Delaware</td>
</tr>
<tr>
<td>8:45 am</td>
<td><strong>FC6–FC10</strong> Bone and mineral metabolism #1</td>
<td>Marriott Ballroom</td>
<td>Virginia, Maryland, Delaware</td>
</tr>
<tr>
<td>9:00 am</td>
<td><strong>FC11–FC15</strong> Bone and mineral metabolism #1</td>
<td>Marriott Ballroom</td>
<td>Virginia, Maryland, Delaware</td>
</tr>
<tr>
<td>9:15 am</td>
<td><strong>NP1</strong> New manipulations of mutant CaSR pathways; and Cartilage natriuretic peptide</td>
<td>Marriott Ballroom</td>
<td>Washington 4-6, Marriott Marshall NE, Marriott Marshall SW</td>
</tr>
<tr>
<td>9:30 am</td>
<td><strong>MTE5:1</strong> Delayed puberty: Causes, evaluation, and management</td>
<td>Marriott Ballroom</td>
<td>Thurgood Marshall SW</td>
</tr>
<tr>
<td>9:45 am</td>
<td><strong>MTE6:1</strong> Pediatric pheochromocytoma/paraganglioma</td>
<td>Marriott Ballroom</td>
<td>Thurgood Marshall SW</td>
</tr>
<tr>
<td>10:00 am</td>
<td><strong>MTE7:1</strong> Pediatric osteoporosis</td>
<td>Marriott Ballroom</td>
<td>Thurgood Marshall NE</td>
</tr>
<tr>
<td>10:15 am</td>
<td><strong>FC16–FC20</strong> Sex differentiation/gonads and disorders of sex development</td>
<td>Marriott Ballroom</td>
<td>Maryland, Virginia, Delaware</td>
</tr>
<tr>
<td>10:30 am</td>
<td><strong>FC21–FC25</strong> Type 2 diabetes and other carbohydrate metabolism #1</td>
<td>Marriott Ballroom</td>
<td>Maryland, Virginia, Delaware</td>
</tr>
<tr>
<td>10:45 am</td>
<td><strong>FC26–FC30</strong> Global health</td>
<td>Marriott Ballroom</td>
<td>Maryland</td>
</tr>
<tr>
<td>11:00 am</td>
<td><strong>PL3</strong> APPES – Prenatal environment and medical consequences by Paul Hofman</td>
<td>Marriott Ballroom</td>
<td></td>
</tr>
<tr>
<td>11:15 am</td>
<td><strong>PL4</strong> PES Lawson Wilkins Lecture – Metabolic pathway disruption leading to Type 2 DM by Mitchell Lazar</td>
<td>Marriott Ballroom</td>
<td></td>
</tr>
<tr>
<td>11:30 am</td>
<td><strong>P2 and Box Lunches</strong></td>
<td>Exhibition Hall</td>
<td></td>
</tr>
<tr>
<td>11:45 am</td>
<td><strong>S</strong> New concepts in diagnosis and treatment of CAH</td>
<td>Marriott Ballroom</td>
<td>Virginia</td>
</tr>
<tr>
<td>12:00 pm</td>
<td><strong>S</strong> Diabetes management of children in resource-limited settings</td>
<td>Marriott Ballroom</td>
<td>Washington 4-6, Thurgood Marshall NE</td>
</tr>
<tr>
<td>12:15 pm</td>
<td><strong>CPE1</strong> Aromatase inhibition</td>
<td>Marriott Ballroom</td>
<td>Virginia</td>
</tr>
<tr>
<td>12:30 pm</td>
<td><strong>S</strong> Growth hormone safety</td>
<td>Marriott Ballroom</td>
<td>Thurgood Marshall NE</td>
</tr>
<tr>
<td>12:45 pm</td>
<td><strong>S</strong> Metabolic syndrome in early childhood</td>
<td>Marriott Ballroom</td>
<td>Thurgood Marshall SW</td>
</tr>
<tr>
<td>1:00 pm</td>
<td><strong>S</strong> Puberty and ovarian disorders</td>
<td>Marriott Ballroom</td>
<td>Maryland</td>
</tr>
<tr>
<td>1:15 pm</td>
<td><strong>FC31–FC35</strong> Bone and mineral metabolism #2</td>
<td>Marriott Ballroom</td>
<td>Washington 4-6, Marriott Marshall NE</td>
</tr>
<tr>
<td>1:30 pm</td>
<td><strong>FC36–FC40</strong> Type 1 Diabetes #1</td>
<td>Marriott Ballroom</td>
<td>Thurgood Marshall NE</td>
</tr>
<tr>
<td>1:45 pm</td>
<td><strong>FC41–FC45</strong> Gender dysphoria</td>
<td>Thurgood Marshall NE</td>
<td></td>
</tr>
<tr>
<td>2:00 pm</td>
<td><strong>FC46–FC50</strong> Obesity, lipids, and co-morbidities #1</td>
<td>Thurgood Marshall SW</td>
<td></td>
</tr>
<tr>
<td>2:15 pm</td>
<td><strong>S</strong> Perspectives on growth and growth disorders</td>
<td>Marriott Ballroom</td>
<td>Virginia</td>
</tr>
<tr>
<td>2:30 pm</td>
<td><strong>S</strong> New therapeutic options for treating genetic obesity</td>
<td>Marriott Ballroom</td>
<td>Thurgood Marshall SW</td>
</tr>
<tr>
<td>2:45 pm</td>
<td><strong>S</strong> The evolving portrait of X-linked hypophosphatemia</td>
<td>Marriott Ballroom</td>
<td>Washington 1-3</td>
</tr>
<tr>
<td>3:00 pm</td>
<td><strong>S</strong> The evolving portrait of X-linked hypophosphatemia</td>
<td>Marriott Ballroom</td>
<td>Washington 1-3</td>
</tr>
<tr>
<td>3:15 pm</td>
<td><strong>S</strong> Perspectives on growth and growth disorders</td>
<td>Marriott Ballroom</td>
<td>Virginia</td>
</tr>
<tr>
<td>3:30 pm</td>
<td><strong>S</strong> New therapeutic options for treating genetic obesity</td>
<td>Marriott Ballroom</td>
<td>Thurgood Marshall SW</td>
</tr>
<tr>
<td>3:45 pm</td>
<td><strong>S</strong> The evolving portrait of X-linked hypophosphatemia</td>
<td>Marriott Ballroom</td>
<td>Washington 1-3</td>
</tr>
</tbody>
</table>

### refreshments

- **Refreshment Break, Poster Viewing and Exhibits**
  - **PL3** APPES – Prenatal environment and medical consequences by Paul Hofman
  - **PL4** PES Lawson Wilkins Lecture – Metabolic pathway disruption leading to Type 2 DM by Mitchell Lazar

### Lunches

- **PES Mentor/Mentee Workshop**
  - **PL3** APPES – Prenatal environment and medical consequences by Paul Hofman
  - **PL4** PES Lawson Wilkins Lecture – Metabolic pathway disruption leading to Type 2 DM by Mitchell Lazar

### Business Meetings

- **Business Mtg**
  - **PES**
    - Marriott Ballroom
  - **SLEP**
    - Marriott Ballroom
  - **ESPE**
    - Thurgood Marshall NE

### SAT

- **SAT**
  - Perspectives on growth and growth disorders
    - Marriott Ballroom
  - New therapeutic options for treating genetic obesity
    - Thurgood Marshall SW
  - The evolving portrait of X-linked hypophosphatemia
    - Washington 1-3

### MOC Session

- **MOC Session**
  - Thurgood Marshall NE
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Session Title</th>
<th>Room</th>
<th>Expert</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Registration Opens (Lobby Level)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 am – 8:30 am</td>
<td><strong>Meet the Expert (MTE1:1)</strong></td>
<td><em>Diagnosis and management of pseudohypoparathyroidism and related conditions</em></td>
<td>Marriott Ballroom</td>
<td>Emily Germain-Lee, United States</td>
</tr>
<tr>
<td>7:30 am – 8:30 am</td>
<td><strong>Meet the Expert (MTE2:1)</strong></td>
<td><em>Distinguishing monogenic forms from type 1 and type 2 diabetes: Does your patient have the right diagnosis?</em></td>
<td>Washington 4-6</td>
<td>Siri Atma Greeley, United States</td>
</tr>
<tr>
<td>7:30 am – 8:30 am</td>
<td><strong>Meet the Expert (MTE3:1)</strong></td>
<td><em>PWS from birth to adulthood</em></td>
<td>Thurgood Marshall NE</td>
<td>Jennifer Miller, United States</td>
</tr>
<tr>
<td>7:30 am – 8:30 am</td>
<td><strong>Meet the Expert (MTE4:1)</strong></td>
<td><em>Pediatric cortical adrenal tumors</em></td>
<td>Thurgood Marshall SW</td>
<td>Margaret de Castro, Brazil</td>
</tr>
</tbody>
</table>
Session Title: Growth and GH/IGF Axis #1
Room: Virginia

FC1
PAPPA2 P.ALA1034VAL KNOCK-IN MOUSE MODEL RECAPITULATES HOMOZYGOUS HUMAN PAPPA2 MUTATION ASSOCIATED WITH SHORT STATURE
Andrew Dauber, MD; Melissa Andrew, BS/BA; Lihong Liao, MD; Vivian Hwa, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States

FC2
GENETIC SCREENING OF PATIENTS WITH CONGENITAL GH DEFICIENCY IN THE GENESIS OBSERVATIONAL PROGRAM: MUTATION FREQUENCY, PHENOTYPE AND GROWTH OUTCOMES
Roland W Pfäffle, MD; Jürgen Klammert, PhD; Heike M Pfäffle, MTA, University of Leipzig, Leipzig, Germany; Serge Amselem, MD, Hôpital d'Enfants Armand-Trousseau , Paris, France; Marie Legendre, PhD, Hôpital Trousseau , Paris, France; Marie-Laure Sobrier, PhD, Inserm US013 , Paris, France; Christopher J Child, PhD; Christine Jones, PhD; Alan G Zimmermann, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Werner F Blum, MD, University of Giessen, Giessen, Germany

FC3
MECHANISMS OF FIBROBLAST GROWTH FACTOR 21 (FGF21) MEDIATED GROWTH HORMONE RESISTANCE IN HUMAN GROWTH PLATE IN CHRONIC CHILDHOOD CONDITIONS
Jayna N Mistry, MRes; Gerard Ruiz-Babot, PhD, Queen Mary University of London, London, United Kingdom; Farasat Zaman, PhD, Karolinska Institutet, Stockholm, Sweden; Lars Sävendahl, MD, PhD, Karolinska University Hospital, Stockholm, Sweden; Leonardo Guasti, PhD; Leo Dunkel, MD, PhD, Queen Mary University of London, London, United Kingdom

FC4
REGULATION OF GROWTH PLATE CHONDROCYTE DIFFERENTIATION BY SPECIFIC MICRORNAS
Youn Hee Jee, MD; Jinhee Wang, PhD; Melissa Jennings, Post-bac, NICHD/NIH, Bethesda, MD, United States; Ola Nilsson, Professor, Karolinska Institutet and University Hospital, Stockholm, Sweden; Julian C. Lui, PhD; Jeffrey Baron, MD, NICHD/NIH, Bethesda, MD, United States

FC5
RESPONSE TO RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 AFTER TWO YEARS OF THERAPY IN TWO PATIENTS WITH PAPP-A2 DEFICIENCY
Maria T Muñoz-Calvo, MD, Hospital Infantil Universitario Niño Jesús/Universidad Autónoma de Madrid, Madrid, Spain; Vicente Barrios, PhD, Hospital Infantil Universitario Niño Jesús, CIBEROBN, Madrid, Spain; Jesus Poza, MD, Hospital Infantil Universitario Niño Jesús/Universidad Autónoma de Madrid, Madrid, Spain; Gabriel Á. Martos-Moreno, MD; PhD., Hospital Infantil Universitario Niño Jesús. UAM , Madrid, Spain; Federico Hawkins, MD; PhD, Hospital 12 de Octubre/Universidad Complutense, Madrid, Spain; Julie A Chowen, PhD, Hospital Infantil Universitario Niño Jesús, CIBEROBN, Madrid, Spain; Luis A Perez-Jurado, MD, Universidad Pompeu Fabra, Barcelona, Spain; Claus Ovrig, PhD, Aarhus University, Aarhus, Denmark; Jan Frystyk, MD, Aarhus University Hospital, Aarhus, Denmark; Jesús Argente, MD, PhD, Hospital Infantil Universitario Niño Jesús. UAM, Madrid, Spain
Session Title: Syndromes
Room: Maryland

FC6
IDENTIFICATION OF SMCHD1 MUTATIONS IN A SEVERE FORM OF KALLMANN SYNDROME (KS) WITH ABSENCE OF THE NOSE (ARHINIA) ATTESTS TO THE POWER OF EXTREME PHENOTYPES IN HUMAN REPRODUCTIVE GENE DISCOVERY

Natalie D Shaw, MD, National Institute of Environmental Health Sciences, Durham, NC, United States; Harrison Brand, PhD, Massachusetts General Hospital, Boston, MA, United States; Zachary A Kupchinsky, PhD, Duke University Medical Center, Durham, NC, United States; Hemant Bengani, PhD, Institute of Genetics and Molecular Medicine, University of Edinburgh Western General Hospital, Edinburgh, United Kingdom; Lacey Plummer, BS/BA, Reproductive Endocrine Unit of the Department of Medicine, Massachusetts General Hospital, Boston, MA, United States; Takako I Jones, PhD, University of Massachusetts, Worcester, MA, United States; Serkan Erdin, PhD, Massachusetts General Hospital, Boston, MA, United States; Kathleen A Williamson, MD, Institute of Genetics and Molecular Medicine, University of Edinburgh Western General Hospital, Edinburgh, United Kingdom; Joe Rainger, PhD, Institute of Genetics and Molecular Medicine, University of Edinburgh Western General Hospital, Edinburgh, United Kingdom; Alexei Storchoev, PhD, Massachusetts General Hospital, Boston, MA, United States; Kaitlin Samocha, PhD, Broad Institute of MIT and Harvard, Cambridge, MA, United States; Benjamin B Curroll, PhD, Massachusetts General Hospital, Boston, MA, United States; Donncha S Dunican, MD, Institute of Genetics and Molecular Medicine, University of Edinburgh Western General Hospital, Edinburgh, United Kingdom; Ryan L Collins, PhD, Massachusetts General Hospital, Boston, MA, United States; Jason R Willer, PhD, Duke University Medical Center, Durham, NC, United States; Angela Lek, PhD, Harvard Medical School, Boston, MA, United States; Mallik Nassan, MD, Mayo Clinic, Rochester, MN, United States; Shahrin Pereira, BS/BA; Tammy Kammin, MS/MA, Brigham and Women's Hospital, Boston, MA, United States; Diane Lucente, MS/MA; Alexandra Silva, BS/BA; Catarina M Seabra, BS/BA; Colby Chiang, PhD; Yu An, PhD, Massachusetts General Hospital, Boston, MA, United States; Morad Ansari, PhD, University of Edinburgh Western General Hospital, Edinburgh, United Kingdom; Jacqueline K Rainger, PhD, Institute of Genetics and Molecular Medicine, University of Edinburgh Western General Hospital, Edinburgh, United Kingdom; Shelaq Joss, PhD, South Glasgow University Hospitals, Glasgow, United Kingdom; Jill Clayton Smith, MD, Institute of Human Development, Manchester Centre for Genomic Medicine, University of Manchester, Manchester Academic Health Science Centre (MAHSC), Manchester, United Kingdom; Margaret F Lippincott, MD; Syliva S Singh, MD; Nirav Patel, BS/BA; Jenny W Jing, BS/BA, Massachusetts General Hospital, Boston, MA, United States; Jennifer R Law, MD, University of North Carolina, Chapel Hill, NC, United States; Nalton Ferrara, MD, Boston Children's Hospital, Boston, MA, United States; Alain Verloes, MD, Robert Debre Hospital, Paris, France; Anita Rauch, MD, University of Zurich, Schlieren-Zurich, Switzerland; Katharina Steindl, MD; Markus Zweier, MD, University of Zurich, Schlieren-Zurich, Switzerland; Ianina Scheer, MD, Children's Hospital, Zurich, Switzerland; Daiiseke Sato, MD, Hokkaido University Graduate School of Medicine, Sapporo, Japan; Nobuhiko Okamoto, MD, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan; Christina Jacobsen, MD, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States; Jeanine Tryggestad, MD, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Steven D. Chernausek, MD, University of Oklahoma Health Science Center, Oklahoma City, OK, United States; Lisa A Schimmenti, MD, Mayo Clinic, Rochester, MN, United States; Benjamin Brasseur, MD, University of Miami Leonard M. Miller School of Medicine, Miami, FL, United States; Claudia Cesaretti, MD, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Milan, Italy; Jose E Garcia-Ortiz, MD, Instituto Mexicano del Seguro Social, Guadalajara, Mexico; Tatiana Pineda Buitrago, MS/MA, Universitario de San Jose, Bogota, Colombia; Orlando Perez Silva, MD, de Medicina de Colombia, Bogota, Colombia; Ijadi D Hoffman, MD, Tufts Medical Center, Boston, MA, United States; Deanna Colacino, MD, ATSOKIN, Munich, Germany; Klaus W Ruprecht, MD, University Hospital of the Saarland, Homburg, Germany; Bart L Loey, MD, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium; Masato Shino, MD, Gunma University Graduate School of Medicine, Gunma, Japan; Angela M Kaindl, MD, Charite-University Medicine Berlin and Berlin Institute of Health, Berlin, Germany; Ravikumar Balasubramanian, MD; Janet E Hall, MD; Stephanie B Seminara, MD, Massachusetts General Hospital, Boston, MA, United States; Daniel Macarthur, PhD, Broad Institute of MIT and Harvard, Cambridge, MA, United States; Steven A Moore, MD, University of Iowa Carver College of Medicine, Iowa City, IA, United States; Koh-Ichiyo Yoshihara, MD, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; James F Gussella, MD, Massachusetts General Hospital, Boston, MA, United States; Joseph A Marsh, PhD, University of Edinburgh Western General Hospital, Edinburgh, United Kingdom; John M Graham, Jr, MD, Cedars Sinai Medical Center, Los Angeles, CA, United States; Angela E Lin, MD, Massachusetts General Hospital, Boston, MA, United States; Nicholas Katsanis, PhD, Duke University Medical Center, Durham, NC, United States; Peter L Jones, PhD, University of Nevada, Reno, NV, United States; William F Crowley, Jr, MD, Massachusetts General Hospital, Boston, MA, United States; Erica E Davis, PhD, Duke University Medical Center, Durham, NC, United States; David R Fitzpatrick, MD, University of Edinburgh Western General Hospital, Edinburgh, United Kingdom; Michael E Talkowski, PhD,
Massachusetts General Hospital, Boston, MA, United States; Chie-Hee Cho, MD, University Hospital of Bern, Bern, Switzerland; Cynthia C Morton, MD, Broad Institute of MIT and Harvard, Cambridge, MA, United States; Richard R Meehan, PhD; Veronica Van Heyningen, MD, Institute of Genetics and Molecular Medicine, University of Edinburgh Western General Hospital, Edinburgh, United Kingdom; Eric C Liao, MD, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States

FC7
METABOLOMIC PROFILE OF SEVERE VERSUS ATTENUATED MUCOPOLYSACCHARIDOSIS TYPE I
Lynda E Polgreen, MD; Patricia I Dickson, MD; Jennifer K Yee, MD; Kent D Taylor, PhD, Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA, United States; David Elashoff, PhD, UCLA, Los Angeles, CA, United States; Ellen Fung, PhD, Children’s Hospital Oakland Research Institute, Oakland, CA, United States; Bradley S. Miller, MD, PhD; Weston P Miller, MD; Paul J Orchard, MD; Troy C Lund, PhD, University of Minnesota Masonic Children’s Hospital, Minneapolis, MN, United States

FC8
MIRAGE SYNDROME: ADDITIONAL CASES WITH SAMD9 MUTATIONS, CLINICAL AND BIOLOGICAL CHARACTERIZATION
Florence Roucher-Boulez, MD; Delphine Mallet-Motak, PhD, Hospices Civils de Lyon Université Lyon 1, Lyon, France; Dulanjalee Kariyawasam, MD, Hospital Necker - Enfants Malades. Université Paris Descartes, Paris, France; Grazia Rezza Pinto, MD, Hospital Necker - Enfants Malades. Université Paris Descartes, Paris, France; Marion Gerard, MD, CHU de Caen, Caen, France; Virginie Ribault, MD, Centre Hospitalier Universitaire, Caen, France; Christel Chalouhi, MD, Hospital Necker - Enfants Malades. Université Paris Descartes, Paris, France; Julien Thevenon, MD, CHU Dijon, Université de Bourgogne, Dijon, France; Raja Brauner, MD, Fondation Rothschild, Paris, France; Patricia Bretones, MD, Hospices Civils de Lyon Université Lyon 1, Lyon, France; Pierre Simon Jouk, MD, CHU de Grenoble site Nord, Grenoble, France; Veronique Tardy-Guidollet, MD, Hospices Civils de Lyon Université Lyon 1, Lyon, France; Candace Ben Signor, MD, CHU Dijon, Université de Bourgogne, Dijon, France; Yves Morel, MD, Hospices civils de Lyon, Université Lyon 1, Lyon, France

FC9
SHOULD 45,X/46,XY BOYS WITHOUT DSD BE EVALUATED? RETROSPECTIVE LONGITUDINAL STUDY OF GROWTH, PUBERTY AND PHENOTYPIC FEATURES OF 34 PATIENTS
Laurence Dumeige, MBBS, University of Paris, Robert Debré Hospital, Paris, France; Livie Chatelais, MD, University Hospital of Angers, Angers, France; Claire Bouvattier, MD, University of Paris, Bicêtre Hospital, Le Kremlin Bicêtre, France; Marc De Kerdanet, MD, University Hospital of Rennes, Rennes, France; Blandine Esteva, MD, University of Paris, Armand Trousseau Hospital, Paris, France; Dinane Samara-Boustani, MD, University of Paris, Necker-Enfants Malades Hospital, Paris, France; Delphine Zenaty, MD, University of Paris, Robert Debré Hospital, Paris, France; Marc Nicolino, MD, University Hospital of Lyon, Paris, France; Sabine Baron, MD, University Hospital of Nantes, Nantes, France; Chantal Metz, MD, Brest Regional Medical Center, Brest, France; Catherine Naud-Sandreau, MD, Bretagne Sud Medical Center, Lorient, France; Clémentine Dupuis, MD, University Hospital of Grenoble, Grenoble, France; Jean-Claude Carel, MD, University of Paris, Robert Debré Hospital, Paris, France; Régis Gautant, MD, University Hospital of Angers, Angers, France; Laetitia Martinerie, MD, University of Paris, Robert Debré Hospital, Paris, France

FC10
CLINICAL AND MOLECULAR ANALYSIS OF PUBERTAL CONTROL IN A COHORT OF SILVER-RUSSELL AND TEMPLE SYNDROMES PATIENTS
Ana Canton, PhD, INSERM UMR S938, UPMC Paris 6, Sorbonne Universities, Paris, France; Madeleine D Harbison, MD, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Walid Abi Habib, PhD, INSERM UMR S938, UPMC Paris 6, Sorbonne Universities, Paris, France; Jennifer Salem, MD, The MAGIC Foundation, Chicago, IL, United States; Annick Blaise, PhD, INSERM UMR S938, UPMC Paris 6, Sorbonne Universities, Paris, France; Sophie Geoffron, MD; Eloise Giabicani, MD, Armand Trousseau Hospital, APHP, Paris, France; Alexander L Jorge, PhD, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; Frédéric Brioude, MD, Hospital Trousseau, Paris, France; Irène Netchine, Professor, INSERM UMR S938, UPMC Paris 6, Sorbonne Universities, Paris, France
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am – 8:30 am</td>
<td>Free Communication Session (FC11-FC15)</td>
<td></td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>Bone and mineral metabolism #1</td>
<td>Delaware</td>
</tr>
<tr>
<td><strong>Room:</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FC11**

**BONE MINERAL DENSITY AFTER CESSION OF GH TREATMENT IN YOUNG ADULTS BORN SGA: A 5-YEAR LONGITUDINAL STUDY**

Carolina CJ Smeets, MD; Manouk Van Der Steen, PhD; Judith S Renes, PhD, Erasmus Medical Centre, Rotterdam, Netherlands; Anita CS Hokken-Koelega, MD, PhD, Erasmus Medical Center / Dutch Growth Research Foundation, Rotterdam, Netherlands

**FC12**

**ESTABLISHMENT OF A HUMAN GROWTH PLATE MODEL WITH IPS CELL- DERIVED CARTILAGE**

Takeshi Kimura, MD, Osaka University, Osaka, Japan; Akihiro Yamashita, PhD, Center for iPS cell Research and Application, Kyoto University, Kyoto, Japan; Keiichi Ozono, MD, PhD, Osaka University Graduate School of Medicine, Osaka, Japan; Noriyuki Tsumaki, MD, Center for iPS cell Research and Application, Kyoto University, Kyoto, Japan

**FC13**

**SYMPTOMATIC VITAMIN D DEFICIENT RICKETS IN MANITOBA - JUST THE TIP OF THE ICEBERG**

Maria-Elena Lautatzis, MD; Atul Sharma, MD, FRCPC, University of Manitoba, Winnipeg, MB, Canada; Celia Rodd, MD, FRCPC, University of Manitoba, Winnipeg, MB, Canada

**FC14**

**KRN23 EFFECTS ON PHOSPHATE AND VITAMIN D METABOLISM IN CHILDREN <5 YEARS OLD WITH X-LINKED HYPOPHOSPHATEMIA (XLH)**

Thomas Carpenter, MD, Yale University, New Haven, CT, United States; Erik Imel, MD, Indiana University School of Medicine, Indianapolis, IN, United States; Gary S Gottesman, MD, Shriners Hospital for Children, St Louis, MO, United States; Javier San Martin, MD; Meng Mao, PhD; Alison Skrinar, PhD, Ultragenyx Pharmaceutical Inc., Novato, CA, United States; Michael P Whyte, MD, Shriners Hospital for Children, and Washington University School of Medicine, St Louis, MO, United States

**FC15**

**INHALED BETA-AGONISTS AND BONE MASS IN CHILDREN AND ADOLESCENTS**

Alexis J Feuer, MD, Weill Cornell Medicine, New York, NY, United States; Ashley Thai, MS/MA, Columbia University, New York, NY, United States; Ishita Kharode, MD, Weill Cornell Medicine, New York, NY, United States; Maria Vogiatzi, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, United States

**8:45 am – 9:45 am**

**New Perspectives (NP1)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:45 am – 9:45 am</td>
<td>New manipulations of mutant CaSR pathways; and Cartilage natriuretic peptide</td>
<td>Washington 4-6</td>
</tr>
<tr>
<td>Session Title:</td>
<td>New manipulations of mutant CaSR pathways; and Cartilage natriuretic peptide</td>
<td>Room: Washington 4-6</td>
</tr>
<tr>
<td>Room:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>New manipulations of mutant CaSR pathways</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rajesh Thakker, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cartilage natriuretic peptide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rob Olney, United States</td>
<td></td>
</tr>
</tbody>
</table>

**8:45 am – 9:45 am**

**Meet the Expert (MTE5:1)**

**Session Title:**

**Delayed puberty: Causes, evaluation, and management**

**Room:** Marriott Ballroom

**Expert:** Yee-Ming Chan, United States

**8:45 am – 9:45 am**

**Meet the Expert (MTE6:1)**

**Session Title:**

**Pediatric pheochromocytoma/paraganglioma**

**Room:** Thurgood Marshall SW

**Expert:** Nalini Shah, India
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
<th>Session Title</th>
<th>Room</th>
<th>Expert</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:45 am – 9:45 am</td>
<td>Meet the Expert (MTE7:1)</td>
<td>Pediatric osteoporosis</td>
<td>Thurgood Marshall NE</td>
<td>Craig Munns, Australia</td>
</tr>
<tr>
<td>8:45 am – 9:45 am</td>
<td>Free Communication Session (FC16-FC20)</td>
<td>Sex differentiation/gonads and disorders of sex development</td>
<td>Maryland</td>
<td></td>
</tr>
</tbody>
</table>

**FC16**

**Mapping the Steroid Metabolome in Inborn Steroidogenic Disorders: Performance of a Novel Computational Approach in Comparison to Conventional GC-MS Analysis**

Elizabeth S Baranowski, MBChB, University of Birmingham, Birmingham, N/A, United Kingdom; Kerstin Bunte, PhD, University of Groningen, Groningen, Netherlands; Cedric HL Shackleton, Professor; Angela E Taylor, PhD; Beverley A Hughes, BS/BA, University of Birmingham, Birmingham, United Kingdom; Michael Biehl, Professor, University of Groningen, Groningen, Netherlands; Peter Tino, Professor, University of Birmingham, Birmingham, United Kingdom; Tulay Gurun, MD, Marmara University, Istanbul, Turkey; Wiebke Arlt, Professor, University of Birmingham, Birmingham, United Kingdom

**FC17**

**Molecular Study of Ras/MAPK Pathway Genes in Patients with Cryptorchidism**

Fernando A Rodríguez, PhD; Carla Vallejos, TM; Nancy Unanue, MD; Maria I Hernández, MD, School of Medicine, University of Chile, Santiago, Chile; Soledad Célis, MD; San Borja – Arriarán Clinical Hospital, Santiago, Chile; Rubén Martín-Arenas, PhD; María Palomares Bralo, PhD; Karen E Heath, PhD, La Paz University Hospital, Madrid, Spain; María T López, MD, San Borja - Arriarán Clinical Hospital, Santiago, Chile; Fernando Cassarola, MD, School of Medicine, University of Chile, Santiago, Chile

**FC18**

**Androgen Insensitivity Due to Increased Methylation in the Androgen Receptor Promoter**

Nadine C Hornig, PhD; Pascal Rodens, Medical Student, Christian-Albrechts-University Kiel & University Hospital Schleswig-Holstein, Kiel, Germany; Hans Udo Schweikert, Prof., University Bonn, Bonn, Germany; Olaf Hiort, ; Ralf Werner, Dr., University Luebeck, Luebeck, Germany; Susanne Gonzalves, MD, Diakonissen-Stiftungs-Krankenhaus, Speyer, Germany; Anne Katrin Eckstein, MD, Praxisklinik Kronshagen, Kronshagen, Germany; Oie Ammerpohl, Prof., Paul-Martin Holterhus, , Christian-Albrechts-University Kiel & University Hospital Schleswig-Holstein, Kiel, Germany

**FC19**

**12 Month Surgical Outcomes Following Genitoplasty in Children with Moderate-to-Severe Genital Atypia**

Kerlly J Bernabé, MPH, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, United States; Natalie J Nokoff, MD, Children's Hospital Colorado, Aurora, CO, United States; Denise Galan, CPNP; Diane Felsen, PhD, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, United States; Christopher E Aston, PhD, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Paul Austin, MD, St. Louis Children's Hospital, St. Louis, MO, United States; Laurence Baskin, MD, University of California, San Francisco Medical Center, San Francisco, CA, United States; Yee-Ming Chan, MD, PhD, Boston Children's Hospital / Harvard Medical School, Boston, MA, United States; Earl Cheng Cheng, MD, Lurie Children's Hospital of Chicago, Chicago, IL, United States; David Diamond, MD, Boston Children's Hospital, Boston, MA, United States; Allyson Fried, CPNP; RN, MSN, BSN, Women and Children's Hospital of Buffalo, Buffalo, NY, United States; Lynette Gonzalez, CRC, University of California, San Francisco Medical Center, San Francisco, CA, United States; Saul Greenfield, MD, Women and Children's Hospital of Buffalo, Buffalo, NY, United States; Thomas Kolon, MD, Children's Hospital of Philadelphia, Philadelphia, PA, United States; Bradley Kroop, MD, Cook Children's Medical Center, Fort Worth, TX, United States; Yegappan Lakshmanan, MD, Children's Hospital of Michigan, Detroit, MI, United States; Sabrina Meyer, CPNP, Women and Children's Hospital of Buffalo, Buffalo, NY, United States; Theresa Meyer, CPN, Lurie Children's Hospital of Chicago, Chicago, IL, United States; Alexandria Mullins, PhD; Larry L Mullins, PhD, Oklahoma State University, Stillwater, OK, United States; Blake Palmer, MD, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Alethea Paradis, MTS, St. Louis Children's Hospital, St. Louis, MO, United States; Pranod Reddy, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Kristy J Scott-Reyes, BS/BA, Cook Children's Medical Center, Fort Worth, TX, United States; Marion Schulte, MHSA, RN, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Jonathan M Swartz, MD, Boston Children's Hospital, Boston, MA, United States; Elizabeth Yerkes, MD, Lurie Children's Hospital of Chicago, Chicago, IL, United States; Cortney Wolfe-Christensen, PhD; Amy Wisniewski, PhD, Cook Children's Medical Center, Fort Worth, TX, United States; Dix Poppas, MD, New York Presbyterian Hospital / Weill Cornell Medicine, New York, NY, United States
ANTENATALLY DETERMINED SESQUIZYGOSITY IN GENDER DISCORDANT MONOCHORIONIC DIAMNIOTIC TWINS (46,XX/46,XY) - POSTNATAL CLINICAL AND GONADAL PHENOTYPE

Louise S Conwell, PhD, Lady Cilento Children’s Hospital, Children’s Health Queensland; Children’s Health Queensland Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, Australia; Gayle E Phillips, MBBS, Department of Health, Queensland Government, Lady Cilento Children’s Hospital and Royal Brisbane and Women’s Hospital; Faculty of Medicine, University of Queensland, Brisbane, Australia; Adayapalam Nandini, PhD, Pathology Queensland, Brisbane, Australia; Peter A Borzi, MBBS, Lady Cilento Children’s Hospital, Children’s Health Queensland; Children’s Health Queensland Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, Australia; Michael T Gabbett, MBBS, Royal Brisbane and Women’s Hospital; School of Medicine, University of Queensland, Brisbane, Australia

8:45 am – 9:45 am   Free Communication Session (FC21-FC25)

**Session Title:** Type 2 diabetes and other carbohydrate metabolism  
**Room:** Virginia  

**FC21**  
**NOVEL METABOLIC PHENOTYPE FROM ACAD 10 DEFICIENCY IN MICE**  
Yan Wang, PhD; Zhengwei Gong, PhD; Emir Tas, MD; Kai Su, MS/MA; Ting Wang, PhD; Wei Chen, PhD; Jerry Vockley, MD; Eric Goetzman, PhD, University of Pittsburgh, Pittsburgh, PA, United States; Radhika Muzumdar, MD, Children’s Hospital of Pittsburgh of UPMC/University of Pittsburgh, Pittsburgh, PA, United States  

**FC22**  
**IMPACT OF METRELEPTIN ON HEPATOMEGALY IN PEDIATRIC PATIENTS WITH GENERALIZED LIPODYSTROPHY**  
Elif A. Oral, MD, Brehm Center for Diabetes, Ann Arbor, MI, United States; Elaine Chiquette, PharmD, Aegerion Pharmaceuticals, Cambridge, MA, United States; James H. Lewis, MD, Georgetown University Hospital, Washington, DC, United States; Alison Long, MD, PhD; Taylor C Salinardi, PhD, Aegerion Pharmaceuticals, Cambridge, MA, United States; Rebecca Brown, MD, National Institutes of Health, Bethesda, MD, United States

**FC23**  
**PREVALENCE OF “PREDIABETES” RANGE HEMOGLOBIN A1C IN NORMAL WEIGHT YOUTH FROM THE HEALTHY STUDY**  
Christine L Chan, MD, University of Colorado School of Medicine/Children’s Hospital Colorado, Aurora, CO, United States; Kimberly L Drews, PhD, George Washington University, Washington, DC, United States; John B Buse, MD/PhD, University of North Carolina School of Medicine, Chapel Hill, NC, United States; Philip S Zeitler, MD, PhD, University of Colorado School of Medicine/Children’s Hospital Colorado, Aurora, CO, United States; Megan M Kelsey, MD, University of Colorado/Children’s Hospital Colorado, Aurora, CO, United States

**FC24**  
**PREDICTIVE UTILITY OF 10-SNPS GENETIC RISK SCORE FOR PEDIATRIC-ONSET TYPE 2 DIABETES**  
America L Miranda Lora, PhD; Mario Molina-Díaz, MD, Hospital Infantil de México Federico Gómez, México, Mexico; Miguel Cruz, PhD, Centro Médico Nacional sXXI, Instituto Mexicano del Seguro Social, México, Mexico; Miguel Klunder Klunder, PhD, Hospital Infantil de México Federico Gómez, México, Mexico

**FC25**  
**TRENDS IN GLYCEMIC MEDICATIONS AND CONTROL IN YOUTHS WITH TYPE 2 DIABETES (T2D): THE SEARCH FOR DIABETES IN YOUTH STUDY**  
R. Ravi Shankar, MD; Cathy Anne Pinto, PhD; Tongtong Wang, PhD, Merck and Co., Inc., Upper Gwynnedd, PA, United States; Jeanette M Stafford, MS/MA; Ralph B D’Agostino, PhD, Wake Forest University, Winston-Salem, NC, United States; Jean M Lawrence, ScD, Kaiser Permanente, Pasadena, CA, United States; Grace Kim, MD; Catherine Pihoker, MD, Seattle Children’s Hospital, Seattle, WA, United States; Dana Dabelea, MD,PhD, University of Colorado Denver, Aurora, CO, United States
### Session Title: Free Communication Session (FC26-F30)

**Room:** Delaware

**Session Title:** EVALUATION OF THE EFFECTIVENESS OF A PEDIATRIC ENDOCRINOLOGY EDUCATION PROGRAM FOR HAITI (PEEP-H): A PRELIMINARY REPORT

**Authors:** Renault Louis, MD, Hôpital Universitaire de Mirebalais, Mirebalais, Haiti; Daphné Cloutier, MD; Marie-Ève Robinson, MD, McGill University Health Centre, Montréal, QC, Canada; Deaarthlie Benardeau, MD; Clorène Cadet, MD, Hôpital Universitaire de Mirebalais, Mirebalais, Haiti; Renée Alcée, MD; Steven Joseph, MD, NPH Haiti Saint Damien Pediatric Hospital, Port-au-Prince, Haiti; Guy Van Vliet, MD, Centre Hospitalier Universitaire Sainte-Justine, Montréal, QC, Canada; Julia Von Oettingen, MD, McGill University Health Centre, Montréal, QC, Haiti

**Session Title:** EARLY LIFE STRESS INDUCES TYPE 2 DIABETES AT ADULTHOOD IN MALE MICE

**Authors:** Hanna Ilchmann, MS/MA; Maiwenn Olier, PhD; Corinne Lencina, research technician; Sandrine Ellero-Simatos, PhD; Michèle Nankap, MS/MA; Ambre Riba, PhD; Caroline Sommer, research technician; Hervé Guillou, PhD; Laurence Guzylack-Piriou, PhD; Vassilia Théodorou, PhD; Sandrine Ménard, PhD, INRA, Toulouse, France

**Session Title:** SEXUAL DIMORPHISM OF SIZE: ONTOGENY AND LIFE HISTORY

**Authors:** Alina German, MD, Bnei Zion medical Center, Haifa, Israel; Ze’Ev Hochberg, MD, PhD, Technion-Israel Institute of Technology, Haifa, Israel

**Session Title:** A STUDY OF THE INCIDENCE OF PERMANENT CONGENITAL HYPOTHYROIDISM BASED ON REEVALUATIONS IN THE NIIGATA PREFEecture JAPAN

**Authors:** Keisuke Nagasaki, MD, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; Hiromi Nyuuzuki, MD; Sunao Sasaki, MD; Yohei Ogawa, MD, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

**Session Title:** SECULAR CHANGES OF ADULT HEIGHTS IN THE NORDIC COUNTRIES

**Authors:** Anton Holmgren, MD, University of Gothenburg/Halland Hospital Halmstad, Gothenburg/Halmstad, Sweden; A. Stefan Aronson, MD, PhD, Halland Hospital Halmstad, Halmstad, Sweden; Aimon Niklasson, MD, PhD; Kerstin Albertsson-Wikland, MD, PhD, Sahlgrenska Academy; University of Gothenburg, Gothenburg, Sweden

### Session Title: Exhibits and Poster viewing (unattended)

**Room:** Exhibition Hall

### Session Title: Plenary (PL3)

**Session Title:** Asia Pacific Paediatric Endocrine Society (APPES) – Prenatal environment and medical consequences

**Room:** Marriott Ballroom

**Speaker:** Paul Hofman, New Zealand

### Session Title: Plenary (PL4)

**Session Title:** Pediatric Endocrine Society Lawson Wilkins Lecture – Interplay of diet, circadian rhythms, the epigenome, and metabolism

**Room:** Marriott Ballroom

**Speaker:** Mitchell Lazar, United States
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Room</th>
<th>Moderators</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 am – 12:30 pm</td>
<td>Poster Session (P2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 am – 12:45 pm</td>
<td><strong>PES Mentor/Mentee Workshop</strong></td>
<td>Madison</td>
<td></td>
</tr>
<tr>
<td>12:45 pm – 2:15 pm</td>
<td><strong>Topic Symposium (S)</strong></td>
<td>Marriott Ballroom</td>
<td>Xiaoping Luo, China &amp; Hugo Boquete, Argentina</td>
</tr>
<tr>
<td></td>
<td><strong>New concepts in diagnosis and treatment of CAH</strong></td>
<td>Marriott Ballroom</td>
<td>Anna Nordenström, Sweden</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Xiaoping Luo, China &amp; Hugo Boquete, Argentina</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pitfalls in the hormonal and molecular diagnosis of congenital adrenal hyperplasia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>New treatment approaches to CAH</td>
</tr>
<tr>
<td>12:45 pm – 2:15 pm</td>
<td><strong>Topic Symposium (S)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Diabetes management of children in resource-limited settings</strong></td>
<td>Virginia</td>
<td>Dipesalema Joel, Botswana &amp; Julia von Oettingen, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Intensive insulin therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Glycaemic control</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Neonatal diabetes management</td>
</tr>
<tr>
<td>12:45 pm – 2:15 pm</td>
<td><strong>Controversies in Pediatric Endocrinology (CPE2)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Aromatase inhibition</strong></td>
<td>Washington 4-6</td>
<td>Mitch Geffner, United States &amp; Michael Joseph O’Grady, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>European data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>American data</td>
</tr>
</tbody>
</table>
### Growth hormone safety

**Session Title:** Growth hormone safety  
**Room:** Thurgood Marshall NE  
**Moderators:** Peter Clayton, United Kingdom & Anders Tidblad, Sweden

1. How has and how should the safety of rhGH be evaluated over time?  
   - Les Robison, United States

2. GH therapy in brain tumor survivors: risk of disease recurrence and second tumours  
   - Charles Sklar, United States

3. Mortality and morbidity after GH therapy in EU SAGhE  
   - Stefano Cianfarani, Italy

### Metabolic syndrome in early childhood

**Session Title:** Metabolic syndrome in early childhood  
**Room:** Thurgood Marshall SW  
**Moderators:** Francesco Chiarelli, Italy & Sylva Arslanian, United States

1. Definition of metabolic syndrome in toddlers and children  
   - Ram Weiss, Israel

2. Prevention of metabolic syndrome in early childhood  
   - Martin Wabitsch, Germany

3. Current treatment of metabolic syndrome in children  
   - Sonia Caprio, United States

### Puberty and ovarian disorders

**Session Title:** Puberty and ovarian disorders  
**Room:** Maryland  
**Moderators:** Hugo Fideleff, Argentina & Suttipong Wacharasindhu, Thailand

1. Recent advancement in the genetics of central precocious puberty  
   - Ana Claudia Latronico, Brazil

2. Novel insights in the etiology of hypogonadotropic hypogonadism  
   - Kemal Topaloglu, United States

3. Novel insights into female reproduction: preservation of fertility in cancer patients  
   - Teresa Woodruff, United States
### Session Title: Bone and mineral metabolism #2
### Room: Washington 4-6

<table>
<thead>
<tr>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FC31</strong></td>
<td><strong>Bone and mineral metabolism #2</strong></td>
</tr>
<tr>
<td><strong>FC32</strong></td>
<td><strong>Room: Washington 4-6</strong></td>
</tr>
<tr>
<td><strong>FC33</strong></td>
<td><strong>Room: Washington 4-6</strong></td>
</tr>
<tr>
<td><strong>FC34</strong></td>
<td><strong>Room: Washington 4-6</strong></td>
</tr>
<tr>
<td><strong>FC35</strong></td>
<td><strong>Room: Washington 4-6</strong></td>
</tr>
</tbody>
</table>

#### FC31
**DIFFERENTIAL EFFECTS OF LOW-WEIGHT, AMENORRHEA AND EXERCISE ON BONE MICROARCHITECTURE AND STRENGTH ESTIMATES AT WEIGHT BEARING AND NON-WEIGHT BEARING SITES IN ADOLESCENT GIRLS AND YOUNG ADULTS**

Nurgun Kandemir, MD, Hacettepe University, Ankara, Turkey; Karen J Campoverde Reyes, MD; Vibha Singhal, MD; Meghan Slattery, NP; Kathryn Ackerman, MD; Shreya Tulsiwani, BS/BA; Hang Lee, PhD; Karen K Miller, MD; Kamryn T Eddy, PhD; Anne Kilbanski, MD; Madhusmita Misra, MD, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

#### FC32
**APPLICATION OF 18F-NAF PET/CT IMAGING IN FIBROUS DYSPLASIA**

Georgios Z Papadakis, MD, Institute of Computer Science, Crete, Greece; Georgios C Manikis, MS/MA, Institute of Computer Science, Crete, Greece; Apostolos H Karantanas, MD, University of Crete School of Medicine, Crete, Greece; Kostas Marias, PhD, Institute of Computer Science, Crete, Greece; Michael T Collins, MD; Alison M Boyce, MD, National Institutes of Health, Bethesda, MD, United States

#### FC33
**POOR CORRELATION BETWEEN DISCREPANCY OF BONE MINERAL DENSITY Z-SCORES BY DUAL-ENERGY X-RAY ABSORPTIOMETRY AND VERTEBRAL FRACTURES IN CHILDREN**

Tasma Harindhanavudhi, MD, University of Minnesota, Minneapolis, MN, United States; Anna Petryk*, MD, *Current affiliation: Alexion Pharmaceuticals, New Haven, CT, United States; Richard Jones, MD, University of Minnesota, Minneapolis, MN, United States; Amanda R Wallin, MD, Karolinska Institutet, Stockholm, Sweden; Sara Van Nortwick, MD, University of Minnesota, Minneapolis, MN, United States; Bradley S. Miller, MD, PhD, University of Minnesota Masonic Children's Hospital, Minneapolis, MN, United States; Tara Holm, MD; Kyriakie Sarafoglu, MD, University of Minnesota, Minneapolis, MN, United States

#### FC34
**THE RELATIONSHIP BETWEEN ADIPOSY AND BONE DENSITY IN U.S. CHILDREN AND ADOLESCENTS**

Cecilia Gállego Suárez, MD; Joyce M Lee, MD; Achamyeleh Gebremariam, MS/MA; Kanakadurga Singer, MD, University of Michigan, Ann Arbor, MI, United States

#### FC35
**CLINICAL AND STRUCTURAL IMPACT OF MUTATIONS AFFECTING THE PLS3 GENE IN PATIENTS WITH BMND18**

Ting Chen, MD, University of Soochow, Suzhou, China; Chenxi Zhang, BS/BA, Medical College of Soochow University, Soochow University, Suzhou, China; Haiying Wu, MD; Rangrong Xie, pediatrician, University of Soochow, Suzhou, China; Fengyun Wang, MD, Children's Hospital of Soochow University, Soochow University, Suzhou, China; Xiuli Chen, pediatrician, University of Soochow, Children's hospital of Soochow university, Suzhou, China; Hui Sun, pediatrician, University of Soochow, Suzhou, China; Fei Xiao, PhD, Medical College of Soochow University, Soochow University, Suzhou, China; Lingji Chen, Pediatrician, University of Soochow, Children's hospital of Soochow university, Suzhou, China
Free Communication Session (FC36-FC40)

**FC36**
**CARNOSINE AS AN ADJUVANT THERAPY IN PEDIATRIC PATIENTS WITH DIABETIC NEPHROPATHY: A RANDOMIZED PLACEBO-CONTROLLED TRIAL**
Nancy S Elbarbary, MD; Eman Abdel Rahman Ismail, MD, Ain Shams University, Cairo, Egypt; Abdel Rahman El-Naggar, MD; Mahitab Hany Hamouda, resident, Modern technology and Information University, Cairo, Egypt; Manal El-Hamamsy, MD, Ain Shams University, Cairo, Egypt

**FC37**
**CONTINUOUS SUBCUTANEOUS INSULIN INFUSION COMPARED TO MULTIPLE DAILY INJECTION REGIMENS IN CHILDREN AND YOUNG PEOPLE AT DIAGNOSIS OF TYPE 1 DIABETES: A PRAGMATIC RANDOMISED CONTROLLED TRIAL AND ECONOMIC EVALUATION (SCPI TRIAL)**
Joanne Blair, MD, Alder Hey Children's Hospital, Liverpool, United Kingdom; Andrew Mckay, MS/MA, Liverpool University, Liverpool, United Kingdom; Colin Ridyard, PhD, Bangor University, Bangor, United Kingdom; Keith Thornborough, RN, Alder Hey Children's Hospital, Liverpool, United Kingdom; Emma Bedson, PhD, Liverpool University, Liverpool, United Kingdom; Matthew Peak, PhD; Mohammed Didi, MRCPCH, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom; Francesca Annan, MS/MA, University College London Hospital, London, United Kingdom; Gregory John, PhD, School of Medicine, Cardiff University, Cardiff, United Kingdom; Dyfrig Hughes, PhD, Bangor University, Bangor, United Kingdom; Carrol Gamble, PhD, Liverpool University, Liverpool, United Kingdom

**FC38**
**ANTI CD4 AND ANTI CD8 ANTIBODY CO-THERAPY INDUCES REMISSION OF DIABETES IN NEW ONSET NOD MICE VIA LOCALIZED INDUCTION OF T CELL EGRESS FROM THE PANCREAS**
Mark Henin, MD; Matthew Clark, PhD; Roland Tisch, PhD, University of North Carolina, Chapel Hill, NC, United States

**FC39**
**THE RISK OF PROGRESSION TO TYPE 1 DIABETES (T1D) IN INDIVIDUALS OF DIVERSE AGES WITH MULTIPLE AUTOANTIBODIES**
Laura M Jacobsen, MD, University of Florida, Gainesville, FL, United States; Carmella Evans-Molina, MD; Linda A Dimaggio, MD, Indiana University School of Medicine, Indianapolis, IN, United States; Robin Goland, MD, Columbia University, New York, NY, United States; Darrell M Wilson, MD, Stanford University, Stanford, CA, United States; Mark Atkinson, PhD, University of Florida, Gainesville, FL, United States; Tandy Aye, MD, Stanford University, Stanford, CA, United States; William Russell, MD, Vanderbilt University, Nashville, TN, United States; John Wentworth, MD, Royal Melbourne Hospital, Melbourne, Australia; Susan Geyer, PhD; David Boulware, MS/MA, University of South Florida, Tampa, FL, United States; Jay Sosenko, MD, University of Miami, Miami, FL, United States

**FC40**
**DOMINANT TNFA AND IMPAIRED IL-2 CYTOKINE EXPRESSION PROFILES OF CD4+ MEMORY T CELLS FROM CHILDREN WITH TYPE 1 DIABETES ARE PROMOTED BY IL-7**
Julia Seyfarth, MD, Heinrich Heine University Duesseldorf, Duesseldorf, Germany; Rosa Sherfat, MD, Medstar Georgetown University Hospital, Washington, DC, United States; Hans-Jürgen Laws, MD, Heinrich Heine University Duesseldorf, Duesseldorf, Germany; Beate Karges, Professor, RWTH Aachen University, Aachen, Germany; Ertan Mayatepek, MD, University Children's Hospital, Düsseldorf, Germany; Thomas Meissner, MD, University Children's Hospital Duesseldorf, Duesseldorf, Germany; Marc Jacobsen, Professor, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
### 2:30 pm – 3:30 pm  Free Communication Session (FC41-FC45)

<table>
<thead>
<tr>
<th>Session Title:</th>
<th>Gender dysphoria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room:</td>
<td>Thurgood Marshall NE</td>
</tr>
</tbody>
</table>

**FC41**
TESTOSTERONE MAKES YOUNG TRANSGENDER POST-PUBERTAL MEN GROW  
Tiffani K Rees, BA MBBS MBA; Sara Kleczewski, BSc RN; Professor Gary E Butler, MD FRCPCH; Elaine Perkins, PA; Caroline E Brain, MBBS MRCP FRCPCH MD; Kirpal Adu-Gyamfi, Physician's Assistant; Claire Goedhart, RN, University College London Hospital, National Gender Identity Development Service, London, United Kingdom

**FC42**
WHAT ARE THE PERSPECTIVES AMONG TRANSGENDER YOUTH AND THEIR PARENTS REGARDING FUTURE FERTILITY? INSIGHTS FROM THE FERTILITY AND REPRODUCTIVE HEALTH SURVEY OF TRANSGENDER YOUTH (FROST) STUDY  
Lyne N. Chiniara, MD; Christine Viner, MD; Herbert J. Bonifacio, MD, MSc, MPH, MA; Mark R. Palmert, MD, PhD, Hospital for Sick Children/University of Toronto, Toronto, ON, Canada

**FC43**
BODY COMPOSITION OF YOUNG ADULT TRANSWOMEN WHO STARTED GENDER REASSIGNMENT IN ADOLESCENCE  
Daniel T Klink, MD, ZNA Queen Paola Children's Hospital, Antwerp, Belgium; Maartje Klaver, MD; Niek Van Regteren, MD; Chung-Wen Mak, MD; Martin Den Heijer, MD; Joost Rotteveel, MD, VU Medical Center, Amsterdam, Netherlands

**FC44**
MENTAL HEALTH CONCERNS AND INSURANCE DENIALS AMONG TRANSGENDER ADOLESCENTS  
Leena Nahata, MD, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH, United States; Gwendolyn P. Quinn, PhD, Moffitt Cancer Center, Morsani College of Medicine, University of South Florida, Tampa, FL, United States; Nicole M. Caltabellotta, BS/BA, The Research Institute at Nationwide Children's Hospital, Columbus, OH, United States; Amy C. Tishelman, PhD, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States

**FC45**
EVALUATING ACCESS TO PRESCRIBED MEDICATIONS AND ASSOCIATED PSYCHIATRIC COMORBIDITIES IN TRANSGENDER YOUTH  
Kristin Dayton, MD; Lindsay Thompson, MD; Rebecca Mercado, MS/MA; Janet Silverstein, MD; Amanda Hicks, PhD; Jeffrey Ferrell, BS/BA; Corey Gallet De St Aurin, BS/BA, University of Florida, Gainesville, FL, United States
<table>
<thead>
<tr>
<th>Session Title:</th>
<th>Free Communication Session (FC46-FC50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room:</td>
<td>Thurgood Marshall SW</td>
</tr>
</tbody>
</table>
| **FC46**     | **ANG1-7 EXERTS ANTI-OBESITY EFFECT THROUGH PROLIFERATION OF BAT**  
Hidechika Morimoto, MD; Jun Mori, MD; Yusuke Tsuma, MD; Shota Fukuhara, MD; Keiichi Shigehara, MD; Kazuki Kodo, MD; Hisakazu Nakajima, MD; Hajime Hosoi, MD, Kyoto prefectural university of medicine, Kyoto, Japan |
| **FC47**     | **USE OF ELEVATED HOMA-IR AND BLOOD PRESSURE VALUES IN DECIDING IN WHICH OBESE CHILDREN SHOULD OGGT BE PERFORMED**  
Rade Vukovic, PhD; Tatjana Milenkovic, PhD; Katarina Mitrovic, PhD; Sladjana Todorovic, MD; Ljiljana Plavsic, MD, Mother and Child Health Care Institute of Serbia “Dr Vukan Cupic”, Belgrade, Serbia; Ivan Soldatovic, PhD, School of Medicine, University of Belgrade, Belgrade, Serbia |
| **FC48**     | **THE RS626283 VARIANT IN THE MBOAT7 GENE-confers an increased risk of non-alcoholic fatty liver disease (NAFLD) and insulin resistance to caucasian youths**  
Giuseppina Rosaria Umano, MD, Yale School of Medicine, New Haven, CT, United States; Anna Di Sessa, MD; Sonia Caprio, MD, Yale University, New Haven, CT, United States; Naga Chalasani, MD, Indiana University, Indianapolis, IN, United States; Wanqing Liu, MD, Purdue University, West Lafayette, IN, United States; Tiebing Liang, MD, Indiana University, Indianapolis, IN, United States; Mary Savoye, RD; Bridget Pierpoint, MS/MA; Mariana Mata, MS/MA; Nicola Santoro, MD, Yale University, New Haven, CT, United States |
| **FC49**     | **STRUCTURAL AND FUNCTIONAL ABNORMALITIES IN THE HYPOTHALAMUS OF OBESE CHILDREN**  
Leticia Esposito Sewaybricker, PhD, State University of Campinas, Campinas, Brazil; Ellen A Schur, MS/MA; Susan J Melhorn, PhD, University of Washington, Seattle, WA, United States; Brunno M Campos, PhD, State University of Campinas, Campinas, Brazil; Mary K Askren, PhD, University of Washington, Seattle, WA, United States; Guilherme AS Nogueira, MS/MA; Mariana P Zambon, PhD; Maria Angela RGM Antonio, PhD; Fernando Cenedes, PhD; Licio A Velloso, PhD; Gil Guerra-Junior, PhD, State University of Campinas, Campinas, Brazil |
| **FC50**     | **STEROID METABOLOMIC SIGNATURE OF INSULIN RESISTANCE IN CHILDHOOD OBESITY**  
Aneta M Gawlik, PhD, Medical University of Silesia, Katowice, Poland; Michael Shmoish, PhD, Technion-Israel Institute of Technology, Haifa, Israel; Michaela F Hartmann, PhD, Justus Liebig University, Giessen, Germany; Ewa Malecka-Tendera, PhD, Medical University of Silesia, Katowice, Poland; Stefan A Wudy, PhD, Justus Liebig University, Giessen, Germany; Ze’Ev Hochberg, MD, PhD, Technion-Israel Institute of Technology, Haifa, Israel |

<table>
<thead>
<tr>
<th>Session Title:</th>
<th>Yearbook of Paediatric Endocrinology (YB1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room:</td>
<td>Maryland</td>
</tr>
</tbody>
</table>
| **Type 2 diabetes, metabolic syndrome and lipids**  
Orit Hamiel, Israel |
| **Antenatal and neonatal endocrinology**  
Khalid Hussain, United Kingdom |
| **Growth and growth factors**  
Stefano Cianfarani, Italy |
| **Adrenals**  
Evangelia Charmandari, Greece |
| **Evidence based medicine in pediatric endocrinology**  
Rod Mitchell, United Kingdom |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 pm – 4:00 pm</td>
<td>Refreshment Break</td>
<td>Exhibition Hall</td>
</tr>
<tr>
<td>4:00 pm – 6:00 pm</td>
<td>Business Meeting</td>
<td></td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>PES Business Meeting, Awards, and Lectures</td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td><strong>Room:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00pm – 4:15pm</td>
<td>Business Meeting</td>
<td></td>
</tr>
<tr>
<td>4:15pm – 4:35pm</td>
<td>Van Wyk Award</td>
<td>Arlan Rosenbloom 2017 Judson J. Van Wyk Award; Intro Janet H. Silverstein, United States</td>
</tr>
<tr>
<td>4:35pm - 4:55pm</td>
<td>Kaplowitz Lecture</td>
<td>Karen Rubin, United States</td>
</tr>
<tr>
<td>4:55pm – 5:15pm</td>
<td>Presidential Lecture</td>
<td>Stephen Rosenthal, United States</td>
</tr>
<tr>
<td>5:15pm – 6:00pm</td>
<td>History Lecture</td>
<td>Walter Miller, 2017 Del and Beverly Fisher Pediatric Endocrinology History Lecture, United States</td>
</tr>
<tr>
<td>4:00 pm – 6:00 pm</td>
<td>Business Meeting</td>
<td></td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>ESPE Business Meeting, Awards, and Lectures</td>
<td>Thurgood Marshall Ballroom NE</td>
</tr>
<tr>
<td><strong>Room:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00pm -5:00pm</td>
<td>Members only</td>
<td></td>
</tr>
<tr>
<td>5:00pm - 6:00pm</td>
<td>ESPE awards: ESPE Research Award, Hormone Research in Paediatrics prizes, IFCAH-ESPE award, ESPE International Outstanding Clinician Award, ESPE Outstanding Clinician Award, ESPE International Award, ESPE Andrea Prader prize</td>
<td></td>
</tr>
<tr>
<td>4:00 pm – 6:00 pm</td>
<td>Business Meeting</td>
<td></td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>SLEP Business Meeting</td>
<td>Virginia</td>
</tr>
<tr>
<td><strong>Room:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00 pm – 7:30 pm</td>
<td>IMPE Satellite Symposium (SAT)</td>
<td></td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>Perspectives on growth and growth disorders</td>
<td>Maryland</td>
</tr>
<tr>
<td><strong>Room:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor:</strong></td>
<td>Pfizer, Inc.</td>
<td></td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>New therapeutic options for treating genetic obesity</td>
<td>Thurgood Marshall SW</td>
</tr>
<tr>
<td><strong>Room:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor:</strong></td>
<td>Rhythm Pharmaceuticals, Inc.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Room</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>6:00 pm – 7:30 pm</td>
<td><strong>IMPE Satellite Symposium (SAT)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>The evolving portrait of X-linked hypophosphatemia</td>
<td><strong>Room:</strong> Washington 1-3</td>
</tr>
<tr>
<td>7:30 pm – 9:30 pm</td>
<td><strong>MOC Session</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td><strong>MOC Session</strong></td>
<td><strong>Room:</strong> Thurgood Marshall NE</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>6:00 am</td>
<td>Registration Opens</td>
<td></td>
</tr>
<tr>
<td>6:15 am</td>
<td>Coffee in Exhibit Hall (7:00-7:30am)</td>
<td></td>
</tr>
<tr>
<td>7:30 am</td>
<td><strong>Breakfast SAT</strong>&lt;br&gt;A rare cause of short stature you don't want to miss&lt;br&gt;Delaware</td>
<td></td>
</tr>
<tr>
<td>7:45 am</td>
<td>FC51–FC55&lt;br&gt;Quality improvement&lt;br&gt;Marriott Ballroom</td>
<td></td>
</tr>
<tr>
<td>7:15 am</td>
<td>MTE8:1&lt;br&gt;Management of hyperthyroidism in children&lt;br&gt;Marriott Ballroom</td>
<td></td>
</tr>
<tr>
<td>7:30 am</td>
<td>MTE9:1&lt;br&gt;Diabetes in the infant&lt;br&gt;Washington 4-6</td>
<td></td>
</tr>
<tr>
<td>7:45 am</td>
<td>MTE6:1&lt;br&gt;Growth and GH/IGF Axis #2&lt;br&gt;Washington 1-3</td>
<td></td>
</tr>
<tr>
<td>7:30 am</td>
<td>MTE6:2&lt;br&gt;Obesity, lipids, and co-morbidities #2&lt;br&gt;Maryland</td>
<td></td>
</tr>
<tr>
<td>7:30 am</td>
<td>MTE6:3&lt;br&gt;Pediatric pheochromocytoma / paraganglioma&lt;br&gt;Virginia</td>
<td></td>
</tr>
<tr>
<td>8:00 am</td>
<td>FC56–FC60&lt;br&gt;Growth and GH/IGF Axis #2&lt;br&gt;Maryland</td>
<td></td>
</tr>
<tr>
<td>8:15 am</td>
<td>FC61–FC65&lt;br&gt;Obesity, lipids, and co-morbidities #2&lt;br&gt;Delaware</td>
<td></td>
</tr>
<tr>
<td>8:30 am</td>
<td>MTE10:1&lt;br&gt;Hyperinsulinemic Hypoglycemia: Management and recent advances&lt;br&gt;Maryland</td>
<td></td>
</tr>
<tr>
<td>8:45 am</td>
<td>MTE11:1&lt;br&gt;Exercising safely with T1DM&lt;br&gt;Washington 4-6</td>
<td></td>
</tr>
<tr>
<td>9:15 am</td>
<td>MTE12:1&lt;br&gt;The etiology and management of Hypophosphatemic Rickets&lt;br&gt;Maryland</td>
<td></td>
</tr>
<tr>
<td>9:30 am</td>
<td>MTE13:1&lt;br&gt;NeuroEndo including hypothalmic pituitary&lt;br&gt;Virginia</td>
<td></td>
</tr>
<tr>
<td>9:45 am</td>
<td>Refreshment Break, Poster Viewing and Exhibits</td>
<td></td>
</tr>
<tr>
<td>10:00 am</td>
<td>PLS: ISPE – Skeletal muscle glucocorticoid receptor and systemic energy metabolism by Hirotoshi Tanaka&lt;br&gt;Marriott Ballroom</td>
<td></td>
</tr>
<tr>
<td>10:45 am</td>
<td>PL6: SLEP – César Bergadá Lecture–Disorders in sex development: a persistent challenge by Alicia Belgorosky&lt;br&gt;Marriott Ballroom</td>
<td></td>
</tr>
<tr>
<td>11:15 am</td>
<td>PL7: CSPEM – Polycystic Ovary Syndrome clinical and genetic characteristics by Junfen Fu and Zijiang Chen&lt;br&gt;Marriott Ballroom</td>
<td></td>
</tr>
<tr>
<td>12:00 pm</td>
<td>P3 and Boxed Lunches</td>
<td></td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Refreshment Break and Exhibits</td>
<td></td>
</tr>
<tr>
<td>3:15 pm</td>
<td>FC81–FC85&lt;br&gt;Type 1 Diabetes #2&lt;br&gt;Marriott Ballroom</td>
<td></td>
</tr>
<tr>
<td>3:30 pm</td>
<td>NP2&lt;br&gt;Microbiome and human endocrinology; &amp; Environmental endocrine disruption: What's new?&lt;br&gt;Marriott Ballroom</td>
<td></td>
</tr>
<tr>
<td>3:45 pm</td>
<td>MTE2:2&lt;br&gt;Distinguishing monogenic forms from type 1 and type 2 diabetes: Does your patient have the right diagnosis?&lt;br&gt;Marriott Ballroom</td>
<td></td>
</tr>
<tr>
<td>4:00 pm</td>
<td>MTE7:2&lt;br&gt;Pediatric osteoporosis&lt;br&gt;Washington 4-6</td>
<td></td>
</tr>
<tr>
<td>4:15 pm</td>
<td>YB2&lt;br&gt;Fetal and neonatal glucose metabolism&lt;br&gt;Maryland</td>
<td></td>
</tr>
<tr>
<td>4:30 pm</td>
<td>FC86–FC90&lt;br&gt;Fetal and neonatal glucose metabolism&lt;br&gt;Maryland</td>
<td></td>
</tr>
<tr>
<td>4:45 pm</td>
<td>FC91–FC95&lt;br&gt;Adrenals #1&lt;br&gt;Thurgood Marshall SW</td>
<td></td>
</tr>
<tr>
<td>5:00 pm</td>
<td>SAT&lt;br&gt;Central precocious puberty: case presentations and discussion of nuances in diagnosis, treatment, and follow-up&lt;br&gt;Maryland</td>
<td></td>
</tr>
<tr>
<td>5:15 pm</td>
<td>SAT&lt;br&gt;Evolving trends in puberty&lt;br&gt;Washington 1-3</td>
<td></td>
</tr>
<tr>
<td>5:30 pm</td>
<td>SAT&lt;br&gt;Updated guidelines for the use of growth hormone therapy in children and adolescents: exploring the impact on clinical practice&lt;br&gt;Thurgood Marshall NE</td>
<td></td>
</tr>
<tr>
<td>5:45 pm</td>
<td>SAT&lt;br&gt;Updated guidelines for the use of growth hormone therapy in children and adolescents: exploring the impact on clinical practice&lt;br&gt;Thurgood Marshall NE</td>
<td></td>
</tr>
</tbody>
</table>

**Daily Program**

**Saturday 9/16/17**

**Registration Opens**

**Coffee in Exhibit Hall (7:00-7:30am)**

**Breakfast SAT**

A rare cause of short stature you don't want to miss

**Delaware**

**Thursday 9/15/17**

**6:00 am**

Registration Opens

**Coffee in Exhibit Hall (7:00-7:30am)**

**Breakfast SAT**

A very special cause of short stature you won't want to miss

**Delaware**

**6:30 am**

FC51–FC55

Quality improvement

**Marriott Ballroom**

**7:00 am**

MTE8:1

Management of hyperthyroidism in children

**Marriott Ballroom**

**7:15 am**

MTE9:1

Diabetes in the infant

**Washington 4-6**

**7:45 am**

MTE6:1

Growth and GH/IGF Axis #2

**Washington 4-6**

**8:00 am**

MTE6:2

Obesity, lipids, and comorbidities #2

**Maryland**

**8:30 am**

MTE10:1

Hyperinsulinemic Hypoglycemia: Management and recent advances

**Maryland**

**9:15 am**

MTE11:1

Exercising safely with T1DM

**Washington 4-6**

**9:30 am**

MTE12:1

The etiology and management of Hypophosphatemic Rickets

**Marriott Ballroom**

**10:00 am**

Refreshment Break, Poster Viewing and Exhibits

**Exhibition Hall**

**10:15 am**

**PL5:** ISPE – Skeletal muscle glucocorticoid receptor and systemic energy metabolism by Hirotoshi Tanaka<br>**Marriott Ballroom**

**10:45 am**

**PL6:** SLEP – César Bergadá Lecture–Disorders in sex development: a persistent challenge by Alicia Belgorosky<br>**Marriott Ballroom**

**11:00 am**

**PL7:** CSPEM – Polycystic Ovary Syndrome clinical and genetic characteristics by Junfen Fu and Zijiang Chen<br>**Marriott Ballroom**

**12:00 pm**

**P3 and Boxed Lunches**

**12:15 pm**

**PES Fellows Lunch Meeting**

**12:00-1:00**

**Madison**

**12:30 pm**

**1:15 pm**

**1:45 pm**

**2:00 pm**

**2:15 pm**

**2:30 pm**

**2:45 pm**

**3:00 pm**

**Refresher Break and Exhibits**

**Exhibition Hall**

**3:15 pm**

**FC81–FC85**

Type 1 Diabetes #2<br>**Marriott Ballroom**

**3:30 pm**

**NP2**

Microbiome and human endocrinology; & Environmental endocrine disruption: What's new?<br>**Marriott Ballroom**

**3:45 pm**

**MTE2:2**

Distinguishing monogenic forms from type 1 and type 2 diabetes: Does your patient have the right diagnosis?<br>**Marriott Ballroom**

**4:00 pm**

**MTE7:2**

Pediatric osteoporosis<br>**Washington 4-6**

**4:15 pm**

**YB2**

Fetal and neonatal glucose metabolism<br>**Maryland**

**4:30 pm**

**FC86–FC90**

Fetal and neonatal glucose metabolism<br>**Maryland**

**4:45 pm**

**FC91–FC95**

Adrenals #1<br>**Delaware**

**5:00 pm**

**SAT**

Central precocious puberty: case presentations and discussion of nuances in diagnosis, treatment, and follow-up<br>**Marriott Ballroom**

**5:15 pm**

**SAT**

Evolving trends in puberty<br>**Washington 1-3**

**5:30 pm**

**SAT**

Updated guidelines for the use of growth hormone therapy in children and adolescents: exploring the impact on clinical practice<br>**Thurgood Marshall NE**

**5:45 pm**

**SAT**

Updated guidelines for the use of growth hormone therapy in children and adolescents: exploring the impact on clinical practice<br>**Thurgood Marshall NE**
### Saturday, September 16

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 am</td>
<td>Registration Opens (Lobby Level)</td>
</tr>
<tr>
<td>6:00 pm – 7:30 pm</td>
<td>IMPE Breakfast Satellite Symposium (SAT)</td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>A rare cause of short stature you don’t want to miss</td>
</tr>
<tr>
<td><strong>Room:</strong></td>
<td>Delaware</td>
</tr>
<tr>
<td><strong>Sponsor:</strong></td>
<td>Sanofi Genzyme</td>
</tr>
<tr>
<td>7:30 am – 8:30 am</td>
<td>Free Communication Session (FC51-FC55)</td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>Quality improvement</td>
</tr>
<tr>
<td><strong>Room:</strong></td>
<td>Thurgood Marshall Ballroom NE</td>
</tr>
</tbody>
</table>

**FC51**
**ABILITY OF ANTI-THYROID Peroxidase AND ANTI-THYROGLOBULIN ANTIBODIES ALONE AND IN COMBINATION TO PREDICT SUBSEQUENT HYPOHYPERTIOSM IN NEWLY DIAGNOSED TYPE 1 DIABETES PATIENTS**

Bhavana Narala, MD, Medical College of Wisconsin, Milwaukee, WI, United States; Evelyn Kuhn, PhD, Children’s Hospital of Wisconsin, Milwaukee, WI, United States; David Wyatt, MD, Medical College of Wisconsin, Milwaukee, WI, United States; Peter Wolfram, MD, Medical College of Wisconsin, Milwaukee, WI, United States

**FC52**
**QUALITY IMPROVEMENT IN THE PERIOPERATIVE MEDICAL MANAGEMENT OF PEDIATRIC THYROIDECTOMY**

Kristina Cossen, MD; Kanika Shanker, MD; Kurt Heiss, MD; Matthew Santore, MD, Emory University, Atlanta, GA, United States; Briana Patterson, MD, Emory University School of Medicine, Atlanta, GA, United States

**FC53**
**URINARY STEROIDOMICS FOR THE MANAGEMENT OF CHILDREN WITH CONGENITAL ADRENAL HYPERPLASIA**

Clemens Kamrath, MD; Lisa Wettstaedt, Medical Student, Justus Liebig University Giessen, Giessen, Germany; Michaela F Hartmann, PhD; Stefan A Wudy, PhD, Justus Liebig University, Giessen, Germany

**FC54**
**PREVENTION OF DIABETES KETOACIDOSIS BY IMPLEMENTATION OF INTENSIVE SICK DAY RULES**

Grace Nelson, MD; Ramin Alemzadeh, MD; Amit Lahoti, MD, University of Tennessee Health Science Center, Memphis, TN, United States

**FC55**
**HYDROCORTISONE GRANULES WITH TASTE MASKING ARE WELL ABSORBED AND TOLERATED IN NEONATES, INFANTS & CHILDREN WITH ADRENAL INSUFFICIENCY**

Uta Neumann, MD, Charité-Universitätsmedizin Berlin, Berlin, Germany; Martin J Whitaker, Prof., Diurnal Limited, Cardiff, United Kingdom; Susanna Wiegand, MD; Heiko Krude, Prof., Charité University medicine Berlin, Berlin, Germany; John Porter, PhD; Madhu Davies, MB; Dena Digweed, BSc, Diurnal Limited, Cardiff, United Kingdom; Richard J Ross, MD, University of Sheffield, Sheffield, United Kingdom; Oliver Blankenstein, PhD, Charité – Universitätsmedizin Berlin, Berlin, Germany

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am – 8:30 am</td>
<td>Meet the Expert (MTE8:1)</td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>Management of hyperthyroidism in children</td>
</tr>
<tr>
<td><strong>Room:</strong></td>
<td>Marriott Ballroom</td>
</tr>
<tr>
<td><strong>Expert:</strong></td>
<td>Julianne Léger, France</td>
</tr>
<tr>
<td>7:30 am – 8:30 am</td>
<td>Meet the Expert (MTE1:2)</td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>Diagnosis and management of pseudohypoparathyroidism and related conditions</td>
</tr>
<tr>
<td><strong>Room:</strong></td>
<td>Thurgood Marshall Ballroom SW</td>
</tr>
<tr>
<td><strong>Expert:</strong></td>
<td>Emily Germain-Lee, United States</td>
</tr>
</tbody>
</table>
7:30 am – 8:30 am  Meet the Expert (MTE9:1)

**Session Title:** Diabetes in the infant  
**Room:** Washington 4-6  
**Expert:** Thomas Danne, Germany

7:30 am – 8:30 am  Free Communication Session (FC56-FC60)

**Session Title:** Growth and GH/IGF Axis #2  
**Room:** Washington 1-3

### FC56
NOVEL DOMINANT-NEGATIVE GH RECEPTOR MUTATIONS EXPANDS THE SPECTRUM OF GHI AND IGF-I DEFICIENCY  
Kanimozhi Vairamani, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Lina Merjaneh, MD, Seattle Children's Hospital, Seattle, WA, United States; Paula Casano-Sancho, MD, Sant Joan de Déu Hospital, Barcelona, Spain; Merve E Sanli, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Alessia David, MD, Imperial College London, London, United Kingdom; Louise A Metherell, PhD; Martin O Savage, MD, William Harvey Research Institute, London, United Kingdom; Jaime Sánchez Del Pozo, MD, Hospital Doce de Octubre. UCM, Madrid, Spain; Philippe Backeljauw, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Ron G Rosenfeld, MD, Oregon Health & Science University, Portland, OR, United States; Javier Aisenberg, MD, Hackensack University Medical Center, Hackensack, NJ, United States; Andrew Dauber, MD; Vivian Hwa, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States

### FC57
TRANSCON CNP, A SUSTAINED-RELEASE PRODRUG OF C-TYPE NATRIURETIC PEPTIDE, EXERTS POSITIVE EFFECTS ON BONE IN YOUNG Cynomolgus Monkeys and in a Mouse Model of Achondroplasia  
Kennett Sprogoe, PhD; Vibeke Mil Breinholt, PhD; Rasmussen Caroline, PhD; Per H Mygind, PhD; Oliver Keil, PhD; Susanne Adermann, PhD; Ulrich Hersel, PhD, Ascendis Pharma, Heidelberg, Germany; Nabil Kaci, PhD; Cornille Maxence, PhD, Inserm U1163-Institut Imagine, Paris, France; Lars H Andersen, PhD, Ascendis Pharma, Hellerup, Denmark; Laurence Legeai-Mallet, PhD, Inserm U1163-Institut Imagine, Paris, France

### FC58
3-YEAR UPDATE OF THE PHASE 2A AND LONG-TERM SAFETY STUDIES (VERTICAL AND VISTA) OF SOMAVARATAN (VRS-317), A LONG-ACTING RHGH FOR THE TREATMENT OF PEDIATRIC GROWTH HORMONE DEFICIENCY  
Bradley S. Miller, MD, PhD, University of Minnesota Masonic Children's Hospital, Minneapolis, MN, United States; Wayne V. Moore, MD, PhD, Children's Mercy Hospital and University of Missouri-Kansas City, Kansas City, MO, United States; Patricia Y. Fechner, MD, Seattle Children's Hospital and University of Washington, Seattle, WA, United States; Huong Jil Nguyen, MD, Sierra Medical Research, Clovis, CA, United States; Quentin L. Van Meter, MD, Van Meter Pediatric Endocrinology, P.C., Atlanta, GA, United States; John S. Fuqua, MD, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, United States; David Ng, PhD, ResearchPoint Global, Inc., Austin, TX, United States; Eric Humphriss, MBA; R. W. Charlton, MD, Versartis, Inc, Menlo Park, CA, United States; George M. Bright, MD, Versartis, Inc., Menlo Park, CA, United States

### FC59
PHENOTYPICAL FEATURES OF PATIENTS WITH A MOLECULAR DEFECT OF THE IGF-1 RECEPTOR AND THE GROWTH RESPONSE TO GROWTH HORMONE TREATMENT  
Marie JE Walenkamp, MD, VU University Medical Center, Amsterdam, Netherlands; Jasmijn ML Robers, BS/BAA; Jan M Wit, Professor, Leiden University Medical Center, Leiden, Netherlands; Gladys RJ Zandwijken, MD, Dutch Growth Research Foundation, Rotterdam, Netherlands; Wilma Oostdijk, MD; Sarina G Kant, MD, Leiden University Medical Center, Leiden, Netherlands; Monique Losekoot, PhD, Leiden University Medical Centre, Leiden, Netherlands

### FC60
BONE MINERAL DENSITY IN YOUNG ADULTS WITH PRADER-WILLI SYNDROME: RESULTS OF A 2-YEAR RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER TRIAL  
Stephany H Donze, MD; Renske J Kuppens, MD, PhD, Erasmus Medical Center / Dutch Growth Research Foundation, Rotterdam, Netherlands; Nienke E Bakker, MD, PhD; Elburch PE Siemensma, MD, PhD, Erasmus Medical Center, Rotterdam, Netherlands; Anita CS Hokken-Koelega, MD, PhD, Erasmus Medical Center / Dutch Growth Research Foundation, Rotterdam, Netherlands
### Session Title: Obesity, lipids, and co-morbidities #2
### Room: Maryland

**FC61**
**THE ROLE OF SOLUBLE LIPID TRANSPORT PROTEINS IN MODULATING LIVER RECEPTOR HOMOLOG-1 (LRH-1) MEDIATED GENE EXPRESSION**
Mireille El Bejjani, MD, Emory University, Atlanta, GA, United States; Suzanne G. Mays, MS/MA; Matthew C. Tillman, BS/BA; Eric A. Ortlund, PhD, Emory University, Atlanta, GA, United States

**FC62**
**BARIATRIC SURGERY DURING THE TRANSITION PHASE IN PRADER-WILLI SYNDROME: LONG-TERM OUTCOME AFTER BILIOPANCREATIC DIVERSION**
Antonino Crino', MD; Danilo Fintini, MD; Alessio Convertino, MD; Sarah Bocchini, MD, Bambino Gesù Hospital, Research Institute, Palidora (Roma), Italy; Graziano Grugni, MD, Italian Auxological Institute, Piancavallo (Verbiana), Italy

**FC63**
**TREATMENT OF TWO POMC DEFICIENT PATIENTS WITH THE MELANOCORTIN-4 RECEPTOR AGONIST SETMELANOTIDE LED TO SUCCESSFUL WEIGHT LOSS**
Peter Kühnen, MD, Charité Universitätsmedizin Berlin, Berlin, Germany; Karine Clément, Professor, Assistance-Publique Hôpitaux de Paris, Paris, France; Keith Gottesdiener, MD, Rhythm pharmaceuticals, Boston, MA, United States; Barbara Wolters, MD, Charité Universitätsmedizin Berlin, Berlin, Germany; Fred Fiedorek, MD; Lex Van Der Ploeg, MD, Rhythm pharmaceuticals, Boston, MA, United States; Oliver Blankenstein, PhD, Charité – Universitätsmedizin Berlin, Berlin, Germany; Susanna Wiegand, MD, Charité University medicine Berlin, Berlin, Germany; Annette Grüters, Professor, Charité Universitätsmedizin Berlin, Berlin, Germany; Heiko Krude, Prof., Charité University medicine Berlin, Berlin, Germany

**FC64**
**ADJUSTING FOR PUBERTAL STATUS REDUCES PREVALENCE OF OBESITY**
O.Yaw Addo, PhD, Rollins School of Public Health Emory, Atlanta, GA, United States; Bradley S. Miller, MD, PhD, University of Minnesota Masonic Children’s Hospital, Minneapolis, MN, United States

**FC65**
**IDENTIFICATION OF RARE GENETIC VARIANTS IN PATIENTS WITH NON-SYNDROMIC EARLY-ONSET OBESITY USING A POOLED DNA SEQUENCING APPROACH**
Gabriel Á. Martos-Moreno, MD; PhD., Hospital Infantil Universitario Niño Jesús. UAM., Madrid, Spain; Clara Serra-Juhé, PhD; Francesc Bou, PhD; Benjamín Rodríguez-Santiago, PhD; Raquel Flores, PhD; Luis A Pérez-Jurado, MD, PhD, Universitat Pompeu Fabra, Barcelona, Spain; Jesús Argente, MD, PhD, Hospital Infantil Universitario Niño Jesús. UAM, Madrid, Spain

### Session Title: Pediatric pheochromocytoma/paraganglioma
### Room: Virginia
### Expert: Khalid Hussain, United Kingdom

**Meet the Expert (MTE6:2)**

**Session Title: Hyperinsulinemic hypoglycemia: Management and recent advances**
**Room: Marriott Ballroom**
**Expert: Nalini Shah, India**

**Meet the Expert (MTE10:1)**

**Session Title: PWS from birth to adulthood**
**Room: Washington 1-3**
**Expert: Jennifer Miller, United States**

**Meet the Expert (MTE3:2)**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Room</th>
<th>Expert</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:45 am – 9:45 am</td>
<td>Meet the Expert (MTE11:1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session Title:</strong> Exercising safely with T1DM</td>
<td></td>
<td>Elizabeth Davis, Australia</td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Thurgood Marshall Ballroom NE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:45 am – 9:45 am</td>
<td>Meet the Expert (MTE12:1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session Title:</strong> The etiology and management of hypophosphatemic rickets</td>
<td></td>
<td>Leanne Ward, Canada</td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Washington 4-6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session Title:</strong> Type 2 diabetes and other carbohydrate metabolism #2</td>
<td></td>
<td>Virginia</td>
</tr>
</tbody>
</table>

**FC66**
DIABETES MELLITUS IN THE LONG-TERM FOLLOW-UP OF NON-PANCREATECTOMISED PATIENTS WITH PERSISTENT HYPERINSULINAEMIC HYPOGLYCAEMIA OF INFANCY DUE TO LOSS-OF-FUNCTION MUTATIONS IN THE ABCC8 GENE: A NEW FORM OF MONOGENIC DIABETES?
Maria Clemente, PhD, Hospital Vall d’Hebron/ Autonomous University, Barcelona, Spain; Ariadna Campos, PhD, Hospital Vall d’Hebron, Barcelona, Spain; Diego Yeste, PhD, Hospital Vall d’Hebron/ Autonomous University. CIBERER, Barcelona, Spain; Maria Caimari, PhD, Hospital Universitario Son Espases, Palma de Mallorca, Spain; Rosa Martinez-Salazar, PhD, BioCrues Health Research Institute, Cruces University Hospital, CIBERDEM, CIBERER, Barakaldo, Spain; Antonio Carrascosa, PhD, Hospital Vall Hebron, Barcelona, Spain

**FC67**
SULPHONYLUREAS ARE A HIGHLY EFFECTIVE AND SAFE LONG-TERM TREATMENT FOR NEONATAL DIABETES DUE TO KCNJ11 MUTATIONS: THE FIRST 10-YEAR FOLLOW-UP STUDY OF A LARGE INTERNATIONAL COHORT
Pamela Bowman, MBBS, University of Exeter, Exeter, United Kingdom; Asta Sulen, BS/BA, University of Bergen, Bergen, Norway; Fabrizio Barbetti, MD, University of Rome Tor Vergata, Rome, Italy; Jacques Beltrand, MD, Faculte de medecine Paris Descartes, Hôtel Universitaire Necker Enfants Malades, Paris, France; Michel Polak, Professor, INSERM U1016, Cochin Institute and INSERM U1163, Imagine Institute, Paris Descartes University, Sorbonne Paris Cité, Necker Children’s University Hospital, Paris, France; Dario Iafusco, MD, Bambino Gesu Children’s Hospital, University of Tor Vergata, Rome, Italy; Pernille Svalastoga, MD, University of Bergen, Bergen, Norway; Torild Skrivervik, MD, University of Oslo, Oslo, Norway; Ivar Klimes, MD, Slovak Academy of Sciences, Bratislava, Slovakia; Ethel Godner, MD, University of Chile, Santiago, Chile; Ellen Tessmann, MD, University of Tennessee, Knoxville, TN, United States; Maciej T Malecki, MD, University Hospital, Jagiellonian University Medical College, Krakow, Poland; Andrew T Hattersley, MD, University of Exeter, Exeter, United Kingdom; Pal R Nyløstad, MD, University of Bergen, Bergen, Norway

**FC68**
PSEUDOACROMEGALY AND INSULIN RESISTANCE, A RARE DISORDER OF DOWNSTREAM INSULIN SIGNALING
Stephen I Stone, MD; Jennifer A Wambach, MD; Francis S Cole, MD; Daniel J Wegner, MS/MA; Fumihiko Urano, MD PhD, Washington University School of Medicine, St. Louis, MO, United States

**FC69**
ADIPOCYTE GAMMA-SECRETASE INHIBITION ALTERS INFLAMMATORY CYTOKINE PRODUCTION
David Sparling, MD, PhD; Nile McCullough, BS/BA, University of Oklahoma, Oklahoma City, OK, United States

**FC70**
THE PREVALENCE OF ABNORMAL LIPIDS AND PREDIABETES IS SIGNIFICANTLY INCREASED IN YOUTH WITH DOWN SYNDROME COMPARED TO TYPICALLY-DEVELOPING PEERS
Sheela N. Magge, MD; Rachel Walega, MS/MA, Children’s National Health System, 111 Michigan Ave NW, DC, United States; Claire I. Cochrane, BS/BA; Babette S. Zemel, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, United States; Andrea Kelly, MD, The Children’s Hospital of Philadelphia, Philadelphia, PA, United States
Session Title: Thyroid  
Room: Maryland

FC71
BORDERLINE NEONATAL TSH LEVELS AND EDUCATIONAL AND DEVELOPMENT OUTCOMES: A POPULATION-BASED RECORD-LINKAGE STUDY
Michelle M. Jack, PhD, Royal North Shore Hospital, Northern Clinical School, University of Sydney, Sydney, Australia; Samantha Lain, PhD; Jason Bentley, PhD, University of Sydney, Sydney, Australia; Veronica Wiley, PhD, The Children’s Hospital at Westmead, Sydney, Australia; Christine Roberts, PhD, Kolling Research Institute, Sydney, Australia; Bridget Wilcken, MD, The Children’s Hospital at Westmead, Sydney, Australia; Natasha Nassar, PhD, University of Sydney, Sydney, Australia

FC72
DETERMINATION OF CALCITONIN REFERENCE RANGES FROM HEALTHY INFANTS, CHILDREN AND ADOLESCENTS – AN IMPORTANT TOOL FOR THE EARLY DIAGNOSIS OF MEDULLARY THYROID CANCER
Felix Eckelt, doctoral candidate; Mandy Vogel, PhD; Mandy Geserick, PhD; Toralf Kirsten, PhD; Yoon Ju Bae, PhD; Michael Schaab, PhD; Antje Koerner, MD; Andreas Hiemisch, PsyD; Joachim Thiery, MD; Roland Pfäeffle, MD; Wieland Kiess, MD, University of Leipzig, Leipzig, Germany; Friedhelm Raue, MD, University of Heidelberg, Heidelberg, Germany; Juergen Kratzsch, PhD, University of Leipzig, Leipzig, Germany

FC73
EPIDEMIOLOGY OF CHILDHOOD HYPERTHYROIDISM IN FRANCE: A NATIONWIDE POPULATION-BASED STUDY
Marie Simon, MD; Rigou Annabel, MS/MA; Le Moal Joëlle, MD; Zeghnoun Abdelkrim, PhD; Le Tertre Alain, PhD; De Crouy-Chanel Perrine, MS/MA, Santé publique France, Paris, France; Florentia Kaguelidou, PhD; Juliane Léger, MD, University of Paris, Robert Debré Hospital, Paris, France

FC74
THE PARIS-IMAGINE “HYPOTHYSEQ NGS PANEL” IS NOW FUNCTIONAL AND BRINGS VALUABLE INFORMATION ON THE GENETICS IN A LARGE COHORT OF CHILDREN WITH CONGENITAL HYPOTHYROIDISM
Athanasia Stoupa, MD, INSERM U1163, Imagine Institute, Paris Descartes University, Sorbonne Paris Cité, Necker Children’s University Hospital, Paris, France; Manelle Gueriouz, BS/BA, IMAGINE Institute Affiliate, Paris, France; Dulanjalee Karyiawasam, MD, PhD, AP-HP, Paris, France; Sylvain Hanein, PhD, IMAGINE Institute Affiliate, Paris, France; Christine Boile-Feyssot, PhD, INSERM U1163, Imagine Institute, Paris Descartes University, Sorbonne Paris Cité, Necker Children’s University Hospital, Paris, France; Johnny Deladoey, Professor, University of Montreal, Montreal, QC, Canada; Gabor Szinnai, MD, PhD, University of Basel, Basel, Switzerland; Michel Polak, Professor, INSERM U1016, Cochin Institute and INSERM U1163, Imagine Institute, Paris Descartes University, Sorbonne Paris Cité, Necker Children’s University Hospital, Paris, France; Aurore Carre, PhD, Paris Descartes University, Sorbonne Paris Cité, Paris, France

FC75
MUTATIONS IN IRS4 ARE ASSOCIATED WITH CENTRAL HYPOTHYROIDISM
Charlotte A. Heinen, MD; Emmely M. De Vries, PhD, Academic Medical Center, Amsterdam, Netherlands; Erica L.T. Van Den Akker, MD, Erasmus MC, Rotterdam, Netherlands; Boudewijn Bakker, MD, Reinier de Graaf Hospital, Delft, Netherlands; Gera Hooreweg-Nijman, MD, St. Antonius Hospital, Nieuwegein, Netherlands; Ferdinand Roelfsema, MD, Leiden University Medical Center, Leiden, Netherlands; Raoul C. Hemnekam, MD; Anita Boelen, MD; Eric Fliers, MD; A.S. Paul Van Trotsenburg, MD, Academic Medical Center, Amsterdam, Netherlands
### Session Title: Free Communication Session (FC76-FC80)

**Room:** Thurgood Marshall Ballroom SW

<table>
<thead>
<tr>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
</table>
| FC76          | **IDENTIFICATION OF GENETIC VARIANTS IN A LARGE COHORT OF PATIENTS WITH CONGENITAL HYPOTHALAMO-PITUITARY DISORDERS**
|               | Louise C Gregory, PhD, UCL Great Ormond Street Institute of Child Health, London, United Kingdom; Mark J McCabe, PhD; Kyriaki S Alatzoglou, PhD; James P Turton, PhD; Emma A Webb, PhD; Hywel Williams, PhD, UCL Great Ormond Street Institute of Child Health, London, United Kingdom; Carles Gaston-Massuet, PhD, Barts & The London Medical School, Queen Mary University of London, London, United Kingdom; Daniel Kelberman, PhD; Mehul Dattani, Professor, UCL Great Ormond Street Institute of Child Health, London, United Kingdom |
| FC77          | **OXYTOCIN IN CHILDHOOD-ONSET CRANIOPHARYNGIOMA - FIRST EXPERIENCES WITH NEUROPSYCHOLOGICAL EFFECTS OF OXYTOCIN ADMINISTRATION**
|               | Hermann L. Müller, MD; Hoffmann Anika, MD; Daubenbüschel Anna, MD; Boekhoff Svenja, Physician's Assistant; Tjaden Kerstin, PhD, Medical Campus University Oldenburg, Oldenburg, Oldenburg, Germany; Özyurt Jale, PsyD, Carl von Ossietzky University, Oldenburg, Germany |
| FC78          | **A NOVEL DENOVO FORKHEAD BOX A2 (FOXA2) MUTATION LEADS TO CONGENITAL HYPERINSULINISM, CRANIOFACIAL DYSMORPHIC FEATURES AND CONGENITAL HYPOPITUITARISM**
|               | Dinesh Giri, FRCPCH, University of Liverpool & Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom; Maria Liliina Vignola, MSc; Angelica Gualtieri, MSc; Valeria Scaglioni, MSc, Queen Mary University of London, London, United Kingdom; Mohammed Didi, MRCPCH, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom; Carles Gaston-Massuet, PhD, Barts & The London Medical School, Queen Mary University of London, London, United Kingdom; Senthil Senniappan, PhD, University of Liverpool & Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom |
| FC79          | **MOLECULAR ANALYSIS OF BRAZILIAN PATIENTS WITH COMBINED PITUITARY HORMONE DEFICIENCY (CPHD) AND ORTHOTOPIC POSTERIOR PITUITARY LOBE (OPP) REVEALS 8 DIFFERENT PROP1 ALTERATIONS WITH THREE NOVEL MUTATIONS**
|               | Joao LO Madeira, MD; Mirian Y Nishi, PhD; Marilena Nakaguma, MD; Anna F Bennedetti, BS/BA; Isabel P Biscotto, MD, University of Sao Paulo, Medical School, São Paulo, Brazil; Thamiris Fernandes, MD, Faculdade de Medicina da Universidade Federal do Espírito Santo, Vitória, Brazil; Thiago Pequeno, MD; Thalita Figueiredo, PhD, State University of Paraíba, Campina Grande, Brazil; Marcela M França, PhD, University of Sao Paulo, Medical School, São Paulo, Brazil; Fernanda A Correa, PhD, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; Aline P Otto, PhD; Milena Abrão, MS/MA, University of Sao Paulo, Medical School, São Paulo, Brazil; Mirta Miras, PhD, Hospital de Niños de Córdoba, Córdoba, Argentina; Silvana Santos, PhD, State University of Paraíba, Campina Grande, Brazil; Alexander A Jorge, PhD, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; Everton F Costaalonga, PhD, Faculdade de Medicina da Universidade Federal do Espírito Santo, Vitória, Brazil; Berenice B Mendonça, PhD, University of Sao Paulo, Medical School, São Paulo, Brazil; Ivo J P Arnhold, PhD; Luciani R Carvalho, PhD, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil |
| FC80          | **DIABETES INSIPIDUS AFTER MODERATE-SEVERE TRAUMATIC BRAIN INJURY IN CHILDREN**
|               | Deepti R Deshpande, MBBS, University of Arizona, Tucson, AZ, United States; Cindy Chin, MD, University of Arizona, College of Medicine, Tucson, AZ, United States; Mark Borgstrom, PhD; Sydney Rice, MD, University of Arizona, Tucson, AZ, United States |

### Session Title: Exhibits and Poster viewing (unattended)

**Room:** Exhibition Hall

### Session Title: Exhibits and Poster viewing (unattended)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Type</th>
<th>Session Title</th>
<th>Room</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 am – 10:45 am</td>
<td>Plenary (PL5)</td>
<td><strong>Japanese Society for Pediatric Endocrinology (JSPE) – Skeletal muscle glucocorticoid receptor and systemic energy metabolism</strong></td>
<td>Marriott Ballroom</td>
<td>Hiroshi Tanaka, Japan</td>
</tr>
<tr>
<td>10:45 am – 11:15 am</td>
<td>Plenary (PL6)</td>
<td><strong>Sociedad Latinoamericana de Endocrinología Pediátrica (SLEP) César Bergadá Lecture—Disorders in sex development: A persistent challenge</strong></td>
<td>Marriott Ballroom</td>
<td>Alicia Belgorosky, Argentina</td>
</tr>
<tr>
<td>11:15 am – 11:45 am</td>
<td>Plenary (PL7)</td>
<td><strong>Chinese Society of Pediatric Endocrinology and Metabolism (CSPEM) – Polycystic ovary syndrome clinical and genetic characteristics</strong></td>
<td>Marriott Ballroom</td>
<td>Junfen Fu, China &amp; Zijiang Chen, China</td>
</tr>
<tr>
<td>11:30 am – 12:30 pm</td>
<td>Poster (P3)</td>
<td><strong>Poster session #3 (author attended) and Box Lunches in Exhibition Hall</strong></td>
<td>Exhibition Hall</td>
<td>For further details see page 80.</td>
</tr>
<tr>
<td>12:00 pm – 1:00 pm</td>
<td>PES Fellows Lunch Meeting</td>
<td><strong>PES Fellows Lunch Meeting</strong></td>
<td>Madison</td>
<td></td>
</tr>
<tr>
<td>1:15 pm – 2:45 pm</td>
<td>Topic Symposium (S)</td>
<td><strong>Epigenetics in pediatric endocrine disorders</strong></td>
<td>Marriott Ballroom</td>
<td>Mehul Dattani, United Kingdom &amp; Cheri Deal, Canada</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Towards the understanding of imprinting disorders</strong></td>
<td></td>
<td>Thomas Eggermann, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Diagnosis and management of Silver-Russell syndrome</strong></td>
<td></td>
<td>Irène Netchine, France</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Epigenetics in neonatal diabetes mellitus and hyperinsulinism</strong></td>
<td></td>
<td>Tohru Yorifuji, Japan</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Room</td>
<td>Moderators</td>
<td>Presentations</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------------------------</td>
<td>-------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>1:15 pm – 2:45 pm</td>
<td><strong>Topic Symposium (S)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session Title:</strong> Gender dysphoria</td>
<td><strong>Room:</strong> Washington 4-6</td>
<td><strong>Moderators:</strong> Stephen Rosenthal, United States &amp; Sabine Hannema, Netherlands</td>
<td>Epigenetic modification of sex differentiation in brain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Margaret M McCarthy, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sex differences in brain and behavior</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Eric Vilain, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical management</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Peggy Cohen-Kettenis, Netherlands</td>
</tr>
<tr>
<td>1:15 pm – 2:45 pm</td>
<td><strong>Controversies in Pediatric Endocrinology (CPE4)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session Title:</strong> Imaging for congenital hypothyroidism</td>
<td><strong>Room:</strong> Thurgood Marshall Ballroom NE</td>
<td><strong>Moderators:</strong> Mark Palmert, Canada &amp; Asaf Oren, Israel</td>
<td>Thyroid Imaging should be a routine step in the diagnosis and therapeutic planning for congenital hypothyroidism</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PRO: Johnny Deladoëy, Canada</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PRO: Stephen Lafranchi, United States</td>
</tr>
<tr>
<td>1:15 pm – 2:45 pm</td>
<td><strong>Topic Symposium (S)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session Title:</strong> Treatment of bone metabolism disorders</td>
<td><strong>Room:</strong> Virginia</td>
<td><strong>Moderators:</strong> Keichi Ozono, Japan &amp; Erik Imel, United States</td>
<td>Update on hypophosphatemic rickets</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Thomas Carpenter, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Update on osteogenesis imperfecta</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Frank Rauch, Canada</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Update on hypoparathyroidism</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rachel Gafni, United States</td>
</tr>
<tr>
<td>2:45 pm – 3:15 pm</td>
<td><strong>Refreshment Break</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Exhibition Hall</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:15 pm – 4:45 pm</td>
<td><strong>Controversies in Pediatric Endocrinology (CPE4)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session Title:</strong> Adult consequences of pediatric endocrine disease</td>
<td><strong>Room:</strong> Thurgood Marshall Ballroom SW</td>
<td><strong>Moderators:</strong> Lars Savendahl, Sweden &amp; Cathy Choong, Australia</td>
<td>Type 1 diabetes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Johnny Ludvigsson, Sweden</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Disorders of sex development</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Olaf Hiort, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Childhood onset hypopituitarism</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gudmundur Johansson, Sweden</td>
</tr>
</tbody>
</table>
3:15 pm – 4:15 pm  Free Communication Session (FC81-FC85)

**Session Title:** Type 1 Diabetes #2  
**Room:** Thurgood Marshall Ballroom NE

**FC81**  
CARDIOVASCULAR AUTONOMIC DYSFUNCTION PREDICTS INCREASING ALBUMIN EXCRETION IN TYPE 1 DIABETES  
David L Lu, MBChir, National University Health System, Singapore, Singapore; David B Dunger, PhD; Loredana Marcovecchio, PhD, University of Cambridge, Cambridge, United Kingdom

**FC82**  
EFFICACY AND SAFETY OF SWITCHING FROM INSULIN DETEMIR TO INSULIN DEGLUDEC WITH MEALTIME INSULIN ASPART IN PEDIATRIC PATIENTS WITH TYPE 1 DIABETES. AN OBSERVATIONAL PROSPECTIVE STUDY  
Nancy S Elbarbary, MD, Ain Shams University, Cairo, Egypt

**FC83**  
CAN AN ELECTRONIC CLINICAL TOOL IMPROVE COMMUNICATION AROUND EXERCISE IN YOUTH WITH TYPE 1 DIABETES?  
Connor A Mitrovich, BS/BA, Seattle Children’s Research Institute, Seattle, WA, United States; Alissa J Roberts, MD, University of Washington, Seattle, WA, United States; Joyce Yi-Frazier, PhD, Seattle Children’s Hospital, Seattle, WA, United States; Craig E Taplin, MBBS, University of Washington, Seattle, WA, United States

**FC84**  
PERSISTENT ELEVATIONS IN BETA CELL DEATH AMONG INDIVIDUALS WITH LONGSTANDING TYPE 1 DIABETES  
Emily K Sims, MD; Sarah Tersey, PhD; Jennifer Nelson, BS/BA; Raghavendra G Mirmira, MD-PhD; Carmella Evans Molina, MD-PhD, Indiana University School of Medicine, Indianapolis, IN, United States

**FC85**  
GLUCOSE CONTROL IN ADOLESCENTS WITH T1D DURING THE MEDTRONIC HYBRID CLOSED-LOOP PIVOTAL TRIAL  
Jennifer Sherr, MD, PhD, Yale University School of Medicine, New Haven, CT, United States; Stuart A Weinzimer, MD, Yale University, New Haven, CT, United States; Robert H Slover, MD, University of Colorado Denver, Aurora, CO, United States; Bruce A Buckingham, MD, Stanford University, Stanford, CA, United States; Amy B Crego, MD, MS, Park Nicollet Clinic Pediatric Endocrinology, Minneapolis, MN, United States; Stacey M Anderson, MD, PhD, University of Virginia, Charlottesville, VA, United States; Timothy S Bailey, MD, AMCR Institute, Escondido, CA, United States; Bruce W Bode, MD, Atlanta Diabetes Associates, Atlanta, GA, United States; Ronald L Braz, MD, Rainier Clinical Research Center, Renton, WA, United States; Satish K Garg, MD, University of Colorado Denver, Aurora, CO, United States; Jacob Ilany, MD, Sheba Medical Center, Tel Hashomer, Israel; John Shin, PhD; Scott W Lee, MD; Toni Cordero, PhD; Francine R Kaufman, MD, Medtronic, Northridge, CA, United States

3:15 pm – 4:15 pm  New Perspectives (NP2)

**Session Title:** Microbiome and human endocrinology; and Environmental endocrine disruption: What’s new?  
**Room:** Marriott Ballroom  
**Moderators:** Ragnar Hanas, Sweden & Mary Lee, United States

**Microbiome and human endocrinology**  
Aleksandar Kostic, United States

**Environmental endocrine disruption: What’s new?**  
Anne-Simon Parent, France
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Room</th>
<th>Expert</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15 pm – 4:15 pm</td>
<td>Meet the Expert (MTE2:2)</td>
<td>Thurgood Marshall Ballroom SW</td>
<td>Siri Atma Greeley, United States</td>
</tr>
<tr>
<td></td>
<td><strong>Session Title:</strong> Distinguishing monogenic forms from type 1 and type 2 diabetes: Does your patient have the right diagnosis?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Thurgood Marshall Ballroom SW</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Expert:</strong> Siri Atma Greeley, United States</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:15 pm – 4:15 pm</td>
<td>Meet the Expert (MTE7:2)</td>
<td>Washington 4-6</td>
<td>Craig Munns, Australia</td>
</tr>
<tr>
<td></td>
<td><strong>Session Title:</strong> Pediatric osteoporosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Washington 4-6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Expert:</strong> Craig Munns, Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:15 pm – 4:15 pm</td>
<td><strong>Yearbook of Paediatric Endocrinology (YB2)</strong></td>
<td>Virginia</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session Title:</strong> Yearbook Session 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Virginia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pituitary and neuroendocrinology</td>
<td>Nicolas De Roux, France</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Obesity and weight regulation</td>
<td>Martin Wabitsch, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bone, growth plate and mineral metabolism</td>
<td>Outi Mäkitie, Finland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oncology and chronic disease</td>
<td>Carla Bizzarri, Italy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Global health for the pediatric endocrinologist</td>
<td>Jean-Pierre Chanoine, Canada</td>
<td></td>
</tr>
<tr>
<td>Session Title:</td>
<td>Fetal and neonatal glucose metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room:</td>
<td>Maryland</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FC86**
RESTORATION OF STEM CELL DERIVED BETA-CELL FUNCTION FROM PERMANENT NEONATAL DIABETES
PATIENT BY CRISPR/CAS9
Shuangyu Ma, BS/BA; Ryan Viola, Lab Manager, Columbia University, New York, NY, United States; Valentino Cherubini, MD, Salesi Hospital, Ancona, Italy; Fabrizio Barbetti, MD, University of Rome Tor Vergata, Rome, Italy; Dieter Egli, PhD, Columbia University, New York, NY, United States

**FC87**
A NOVEL SYNDROME OF HYPERINSULINAEMIC HYPOGLYCEMIA AND POLYCYSTIC KIDNEYS DUE TO A PROMOTOR MUTATION IN PMM2
Oscar Rubio R Cabezas, MD, Hospital Infantil Universitario Niño Jesús, Madrid, Spain; Sarah Flanagan, PhD, University of Exeter Medical School, Exeter, United Kingdom; Horia Stanescu, PhD, University College London, London, United Kingdom; Hi-Pkd Consortium, PhD, Multiple Collaborations, United Kingdom; Robert Kleta, MD; Detlef Bockenhauer, MD, University College London, London, United Kingdom; Sian Ellard, Prof., University of Exeter Medical School, Exeter, United Kingdom; Khalid Hussain, MD, Sidra Medical And Research Center, Doha, Qatar

**FC88**
MODELING CONGENITAL HYPERINSULINISM IN PATIENT STEM CELL DERIVED BETA-LIKE CELLS
Väinö Lithovius, Bachelor of Medicine; Jonna Saarimäki-Vire, PhD; Diego Balboa, MS/MA; Jarkko Ustinov, MS/MA; Timo Otonkoski, MD/PhD/Prof., University of Helsinki, Helsinki, Finland

**FC89**
EFFECT OF EXENDIN-(9-39) ON GLUCOSE AND INSULIN RESPONSES TO A MIXED MEAL AND A PROTEIN LOAD IN CHILDREN WITH HYPERINSULINISM
Darko Stefanovski, PhD, University of Pennsylvania, Philadelphia, PA, United States; Mary E Vajravelu, MD, The Children’s Hospital of Philadelphia, Philadelphia, PA, United States; Diva D De Leon Crutchlow, MD, Perelman School of Medicine at the University of Pennsylvania/The Children’s Hospital of Philadelphia, Philadelphia, PA, United States

**FC90**
RISK FACTORS FOR PERINATAL STRESS-INDUCED HYPERINSULINISM
Courtney L Reynolds, MPH; Lisa Truong, CPNP; Larry Rodriguez, RN; Jonathon Nedrelow, MD; Paul Thornton, MD, Cook Children’s Medical Center, Fort Worth, TX, United States
3:15 pm – 4:15 pm  |  Free Communication Session (FC91-FC95)

**Session Title:** Adrenals #1  
**Room:** Delaware

**FC91**  
A MIRAGE SYNDROME PATIENT WITHOUT HEMATOLOGICAL PHENOTYPES: INACTIVATION OF A GERMLINE ACTIVATING SAMD9 MUTATION BY A SOMATICALLY ACQUIRED NONSENSE MUTATION IN HEMATOPOIETIC CELLS  
Hirohito Shima, MD, National Research Institute for Child Health and Development, Tokyo, Japan; Yumiko Nomura, MD; Kazuhiko Sugimoto, MD; Akira Satoh, MD, Hirosaki National Hospital, Hirosaki, Japan; Tsutomo Ogata, Professor, Hamamatsu University School of Medicine, Hamamatsu, Japan; Maki Fukami, PhD; Satoshi Narumi, MD, National Research Institute for Child Health and Development, Tokyo, Japan

**FC92**  
HIGH DHEAS AT AGE 7 ARE ASSOCIATED TO HIGHER GLYCEMIA DURING PUBERTY BUT NOT METABOLIC SYNDROME  
Ana Pereira, PhD; Camila Corvalan, PhD; Paulina M Merino, MD, University of Chile, Santiago, Chile; German Iñiguez, PhD, University of Chile/Faculty of Medicine, Santiago, Chile; Veronica Mericq, MD, University of Chile, Santiago, Chile

**FC93**  
ALTERED STEROID AND DRUG METABOLISM BY A P450 OXIDOREDUCTASE VARIANT FOUND IN APPARENTLY NORMAL POPULATION  
Florence Roucher-Boulez, MD, Hospices Civils de Lyon Université Lyon 1, Lyon, France; Shaheena Parween, PhD, University Children’s Hospital, University of Bern, Bern, Switzerland; Yves Morel, MD, Hospices civils de Lyon, Université Lyon 1, Lyon, France; Amit V. Pandey, PhD, University Children’s Hospital Bern, Bern, Switzerland

**FC94**  
BIOAVAILABILITY OF ORAL HYDROCORTISONE CORRECTED FOR BINDING PROTEINS AND MEASURED BY LC-MS/MS USING SERUM CORTISOL AND SALIVARY CORTISONE  
Richard J Ross, MD, University of Sheffield, Sheffield, United Kingdom; Trevor N Johnson, PhD, Simcyp, Sheffield, United Kingdom; Martin J Whitaker, PhD, Diurnal Ltd, Sheffield, United Kingdom; Brian Keevil, MD, University Hospital of South Manchester, Manchester, United Kingdom

**FC95**  
SIMULTANEOUS PROFILING OF 17 STEROID HORMONES USING LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY IN NEWBORN AND EARLY INFANCY  
Ece Öge Erver, MD; Pınar Vatansever, PhD, Marmara University, Faculty of Medicine, Istanbul, Turkey; Omer Guran, MD; Leyla Bilgin, Assoc Professor, Health Sciences University Umranıye Training and Research Hospital, Istanbul, Turkey; Perran Baran, professor; Serap Turan, Professor; Goncaal Haklar, professor; Abdullah Bereket, Professor; Tulay Guran, Assoc Professor, Marmara University, Faculty of Medicine, Istanbul, Turkey
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Session Title</th>
<th>Room</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 pm – 6:00 pm</td>
<td>IMPE Satellite Symposium (SAT)</td>
<td>Central precocious puberty: case presentations and discussion of nuances in diagnosis, treatment, and follow-up</td>
<td>Marriott Ballroom</td>
<td>Abbvie</td>
</tr>
<tr>
<td>4:30 pm – 6:00 pm</td>
<td>IMPE Satellite Symposium (SAT)</td>
<td>Evolving trends in puberty</td>
<td>Washington 1-3</td>
<td>Endo Pharmaceuticals</td>
</tr>
<tr>
<td>4:30 pm – 6:00 pm</td>
<td>IMPE Satellite Symposium (SAT)</td>
<td>Updated guidelines for the use of growth hormone therapy in children and adolescents: Exploring the impact on clinical practice</td>
<td>Thurgood Marshall NE</td>
<td>Versartis, Inc.</td>
</tr>
</tbody>
</table>
### Sunday Program

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Registration Opens</td>
</tr>
<tr>
<td>6:30 am</td>
<td>Coffee in Exhibit Hall (7:00-7:30 am)</td>
</tr>
<tr>
<td>7:30 am</td>
<td>MTE9:2 Diabetes in the infant</td>
</tr>
<tr>
<td>7:30 am</td>
<td>FC96–FC100 Adrenal #2</td>
</tr>
<tr>
<td>7:30 am</td>
<td>FC101–FC105 Multisystem endocrine disorders</td>
</tr>
<tr>
<td>7:30 am</td>
<td>Young Investigator Pres. APPES, PES, ESPE, APEG awards presented</td>
</tr>
<tr>
<td>7:30 am</td>
<td>MTE12:2 The etiology and management of hypophosphatemic rickets</td>
</tr>
<tr>
<td>7:30 am</td>
<td>MTE5:2 Delayed puberty: causes, evaluation, and management</td>
</tr>
<tr>
<td>7:30 am</td>
<td>MTE8:2 Management of hypothyroidism in children</td>
</tr>
<tr>
<td>8:00 am</td>
<td>Marriott Ballroom Wilson Washington 1-3</td>
</tr>
<tr>
<td>8:15 am</td>
<td>Marriott Ballroom Wilson Washington 1-3</td>
</tr>
<tr>
<td>8:30 am</td>
<td>Marriott Ballroom Wilson Washington 1-3</td>
</tr>
<tr>
<td>8:45 am</td>
<td>Marriott Ballroom Wilson Washington 1-3</td>
</tr>
<tr>
<td>9:00 am</td>
<td>Marriott Ballroom Wilson Washington 1-3</td>
</tr>
<tr>
<td>9:15 am</td>
<td>Marriott Ballroom Wilson Washington 1-3</td>
</tr>
<tr>
<td>9:30 am</td>
<td>Marriott Ballroom Wilson Washington 1-3</td>
</tr>
<tr>
<td>9:45 am</td>
<td>Marriott Ballroom Wilson Washington 1-3</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Refreshment Break and Exhibits Exhibition Hall</td>
</tr>
<tr>
<td>10:15 am</td>
<td>S Pharmacotherapy for hypothalamic obesity Virginia Maryland Marriott Ballroom</td>
</tr>
<tr>
<td>10:30 am</td>
<td>S New insights into growth disorders Maryland Marriott Ballroom</td>
</tr>
<tr>
<td>10:45 am</td>
<td>S CPE3 Is there a role for early surgery in the management of DSD? Washington 4-6 Maryland Marriott Ballroom</td>
</tr>
<tr>
<td>11:00 am</td>
<td>S Thyroid conundrums Washington 4-6 Maryland Marriott Ballroom</td>
</tr>
<tr>
<td>11:15 am</td>
<td>S Technology and diabetes Washington 1-3 Marriott Ballroom</td>
</tr>
<tr>
<td>11:30 am</td>
<td>PL8 ESPE – Disorders of the pituitary-thyroid axis: insights from human genetics by Krishna Chatterjee Marriott Ballroom</td>
</tr>
<tr>
<td>11:45 am</td>
<td>PL9 President’s Poster Awards Marriott Ballroom</td>
</tr>
<tr>
<td>12:00 pm</td>
<td>Closing Remarks</td>
</tr>
</tbody>
</table>

**Location:**
- Marriott Ballroom
- Washington 1-3
- Delaware
- Maryland
- Virginia
### Sunday, September 17

#### 6:30 am
Registration Opens (Lobby Level)

#### 7:30 am – 8:30 am
Meet the Expert (MTE9:2)

**Session Title:** Diabetes in the Infant  
**Room:** Marriott Ballroom  
**Expert:** Thomas Danne, Germany

#### 7:30 am – 8:30 am
Free Communication Session (FC96-100)

**FC96**  
**Session Title:** Low Vitamin D Receptor (VDR) Impacts Pediatric Adrenocortical Tumor Behavior While VDR Activation Represses Wnt/b-Catenin Signaling and Adrenocortical Cell Proliferation  
**Room:** Adrenal #2  
**Expert:** Wilson  
*Ana C Bueno, PhD, Ribeirao Preto Medical School - University of Sao Paulo, Ribeirao Preto, Brazil; Leticia F Leal, PhD, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil; Deborha C Games, PhD, Federal University of Uberlandia, Uberlandia, Brazil; Ana P Montalba, PhD, Ribeirao Preto Medical School, Ribeirao Preto, Brazil; Silvia R Brandalise, PhD; Maria J Masteralilla, PhD; Izilda A Cardinalli, PhD; Jose A Yunes, PhD, Boldrinini Children's Center, Campinas, Brazil; Luiz G Tone, PhD; Carlos A Scrideli, PhD; Ayrton C Moreira, PhD; Carlos AF Molina, PhD; Fernando F Ramalho, PhD; Silvio Tucci, PhD; Leandra NZ Ramalho, PhD; Margaret De Castro, PhD; Sanir R Antonini, PhD, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil*

**FC97**  
**Session Title:** Would Molecular Testing Identify Cases of Congenital Adrenal Hyperplasia Missed by Newborn Screening?  
**Room:** Wilson  
*Ana C Bueno, PhD, Ribeirao Preto Medical School - University of Sao Paulo, Ribeirao Preto, Brazil; Leticia F Leal, PhD, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil; Deborha C Games, PhD, Federal University of Uberlandia, Uberlandia, Brazil; Ana P Montalba, PhD, Ribeirao Preto Medical School, Ribeirao Preto, Brazil; Silvia R Brandalise, PhD; Maria J Masteralilla, PhD; Izilda A Cardinalli, PhD; Jose A Yunes, PhD, Boldrinini Children's Center, Campinas, Brazil; Luiz G Tone, PhD; Carlos A Scrideli, PhD; Ayrton C Moreira, PhD; Carlos AF Molina, PhD; Fernando F Ramalho, PhD; Silvio Tucci, PhD; Leandra NZ Ramalho, PhD; Margaret De Castro, PhD; Sanir R Antonini, PhD, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil*

**FC98**  
**Session Title:** Mutation in SAMD9 Extends the Genetic and Clinical Spectrum of Triple A Syndrome  
**Room:** Wilson  
*Angela Huebner, PhD, Technische Universität Dresden, Dresden, Germany; Satoshi Narumi, MD, National Research Institute for Child Health and Development, Tokyo, Japan; Dana Landgraf, Research Technician; Felix Reschke, MD; Ramona Jühlken, PhD; Katrin Koehler, PhD, Technische Universität Dresden, Dresden, Germany*

**FC99**  
**Session Title:** Serum Cortisol and Salivary Cortisone and Frequency of Sampling to Estimate Cortisol Exposure  
**Room:** Wilson  
*Richard J Ross, MD; Robert F Harrison, MD; Miguel Debono, PhD, University of Sheffield, Sheffield, United Kingdom; Martin J Whitaker, PhD, Diurnal Ltd, Sheffield, United Kingdom; Brian G Keevil, MD, University Hospital of South Manchester, Sheffield, United Kingdom; John Newell-Price, MD, University of Sheffield, Sheffield, United Kingdom*

**FC100**  
**Session Title:** 17OH-Pregnenolone Seems a Major Drive of Androgen Excess in Patients with 11β-Hydroxylase Deficiency  
**Room:** Wilson  
*Melek Yildiz, MD, Kanuni Sultan Suleyman Education and Research Hospital, Istanbul, Turkey; Serap Turan, Professor, Marmara University, Faculty of Medicine, Istanbul, Turkey; Teoman Akcay, Assoc Professor, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey; Zeynep Atay, Assoc Professor, Marmara University, Faculty of Medicine, Istanbul, Turkey; Hasan Onal, Assoc Professor, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey; Tugba Baris, PhD, Health Sciences University, Haseki Diagnostic Center, Istanbul, Turkey; Goncaoglu Haklar, Professor, Marmara University, Istanbul, Turkey; Abdullah Bereket, Professor, Marmara University, Faculty of Medicine, Istanbul, Turkey; Tulay Guran, MD, Marmara University, Istanbul, Turkey*
7:30 am – 8:30 am Free Communication Session (FC101-FC105)

Session Title: Multisystem endocrine disorders
Room: Washington 1-3

FC101
UNDERSTANDING WOLFRAM SYNDROME: GENETICS, FUNCTIONALITY & ALLELIC VARIATIONS
Melissa Riachi, MS/MA; Mark Kristiansen, PhD, University College London Great Ormond Street Institute of Child Health, London, United Kingdom; Sebahat Yilmaz, Associate Prof; Zehra Aycan, Prof; Erdal Kurnaz, MD, Dr Sami Ulus Training and Research Children’s Hospital, Istanbul, Turkey; Nanna Dahl Rendtorff, PhD; Lisbeth Tranebjaerg, Prof, University Hospital / University of Copenhagen, Copenhagen, Denmark; Robert Kleta, Prof, University College London Faculty of Medical Sciences, London, United Kingdom; Detlef Bockenhauer, Prof, University College London, Faculty of Medical Sciences, London, United Kingdom; Maria Ritter - Glindzicz, Prof, University College London Great Ormond Street Institute of Child Health, London, United Kingdom; Khalid Hussain, Division chief, Sidra Medical and Research Center, Doha, Qatar

FC102
UNCOVERING A NEW MECHANISM IN THE PIGMENTARY HYPERTRICHOSIS AND NON-AUTOIMMUNE DIABETES MELLITUS (PHID) SYNDROME INVOLVING THE 3'UTR
Melissa Riachi, MS/MA, University College London Great Ormond Street Institute of Child Health, London, United Kingdom; Feyza Darendeliler, Prof; Firdevs Bas, Prof, Istanbul Faculty of Medicine, Istanbul, Turkey; Khalid Hussain, Division chief, Sidra Medical and Research Center, Doha, Qatar

FC103
PROGRESSION OF DIABETES MELLITUS IN WOLFRAM SYNDROME
Bess A Marshall, MD; Neil H White, MD; Tamara Hershey, PhD, Washington University in St. Louis, St. Louis, MO, United States

FC104
A REVIEW OF GENOTYPE-PHENOTYPE PRESENTATIONS IN PATIENTS WITH PSEUDOHYPOALDOSTERONISM TYPE 1 FOLLOWING THE IDENTIFICATION OF NOVEL MUTATIONS
Jaya Sujatha Gopal-Kothandapani, MRCPCH, University of Sheffield, Sheffield, United Kingdom; Arpan Doshi, Medical Student, Sheffield Medical School, Sheffield, United Kingdom; Christian Martin, MRCP, Nottingham University Hospital, Nottingham, United Kingdom; Talat Mushtraq, MD, The Leeds Teaching Hospitals, Leeds, United Kingdom; Indraneel Banerjee, MD, Central Manchester University Hospitals, Manchester, United Kingdom; Raja Padidela, MD, Royal Manchester Children's Hospital, Manchester, United Kingdom; Renuka Ramakrishnan, MRCPCH, Alder Hey Children's Hospital, Liverpool, United Kingdom; Catherine Owen, PhD; Timothy Cheetham, MD, Royal Victoria Infirmary, Newcastle, United Kingdom; Kath Smith, MSc; Paul Dimitri, PhD, Sheffield Childrens Hospital, Sheffield, United Kingdom

FC105
PANCREATIC INSULINOMAS IN CHILDHOOD: CLINICAL, MORPHOLOGICAL AND GENETIC CHARACTERISTICS OF 16 CHILDREN
Maria Melikyan, PhD, Endocrine research center, Moscow, Russian Federation; Sergey Makarov, MD, Russian Children’s Clinical Hospital, Moscow, Russian Federation; Larisa Gurevich, PhD, M. F. Vladimirsky regional clinical institute, Moscow, Russian Federation; Yuriy Sokolov, PhD, paediatric municipal clinical hospital, Moscow, Russian Federation; Henrik t Christesen, PhD, Odense University Hospital, Odense, Denmark
### Young Investigator Presentations

**Session Title:** Young Investigator Award presentations  
**Room:** Maryland  
**Moderator:** Saul Malozowski (SLEP) and Muhammad Yazid Jalaludin (APPES)  
**APPES: Kaichi-Kida Award**  
Asako Tajima, Jikei University School of Medicine  
**PES Clinical Scholar**  
Shana McCormak, Children’s Hospital of Philadelphia  
**ESPE Young Investigator Awardee**  

**ESPE Young Investigator Awardee**  
**APEG 2016 Young Investigator Award**  
*Quynh Nhu Nguyen, University of Melbourne, Australia*

### Meet the Expert (MTE12:2)

**Session Title:** The etiology and management of hypophosphatemic rickets  
**Room:** Delaware  
**Expert:** Leanne Ward, Canada

### Meet the Expert (MTE5:2)

**Session Title:** Delayed puberty: causes, evaluation, and management  
**Room:** Washington 4-6  
**Expert:** Yee-Ming Chan, United States

### Meet the Expert (MTE8:2)

**Session Title:** Management of hyperthyroidism in children  
**Room:** Virginia  
**Expert:** Julianne Léger, France

### Yearbook of Paediatric Endocrinology (YB3)

**Session Title:** Yearbook Session 2  
**Room:** Washington 4-6  
**Editor’s choice**  
Ken Ong, United Kingdom  
**Thyroid**  
Gabor Szinnai, France  
**Reproductive endocrinology**  
Olle Soder, Sweden  
**Type 1 diabetes**  
TBD  
**The year in science & medicine**  
Ze’ev Hochberg, Israel
Session Title: Puberty  
Room: Maryland

**FC106**

**Paternally Inherited DLK1 Deletion as a Novel Cause of Familial Central Precocious Puberty**

Andrew Dauber, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Marina Cunha-Silva, MD; Delanie Maceda, MD; Vinicius Brito, MD, Universidade de São Paulo, São Paulo, Brazil; Ana Paula Abreu, MD, Brigham and Women's Hospital, Boston, MA, United States; Stephanie Roberts, MD, Boston Children's Hospital, Boston, MA, United States; Luciana Montenegro, PhD, Universidade de São Paulo, São Paulo, Brazil; Melissa Andrew, BS/BA, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Andrew Kriby, BS/BA, Massachusetts General Hospital, Boston, MA, United States; Matthew Weirauch, PhD; Guillaume Labilloy, MS/MA, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Danielle Bessa, MD, Universidade de São Paulo, São Paulo, Brazil; Rona Carroll, PhD, Brigham and Women's Hospital, Boston, MA, United States; Dakota Jacobs, MS/MA; Patrick Chappell, PhD, College of Veterinary Medicine, Oregon State University, Corvallis, OR, United States; Berenice B Mendonca, PhD, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; David Haig, PhD, Harvard University, Cambridge, MA, United States; Ursula Kaiser, MD, Brigham and Women's Hospital, Boston, MA, United States; Ana Claudia Latronico, MD, Universidade de São Paulo, São Paulo, Brazil

**FC107**

**Deletion of the Uridine Diphosphate Glucuronyltransferase UGT2B17 Gene is Associated with Delayed Pubarche in Healthy Boys**

Annette Mouritsen, MD, PhD; Alexander S Busch, MD; Lise Aksglaede, MD, PhD; Ewa Rajpert-De Meyts, PhD, Rigshospitalet, Copenhagen, Denmark; Anders Juul, PhD, Rigshospitalet, Denmark, Copenhagen, Denmark

**FC108**

**Extreme Hyperandrogenism Worsens Metabolic but Not Dermatologic Findings Within Obese Adolescents with Polycystic Ovarian Syndrome**

Melanie Cree-Green, MD, PhD; Michelle Torres, MD, PhD; Laura Pyle, PhD, University of Colorado/Children's Hospital Colorado, Aurora, CO, United States; Ann Scherzinger, PhD, University of Colorado, Aurora, CO, United States; Megan M Kelsey, MD; Kristen J Nadeau, MD, MS, University of Colorado/Children's Hospital Colorado, Aurora, CO, United States

**FC109**

**Discovery of Mutations in Multiple Genes Controlling GnRH Neuronal Migration and Development in Patients with Self-Limited Delayed Puberty**

Sasha R Howard, MBBS, Queen Mary University of London, London, United Kingdom; Valentina Andre, PhD, University of Milan, Milan, Italy; Leo Guasti, PhD; Claudio P Cabrera, PhD; Michael R Barnes, PhD, Queen Mary University of London, London, United Kingdom; Anna Cariboni, PhD, University of Milan, Milan, Italy; Leo Dunkel, MD, PhD, Queen Mary University of London, London, United Kingdom

**FC110**

**Use of Testosterone Gel Compared to Intramuscular Formulation for Puberty Induction in Males with Constitutional Delay of Growth and Puberty**

Danilo Fintini, MD, Bambino Gesù Children's Hospital, Rome, Italy; Laura Chioma, MD; Giulia Papucci, MD, Bambino Gesù Children's Hospital, Rome, Italy; Marco Cappa, MD, Bambino Gesù Children's Hospital, Rome, Italy
<table>
<thead>
<tr>
<th>Session Title:</th>
<th>Late Breaking Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room:</td>
<td>Delaware</td>
</tr>
</tbody>
</table>

**FC111**  
**BIG FAT SECRET: DISRUPTION OF T CELL HOMEOSTASIS BY CYCLIN DEPENDENT KINASE 5 ACTIVITY IS CRITICAL IN THE PATHOGENESIS OF INFLAMMATION-INDUCED OBESITY**  
Priyanka Bakhtiani, MD, UH Rainbow Babies and Children's Hospital/ Case Western University, Cleveland, OH, United States; Tej Pareek, PhD, UH Rainbow Babies and Children's Hospital, Cleveland, OH, United States; Sumana Narasimhan, MD, Cleveland Clinic Children’s Hospital, Cleveland, OH, United States; Hsi-Ju Wei, PhD, Case Western Reserve University, Cleveland, OH, United States; John Letterio, MD, UH Rainbow Babies and Children’s Hospital, Cleveland, OH, United States

**FC112**  
**HISTONE PHOSPHORYLATION BY THE KINASE OF TRANSIENT RECEPTOR POTENTIAL MELASTATIN 6 (TRPM6) ATTENUATES ADJACENT ARGinine METHYLATION IN DISORDERED PEDIATRIC MINERAL METABOLISM**  
Nora Renthal, PhD, Boston Children's Hospital, Boston, MA, United States; Grigory Krapivinsky, PhD; David E Clapham, PhD, Boston Children's Hospital, Boston, MA, United States

**FC113**  
**INFLUENCE OF GROWTH HORMONE THERAPY IN THE OCCURRENCE OF SECOND NEOPLASM IN SURVIVORS OF CHILDHOOD CANCER.**  
Cécile Thomas-Teinturier, MD, AP-HP Hopitaux Paris-Sud Site Bicêtre, Le Kremlin-Bicêtre, France; Isabelle Oliver-Petit, MD, Hôpital Purpan, Toulouse, France; Hélène Paquement, MD, Institut Curie, Paris, France; Odile Oberlin, MD, Institut Gustave Roussy, Villejuif, France; Martine Munzer, MD, American Memorial hospital, Reims, France; Florent De Vathaire, PhD, Institut Gustave Roussy, Villejuif, France

**FC114**  
**IMPROVING OUTCOMES IN ADOLESCENTS WITH POORLY CONTROLLED TYPE 1 DIABETES**  
Catherine Stanger, PhD; Amy Hughes Lansing, PhD; Emily Scherer, PhD; Alan Budney, PhD, Geisel School of Medicine, Hanover, NH, United States; Ann S Christiano, APRN; Samuel J Casella, MD, Children's Hospital at Dartmouth, Lebanon, NH, United States

**FC115**  
**RAPID MULTISTEROID MASS SPECTROMETRY (MS) PROFILING COMBINED WITH SIMULTANEOUS GONADAL PEPTIDE MEASUREMENT ALLOWED FOR IMMEDIATE DIAGNOSIS OF MAJOR DISORDERS OF SEX DEVELOPPEMENT (DSD) AND EARLY GENDER ASSIGNMENT IN A COHORT OF 92 NEONATES**  
Fatma Chebbi, MD; Marie-Christine Temple, MD, CHU COCHIN, PARIS, France; Cyril Amouroux, MD, CHRU Montpellier, MONTPELLIER, France; Françoise Paris, MD,PhD, CHRU de Montpellier, MONTPELLIER, France; Laetitia Martinerie, MD, University of Paris, Robert Debré Hospital, Paris, France; Karine Braun, MD; Hélène Bony, MD, CHU Amiens, AMIENS, France; Jean-Claude Carel, MD, University of Paris, Robert Debré Hospital, Paris, France; Najiba Lahlou, MD,PhD, University Paris Descartes, Paris, France

### Meet the Expert (MTE11:2)

**Session Title:** Exercising safely with T1DM  
**Room:** Virginia  
**Expert:** Elizabeth Davis, Australia

### Meet the Expert (MTE4:2)

**Session Title:** Pediatric cortical adrenal tumors  
**Room:** Marriott Ballroom  
**Expert:** Margaret de Castro, Brazil
8:45 am – 9:45 am  Meet the Expert (MTE10:2)  
**Session Title:** Neonatal hypoglycemia  
**Room:** Washington 1-3  
**Expert:** Khalid Hussain, United Kingdom  

9:45 am – 10:15 am  Refreshment Break  
**Room:** Exhibition Hall  

10:15 am – 11:45 am  Topic Symposium (S)  
**Session Title:** Pharmacotherapy for hypothalamic obesity  
**Room:** Virginia  
**Moderators:** Renson Mukhwana, Kenya & Andrea Haqq, Canada  
- New aspects in hypothalamic regulation of weight  
  Sadaf Farooqi, United Kingdom  
- Medical therapy for hypothalamic obesity (HyOb)  
  Ze’ev Hochberg, Israel  
- Surgical therapy for hypothalamic obesity (HyOb)  
  Thomas H. Inge, United States  

10:15 am – 11:45 am  Topic Symposium (S)  
**Session Title:** New insights into growth disorders  
**Room:** Marriott Ballroom  
**Moderators:** Jeffrey Baron, United States & Ola Nilsson, Sweden  
- Insulin and IGF1 receptor signaling  
  Susumu Kanzaki, Japan  
- Genomic aspects  
  Andrew Dauber, United States  
- Outcomes after fetal growth restriction  
  Verónica Mericq, Chile  

10:15 am – 11:45 am  Controversies in Pediatric Endocrinology (CPE3)  
**Session Title:** Is there a role for early surgery in the management of DSD?  
**Room:** Washington 4-6  
**Moderators:** Martine Cools, Belgium & Anna Nordenstrom, Sweden  
- Legal considerations  
  Olaf Hiort, Germany  
- Urology perspective  
  Earl Cheng, United States  
- Psychology perspective  
  Amy Wisniewski, United States
### Sunday, Sept 17

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Room</th>
<th>Moderators</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 am – 11:45 am</td>
<td><strong>Topic Symposium (S)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>Thyroid conundrums</td>
<td>Maryland</td>
<td>David Allen, United States, &amp; Michel Polak, France</td>
</tr>
<tr>
<td><strong>Moderators:</strong></td>
<td>Thyroid axis dysfunction in Down Syndrome</td>
<td>Paul van Trotsenburg, Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-thyroidal illness syndrome</td>
<td></td>
<td>Anita Boelen, Netherlands</td>
</tr>
<tr>
<td></td>
<td>Thyroid axis disruption by obesity</td>
<td></td>
<td>Thomas Reinehr, Germany</td>
</tr>
<tr>
<td>10:15 am – 11:45 am</td>
<td><strong>Topic Symposium (S)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>Technology and diabetes</td>
<td>Washington 1-3</td>
<td>Michelle Jack, Australia &amp; Jamie Wood, United States</td>
</tr>
<tr>
<td><strong>Moderators:</strong></td>
<td>Use of apps &amp; phones in diabetes management</td>
<td>Joseph Cafazzo, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Smart insulins and novel delivery systems</td>
<td>Zhen Gu, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Update on artificial pancreas development</td>
<td>Roman Hovorka, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>12:00 pm – 12:30 pm</td>
<td><strong>Plenary (PL8)</strong></td>
<td>Marriott Ballroom</td>
<td>Krishna Chatterjee, United Kingdom</td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>European Society for Paediatric Endocrinology (ESPE) – Disorders of the pituitary-thyroid axis: insights from human genetics</td>
<td>Marriott Ballroom</td>
<td>Krishna Chatterjee, United Kingdom</td>
</tr>
<tr>
<td>12:30 pm – 1:15 pm</td>
<td><strong>Plenary (PL9)</strong></td>
<td>Marriott Ballroom</td>
<td></td>
</tr>
<tr>
<td><strong>Session Title:</strong></td>
<td>Awards and Closing Remarks</td>
<td>Marriott Ballroom</td>
<td>President’s Poster Awards, Human Growth Foundation Award, Cuttler Award, ESPE Henning Andersen Prize Awards</td>
</tr>
<tr>
<td><strong>Room:</strong></td>
<td></td>
<td>Marriott Ballroom</td>
<td></td>
</tr>
<tr>
<td><strong>Speaker:</strong></td>
<td>Awards and Closing Remarks</td>
<td>Marriott Ballroom</td>
<td></td>
</tr>
<tr>
<td><strong>Closing Remarks:</strong></td>
<td>and 2021 International Meeting announcement</td>
<td>Marriott Ballroom</td>
<td>David Allen, United States &amp; Peter Clayton, United Kingdom</td>
</tr>
</tbody>
</table>
Poster Sessions

The Poster Exhibition is located within the Exhibition Hall. The posters are on display the first three days of the meeting. By looking at the poster number you can find the area and the day of the poster presentation.

Day Category
P1-100

The first number indicates the day of presentation (e.g., P1 for Thursday, September 14; P2 for Friday, September 15; and P3 for Saturday, September 16).

The second number indicates the category of the poster (please see the poster index on the next page for the category index).

Meet the Author Poster Sessions

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>Thursday 5:45pm - 6:45pm</td>
</tr>
<tr>
<td>P2</td>
<td>Friday 11:30am-12:30pm</td>
</tr>
<tr>
<td>P3</td>
<td>Saturday 12:00pm-1:00pm</td>
</tr>
</tbody>
</table>

Poster Mount/Removal Schedule

<table>
<thead>
<tr>
<th>Day</th>
<th>Set Up</th>
<th>Removal</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1:</td>
<td>Thursday 4:00pm</td>
<td>8:00pm</td>
</tr>
<tr>
<td>P2:</td>
<td>Friday 7:00am</td>
<td>12:30pm</td>
</tr>
<tr>
<td>P3:</td>
<td>Saturday 7:00am</td>
<td>1:00pm</td>
</tr>
</tbody>
</table>

Please Note: Any poster not taken down by the time indicated above will be removed by show management and may be picked up at the registration desk. Posters not picked up by Sunday, September 17, 2017 at 12:00pm will be discarded.
**POSTER SESSION 1**  
**Thursday, September 14, 2017, 5:45pm-6:45pm**  
P1 – Adrenals: 100’s  
P1 – Bone and mineral metabolism: 200’s  
P1 – Fetal and neonatal endocrinology and metabolism, including hypoglycemia: 500’s  
P1 – Growth and GH/IGF Axis: 800’s  
P1 – Multisystem endocrine disorders: 900’s  
P1 – Neuroendocrinology including hypothalamic pituitary: 1000’s  
P1 – Obesity, lipids, and co-morbidities: 1100’s  
P1 – Other: 1200’s  
P1 – Puberty: 1300’s  
P1 – Quality improvement: 1400’s  
P1 – Sex differentiation/gonads and disorders of sex development: 1500’s  
P1 – Syndromes: 1600’s  
P1 – Thyroid: 1700’s  
P1 – Type 1 diabetes: 1800’s  
P1 – Type 2 diabetes and other carbohydrate metabolism: 1900’s

**POSTER SESSION 2**  
**Friday, September 15, 2017, 11:30am-12:30pm**  
P2 – Adrenals: 100’s  
P2 – Bone and mineral metabolism: 200’s  
P2 – Ethics in endocrinology: 400’s  
P2 – Fetal and neonatal endocrinology and metabolism, including hypoglycemia: 500’s  
P2 – Global health: 700’s  
P2 – Growth and GH/IGF Axis: 800’s  
P2 – Neuroendocrinology including hypothalamic pituitary: 1000’s  
P2 – Obesity, lipids, and co-morbidities: 1100’s  
P2 – Other: 1200’s  
P2 – Puberty: 1300’s  
P2 – Sex differentiation/gonads and disorders of sex development: 1500’s  
P2 – Syndromes: 1600’s  
P2 – Thyroid: 1700’s  
P2 – Type 1 diabetes: 1800’s  
P2 – Type 2 diabetes and other carbohydrate metabolism: 1900’s
POSTER SESSION 3  
Saturday, September 16, 2017, 12:00pm-1:00pm

P3 – Adrenals: 100’s
P3 – Bone and mineral metabolism: 200’s
P3 – Endocrine care transition: 300’s
P3 – Fetal and neonatal endocrinology and metabolism, including hypoglycemia: 500’s
P3 – Gender dysphoria: 600’s
P3 – Growth and GH/IGF Axis: 800’s
P3 – Neuroendocrinology including hypothalamic pituitary: 1000’s
P3 – Obesity, lipids, and co-morbidities: 1100’s
P3 – Puberty: 1300’s
P3 – Sex differentiation/gonads and disorders of sex development: 1500’s
P3 – Syndromes: 1600’s
P3 – Thyroid: 1700’s
P3 – Type 1 diabetes: 1800’s
P3 – Type 2 diabetes and other carbohydrate metabolism: 1900’s

*Please note: Accepted abstracts are online, as a supplement to Hormone Research in Paediatrics (Vol. 88, Supplement 1, 2017). The Abstracts are available on the Meeting website in PDF, as well as the mobile app. In addition, a USB-stick version is given to registrants on a first-come-first-serve basis. Please collect the USB-stick at the Novo Nordisk exhibition booth by using the voucher received in the Meeting bag.
The African Society for Paediatric and Adolescent Endocrinology (ASPAE) is an international organisation with several members from African countries whose aim is to promote the highest levels of knowledge, research, education and clinical practice of paediatric endocrinology and metabolism throughout Africa.

ASPAE was formed in July 2009 and it is dedicated to serve its members and the international scientific community. It is also aims at being involved in promoting the interests of the general public and in advising on African health policy in the area of paediatric endocrinology. ASPAE is committed to welcoming and establishing close relationships with other Scientific Societies in the world.

We would like to take this opportunity to invite you to our upcoming 9th Annual Meeting of ASPAE which will be held in Nairobi, Kenya from 14-15th March 2018. To get more information about us, please visit our website at www.aspaed.org.
Chiang Mai literally means “new city” but the city is known as “Rose of the North”. It is a cultural and natural wonderland with ethnic diversity, a multitude of attractions and welcoming hospitality. Delegates can experience both historical and modern Thai culture coexisting side by side. The city of Chiang Mai features centuries old pagodas and temples next to modern convenience stores and boutique hotels.

The largest city in the northern part of Thailand, Chiang Mai is internationally recognised as one of the country’s most distinctive cities and a truly engaging conference destination as it represents a harmonious blend of the province’s culture and environment which are amongst its strongest features.

www.appes2018.org
Australasian Paediatric Endocrine Group
Annual Scientific Meeting

29 July – 1st August 2018
Newcastle, NSW, Australia

Destination: Newcastle, NSW
Newcastle is located north of Sydney and is home to world famous beaches, cool bars, delicious food, fascinating history and a lively arts and music scene.

STAY CONNECTED WITH APEG
Australasian Paediatric Endocrine Group-APEG

The Chinese Society of Pediatric Endocrinology and Metabolism (CSPEM) is a national organization, under the Chinese Pediatric Society, founded in 1985. Our mission is to promote the highest levels of clinical care for infants, children and adolescents with endocrine disorders and metabolic diseases throughout China.

It does so by:

- Advancing excellence in paediatric endocrinology, genetics and metabolism by promoting research, education and medical practice.
- Developing and assessing evidence-based clinical practice guidelines and standards of care.
- Promoting and supporting education and research by organizing annual scientific meetings and multicenter clinical researches.
- Contributing to the public health through our publicity activities to facilitate early diagnosis and treatment.
- Enhancing the communication and academic exchanges with international scientific community, other societies and institutions.

Please join our plenary session in the upcoming 10th International Meeting of Pediatric Endocrinology

**Topic**  
Polycystic ovary syndrome clinical and genetic characteristics

**Speaker**  
Prof. Junfen FU and Prof. Zijiang CHEN

**Chair**  
Prof. Xiaoping Luo

**Time**  
11:15-11:45 16-September-2017
Come and visit Booths 510 and 512 to meet the ESPE team and find out more about our membership.

Join us today
ESPE welcomes new members at every stage of their career with an active interest in paediatric endocrinology.

Membership benefits:
- Save up to €220 on Meeting registration fees
- Over €500,000 awarded each year in grants, awards and fellowships
- Interactive learning through education and training programmes
- Recognition in the field through our prestigious awards
- Reduced rates to *Hormone Research in Paediatrics*
- Voting for who runs the Society
- Get connected – online members’ directory
- Latest paediatric endocrinology news straight to your mailbox, Facebook and Twitter

Save the Date
57th Annual ESPE Meeting
Prevention and therapeutic innovations in paediatric endocrinology
27-29 September, Athens, Greece

www.eurospe.org  facebook.com/EuroSPE  twitter.com/EuroSPE
About JSPE

Founded in 1967, the Japanese Society for Pediatric Endocrinology (JSPE) has been leading the field of pediatric endocrinology and pediatric diabetes in Japan. JSPE has over 1,300 clinicians and researchers, who have specialized in pediatric endocrinology and diabetes. JSPE will keep on promoting the scientific research regarding children’s growth, development and maturation, in order to broaden our knowledge for pediatrics. At the same time, JSPE hopes to contribute to the public health through our research activities.

51th Annual Meeting of the JSPE

Shinobu Ida, M.D., Chair, JSPE 2017

Date: Sep.28 (Thu.)-30 (Sat.), 2017
Venue: Umeda Sky Building, Osaka, JAPAN
Chair: Shinobu Ida M.D., Ph.D.
(Osaka Women’s and Children's Hospital)
Theme: Growth, Nutrition and Development
Web: http://jspe2017.umin.jp

Our Journal - Clinical Pediatric Endocrinology -

Clinical Pediatric Endocrinology is the official Journal of JSPE and is published quarterly. Articles are accepted for publication on the understanding that they contribute to the progress of the field of clinical endocrinology and metabolism from infancy through adolescence and that they have not been or will not be published elsewhere except in an abstract form. We would like to invite you to contribute a research article for publication in CPE!

See More http://jspe.umin.jp/eng/journal/index.html
Our mission is to foster the development of Paediatric Endocrinology and Diabetes in all countries of Latin America, promoting the exchange of basic and clinical knowledge applied to the prevention, diagnosis and treatment of endocrine disorders in infants, children and adolescents.

JOIN SLEP  www.slep.com.br  members@slep.com.br

Plenary 6, Saturday 16 September 10.45 AM

The SLEP - César Bergadá Lecture

Disorders in Sex Development: a Persistent Challenge

by Dr. Alicia Belgorosky

This plenary lecture will discuss the complex issue of DSD. The understanding of the genetic basis of disease has a tremendous importance to recommend newborn sex assignment, better targeted therapies and genetic counseling.

SLEP will be honoured to host the International Meeting of Paediatric Endocrinology 2021 in Buenos Aires - Argentina

Rodolfo Rey and Ignacio Bergadá, Co-chairs
JOIN A LEADING CHILDREN'S HOSPITAL IN SOUTH FLORIDA
PEDIATRIC ENDOCRINOLOGY CAREER OPPORTUNITIES

The leading children's hospital in Broward and Palm Beach counties is seeking motivated and experienced physicians to fill two open pediatric endocrinology positions.

In addition to joining a group of more than 250 hospital-employed physicians, including the full range of pediatric specialists, the successful candidates will integrate into a reputable and established group of five board-certified pediatric endocrinologists.

All applicants must be board-certified, dedicated to patient- and family-centered care, and above all, enjoy living in a beautiful, multicultural beachside paradise.

To see job descriptions or to submit your CV for consideration, please visit memorialphysician.com.

visit memorialphysician.com
Understanding short stature beyond the GH-IGF axis

Satellite symposium
Thursday 14 September 2017, 16:15 – 17:45
Washington Room 1–3

Programme

16:15–16:25  Introduction from the Chairs
Horacio Domené, Irene Nètchine,
Argentina  France

16:25–16:50  Genotype/phenotype characterization of newly discovered growth disorders
Christiaan de Bruin, The Netherlands

16:50–17:15  Epigenetic and environmental impact on growth and development
Ken Ong, UK

17:15–17:40  Novel treatment approaches of short stature
Steven Chernausek, USA

17:40–17:45  Summary and close
Hotel Floor Plan, *Lobby Level*
Hotel Floor Plan, *Exhibition Level*
Hotel Floor Plan, Mezzanine Level
**Exhibition Hall Participants**

<table>
<thead>
<tr>
<th>Booth</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>106</td>
<td>Endo Pharmaceuticals</td>
</tr>
<tr>
<td>111</td>
<td>Sandoz</td>
</tr>
<tr>
<td>114</td>
<td>Sanofi Genzyme</td>
</tr>
<tr>
<td>117</td>
<td>Pfizer</td>
</tr>
<tr>
<td>122</td>
<td>The MAGIC Foundation</td>
</tr>
<tr>
<td>126</td>
<td>Rhythm</td>
</tr>
<tr>
<td>127</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>132</td>
<td>Ultragenyx Pharmaceutical</td>
</tr>
<tr>
<td>136</td>
<td>Prader-Willi Syndrome Association</td>
</tr>
<tr>
<td>200</td>
<td>AbbVie</td>
</tr>
<tr>
<td>201</td>
<td>LabCorp-Endocrine Sciences</td>
</tr>
<tr>
<td>204</td>
<td>Alexion</td>
</tr>
<tr>
<td>301</td>
<td>Ascendis Pharma A/S</td>
</tr>
<tr>
<td>303</td>
<td>Versartis, Inc</td>
</tr>
<tr>
<td>311</td>
<td>Ferring Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>317</td>
<td>Merck KGaA</td>
</tr>
<tr>
<td>401</td>
<td>BioMarin</td>
</tr>
<tr>
<td>405</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>411</td>
<td>Insulet Corporation</td>
</tr>
<tr>
<td>413</td>
<td>Lilly USA, LLC</td>
</tr>
<tr>
<td>417</td>
<td>Ferring Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>419</td>
<td>Global Pediatric Endocrinology and Diabetes</td>
</tr>
<tr>
<td>421</td>
<td>Fight ALD</td>
</tr>
<tr>
<td>423</td>
<td>Congenital Hyperinsulinism International</td>
</tr>
<tr>
<td>425</td>
<td>Ipsen Biopharmaceuticals, Inc.</td>
</tr>
<tr>
<td>429</td>
<td>Growth Analyser BV</td>
</tr>
<tr>
<td>433</td>
<td>OPKO Health</td>
</tr>
<tr>
<td>498</td>
<td>Cook Children’s Health Care System</td>
</tr>
<tr>
<td>500</td>
<td>Sonic Bone Medical</td>
</tr>
<tr>
<td>502</td>
<td>International Society for Pediatric and Adolescent Diabetes (ISPAD)</td>
</tr>
<tr>
<td>508</td>
<td>Endocrine Society</td>
</tr>
<tr>
<td>510</td>
<td>European Society for Paediatric Endocrinology (ESPE)</td>
</tr>
<tr>
<td>512</td>
<td>International Consortium of Pediatric Endocrinology (ICPE)</td>
</tr>
<tr>
<td>611</td>
<td>Visiana</td>
</tr>
<tr>
<td>613</td>
<td>Aegerion Pharmaceuticals, a Novelion Therapeutics Company</td>
</tr>
<tr>
<td>615</td>
<td>Arbor Pharmaceuticals, LLC</td>
</tr>
</tbody>
</table>

*The following organizations will have an information table in the Atrium Area:*
- Karger
- African Society for Paediatric and Adolescent Endocrinology (ASPAE)
- Asia Pacific Paediatric Endocrine Society (APPES)
- Chinese Society of Pediatric Endocrinology and Metabolism (CSPEM)
- Growth Hormone Research Society (GRS)
- Pediatric Endocrine Society (PES)
- Sociedad Latinoamericana de Endocrinología Pediátrica (SLEP)
Platinum Sponsors

Merck KGaA,
Darmstadt, Germany

www.merckgroup.com

Pfizer

www.pfizer.com

SANDOZ A Novartis Division

For US doctors/delegates
www.us.sandoz.com

For Non-US doctors/delegates
www.sandoz.com

internationalmeeting2017.org